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Abstract

Obesity is a disorder of energy balance in which energy intake exceeds energy
expenditure. Methods to control obesity through limiting energy intake have had limited
success, and it is widely recognized that energy expenditure must also be increased if
long-term weight loss is to be achieved. Uncoupling proteins (UCPs) are a family of
integral membrane proteins of mitochondrial inner membrane, where they uncouple the
process of mitochondrial respiration from oxidative phosphorylation, diminishing the
resulting production of ATP and decreasing the metabolic efficiency of the organism.
Thus, UCPs provide new molecular targets for increasing energy expenditure. Unlike the
other UCP family members, UCP2 is ubiquitously expressed, with the highest level in
white adipose tissue. Stimulation of mitochondrial uncoupling in adipocytes in vitro
demonstrates a direct inhibitory effect on lipogenesis and suppression on lipolysis via a
calcium dependent mechanism, indicating a potential role of UCP2 in regulation of
adiposity.
Previous studies demonstrate that intracellular Ca2+ ([Ca2+]i ) plays a key role in
metabolic disorders associated with obesity. [Ca2+]i can clearly be modulated by the
calcitrophic hormone 1α, 25-dihydroxyvitamin D3 (1α, 25-(OH)2-D3), which appears to
have both genomic and non-genomic action in adipocytes. 1α, 25-(OH)2-D3 modulates
adipocyte Ca2+ signaling directly, resulting in an increased lipogenesis and decreased
lipolysis. In addition, 1α, 25-(OH)2-D3 plays a genomic role in regulating adipocyte
v

UCP2 expression levels, indicating that the regulation of UCP2 and the resulting
increased core temperature may contribute to increased rates of energy dissipation.
Accordingly, the suppression of 1α, 25-(OH)2-D3 by increasing dietary calcium
attenuates adiposity by decreasing triglyceride accumulation in the adipocytes: increasing
dietary calcium results in a net reduction in fat mass in the absence of caloric restriction,
a marked augmentation of body weight and fat loss during energy restriction, and an
inhibition of weight and fat regain after food restriction in mice.
Although these anti-obesity effects of dietary calcium are due, in part, to
enhanced metabolic rate and thermogenic processes, it is also possible that a loss of
adipocytes would result in a deficit cells for lipid esterification as the body recovers.
Physiological doses of 1α, 25-(OH)2-D3 inhibit apoptosis in differentiated 3T3-L1
adipocytes, and the suppression of 1α, 25-(OH)2-D3 in vivo by increasing dietary calcium
stimulates adipocyte apoptosis in refeeding following energy restriction in aP2 transgenic
mice, indicating that the stimulation of adipocyte apoptosis contributes to adiposity
reduction after high calcium diet administration. UCP2 plays a direct role in modulating
adipocyte apoptosis by inducing mitochondrial potential collapse and inhibiting ATP
production. Overexpression of UCP2 in adipocyte stimulates apoptosis while inhibition
of mitochondrial uncoupling either by chemical inhibitor GDP or by siRNA duplexes
suppresses adipocyte apoptosis. Accordingly, suppression of UCP2 by physiologically
low doses of 1α, 25-(OH)2-D3, which can be induced by low dietary calcium, decreases
apoptosis. Although 1α, 25-(OH)2-D3 causes dose-dependent stimulation on [Ca2+]i levels,
low doses of 1α, 25-(OH)2-D3 decrease mitochondrial calcium accumulation while a high
vi

dose of 1α, 25-(OH)2-D3 induces markedly greater increase in [Ca2+]i and stimulates
calcium storage in mitochondria. Bay K 8644, which is a Ca 2+ ionophore and can mimic
the stimulatory effect of 1α, 25-(OH)2-D3 on [Ca2+]i without exerting effects on UCP2,
causes a dose-dependent increases in apoptosis and mitochondrial calcium accumulation,
indicating that stimulation of pharmaceutical high dose 1α, 25-(OH)2-D3 on apoptosis is a
calcium-dependent effect.
In summary, present data support the concept that dietary calcium exerts antiobesity effects in aP2 transgenic mice under conditions of varying nutrient status. In
addition, this study extended our observation that dietary calcium not only regulates
adipocyte size by decreasing lipid accumulation, but also modulates adipocyte number by
stimulating apoptotic death. These anti-obesity effects of dietary calcium are attributable
to the up-regulation of UCP2, which stimulates energy expenditure, fat utilization and
adipocyte apoptosis in white adipose tissue. Accordingly, these data indicate an important
role of increasing dietary calcium in prevention and management of obesity.
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Methods.

Data are expressed as mean ± SE (n =12).
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effects on lipogenesis: it inhibits FAS activity via a Ca2+independent mechanism and stimulates of FAS expression via
a Ca2+-dependent metabolism.
Figure 5-1

Caspase-1 expression in 3T3-L1 and UCP2 transfected
3T3-L1 adipocytes. Primary-cultured adipocytes were treated
with or without 1α, 25-(OH)2-D3 (0.1nM, 1nM, 5Nm, 10nM,
and 100nM) and DNP (25µM and 50µM) for 24 h for mRNA
levels. Caspase-1 mRNA levels were measured by real-time
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PCR and these measurements were conducted as described in
Materials and Methods. Data are expressed as mean ± SE (n
=6). Different letters above the bars indicate a significant
difference at level of p<0.05.
Figure 5-2

Caspase-3 expression in 3T3-L1 and UCP2 transfected
3T3-L1 adipocytes. Primary-cultured adipocytes were treated
with or without 1α, 25-(OH)2-D3 (0.1nM, 1nM, 5Nm, 10nM,
and 100nM) and DNP (25µM and 50µM) for 24 h for mRNA
levels. Caspase-1 mRNA levels were measured by real-time
PCR and these measurements were conducted as described in
Materials and Methods. Data are expressed as mean ± SE (n
=6). Different letters above the bars indicate a significant
difference at level of p<0.05.
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Figure 5-3

Bcl-2/Bax

expression

ratio

in

3T3-L1

and

UCP2

transfected 3T3-L1 adipocytes. Primary-cultured adipocytes
were treated with or without 1α, 25-(OH)2-D3 (0.1nM, 1nM,
10nM, and 100nM) and DNP (25µM and 50µM) for 24 h for
mRNA levels. Caspase-1 mRNA levels were measured by
real-time PCR and these measurements were conducted as
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described in Materials and Methods. Data are expressed as
mean ± SE (n =6). Different letters above the bars indicate a
significant difference at level of p<0.05.
Figure 5-4

Effect of dietary calcium on caspase-1 expression white
adipose tissue of aP2-agouti transgenic mice. Diet and
animal administration was conducted as described in Materials
and Methods. Data are expressed as mean ± SE (n =8).
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Difference letters above the bars indicate a significant
difference at level of p<0.05.
Figure 5-5

Effect of dietary calcium on caspase-3 expression white
adipose tissue of aP2-agouti transgenic mice. Diet and
animal administration was conducted as described in Materials
and Methods. Data are expressed as mean ± SE (n =8).
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Difference letters above the bars indicate a significant
difference at level of p<0.05.
Figure 5-6

Effect of dietary calcium on Bcl-2/Bax expression in white
adipose tissue of aP2-agouti transgenic mice. Diet and
animal administration was conducted as described in Materials
and Methods. Data are expressed as mean ± SE (n =8).
Difference letters above the bars indicate a significant
difference at level of p<0.05.
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Figure 5-7

Mitochondrial potential in 3T3-L1 and UCP2 transfected
3T3-L1 adipocytes. Primary-cultured adipocytes were treated
with or without 1α, 25-(OH)2-D3 (0.1nM, 1nM, 5Nm, 10nM,
and 100nM) for 4h before assay. Mitochondrial potential were
measured using fluorospectrometry as described in Materials
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and Methods. Data are expressed as mean ± SE (n =6).
Different letters above the bars indicate a significant difference
at level of p<0.05.
Figure 5-8

ATP production in 3T3-L1 and UCP2 transfected 3T3-L1
adipocytes. Primary-cultured adipocytes were treated with or
without 1α, 25-(OH)2-D3 ( 1nM, 5nM, 10nM, and 100nM) for
4h before assay. ATP levels were measured using a microplate
luminometer as described in Materials and Methods. Data are

256

expressed as mean ± SE (n =6). Different letters above the bars
indicate a significant difference at level of p<0.05.
Figure 5-9

Intracellular

calcium

levels

in

3T3-L1

and

UCP2

transfected 3T3 L1 adipocytes. Primary-cultured adipocytes
were treated with or without 1α, 25-(OH)2-D3 ( 1nM, 5nM,
10nM, and 100nM) instantly before assay. Intercellular
calcium levels were measured using a dual wavelength
fluorescence microscope as described in Materials and
Methods. Data are expressed as mean ± SE (n =6). Different
letters above the bars indicate a significant difference at level
of p<0.05.
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Figure 5-10

Mitochondrial calcium levels in 3T3-L1 and UCP2
transfected 3T3-L1 adipocytes. Primary-cultured adipocytes
were treated with or without 1α, 25-(OH)2-D3 (1nM, 5nM,
10nM, and 100nM) instantly before assay. Mitochondrial
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calcium levels were measured using a dual wavelength
fluorescence microscope as described in Materials and
Methods. Data are expressed as mean ± SE (n =6).
Figure 5-11

Schematic illustration of effects and mechanisms of 1α, 25(OH)2-D3 on adipocyte apoptosis. Physiological low doses of
1α, 25-(OH)2-D3 restore mitochondrial potential and ATP
production by suppressing UCP2, thereby inhibiting apoptosis.
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By contrast, high dose of 1α, 25-(OH)2-D3 induces
mitochondrial calcium overload and stimulates apoptosis.
Figure 6-1

Western blot with anti-mouse UCP2 antibody of cell lysates
harvested 48hrs after siRNA transfection for evaluation of
UCP2 protein reduction (upper panel).The internal control
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actin is shown in the low panel. Blot shown is representative of
three similar experiments.
Figure 6-2

Mitochondrial potential in 3T3-L1 and siRNA transfected
3T3-L1 adipocytes (UCP2 ko). Data are expressed as mean ±
SE (n =6). Different letters above the bars indicate a
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significant difference at level of p<0.05.
Figure 6-3

Caspase-3 expression in 3T3-L1 and siRNA transfected
3T3-L1 adipocytes (UCP2 ko). Data are expressed as mean ±
SE (n =6). Different letters above the bars indicate a
significant difference at level of p<0.05.
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Figure 6-4

Effect of mitochondrial uncoupling inhibitor GDP on
mitochondrial potential in 3T3-L1 adipocytes. Data are
expressed as mean ± SE (n =6). Different letters above the bars
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indicate a significant difference at level of p<0.05.
Figure 6-5

Effect of mitochondrial uncoupling inhibitor GDP on
caspase-3 expression in 3T3-L1 adipocytes. Data are
expressed as mean ± SE (n =6). Different letters above the bars
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indicate a significant difference at level of p<0.05.
Figure 6-6

Effect of calcium channel ionophore Bay K 8644 on
intracellular calcium levels in 3T3-L1 adipocytes. Data are
expressed as mean ± SE (n =6). Different letters above the bars
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indicate a significant difference at level of p<0.05.
Figure 6-7

Effect of mitochondrial uncoupling inhibitor GDP and
calcium channel ionophore Bay K 8644 on mitochondrial
potential in 3T3-L1 adipocytes. Data are expressed as mean
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± SE (n =6). Different letters above the bars indicate a
significant difference at level of p<0.05.
Figure 6-8

Effect of calcium channel ionophore Bay K 8644 on
caspase-3 expression in 3T3-L1 adipocytes. Data are
expressed as mean ± SE (n =6). Different letters above the bars
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indicate a significant difference at level of p<0.05.
Figure 6-9

Effect of mitochondrial uncoupling inhibitor GDP and
calcium channel ionophore Bay K 8644 on caspase-3
expression in 3T3-L1 adipocytes. Data are expressed as mean
± SE (n =6). Different letters above the bars indicate a
significant difference at level of p<0.05.
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Figure 6-10

Effect of calcium channel ionophore Bay K 8644 on
mitochondrial calcium in 3T3-L1 adipocytes. Data are
expressed as mean ± SE (n =6).
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Part One
Literature Review

1

1.1 Introduction
The worldwide prevalence of obesity is increasing at an alarming rate, with major
adverse consequences for human health (1-2). Obesity results from a chronic imbalance
between energy intake and expenditure (3-4). This imbalance can result from either
overeating or a constitutional decrease in one or several of the components of energy
expenditure, including resting metabolic rate, diet-induced thermogenesis, or exerciserelated thermogenesis. Methods to control obesity through limiting energy intake have
had modest success (5). In addition, metabolic rate is decreased with extreme calorie
restriction. This decrease persists after the dieting period has ended, often leading to rapid
weight regain (6). It is widely recognized that energy expenditure must be increased if
long-term weight loss is to be achieved.
Uncoupling proteins (UCPs) are a family of integral membrane proteins of
mitochondrial inner membrane, where they uncouple the process of mitochondrial
respiration from oxidative phosphorylation, diminishing the resulting production of ATP
and decreasing the metabolic efficiency of the organism (7-8). Thus, UCPs provide new
molecular targets for increasing energy expenditure. It is widely acknowledged that the
brown adipose tissue (BAT) mitochondrial uncoupling protein (UCP1) plays a pivotal
role in adaptive thermogenic responses (9). Two homologues of UCP1 (UCP2 and UCP3)
have recently been identified and population-based genetic studies have linked them with
basal metabolic rate, while in vitro studies report that both have proton transport activity
and may thus be involved in regulation of energy homeostasis and hence obesity (10).
The function of UCPs may not be restricted to thermoregulation and there is now
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substantial data linking UCP expression levels to fatty acid metabolism and fatty acid
flux into various tissues (11). One hypothesis indicates that UCP2 and UCP3 may
function as a free fatty acid transporter and thereby increase fatty acid utilization. Unlike
the other family members, UCP2 is ubiquitously expressed, with the highest level in
white adipose tissue. Lipid metabolism of adipose tissue is affected by the energy status
of fat cells (12). Previous experiments indicated the dependence of both lipogenesis and
lipolysis on ATP levels in adipocytes (13). Thus, UCP-induced respiratory uncoupling in
adipocytes that results in stimulation of energy dissipation and depression of ATP
synthesis may contribute to the control of lipid metabolism. This hypothesis, however,
requires further investigation.
Previous studies of the agouti gene demonstrate a key role for intracellular Ca2+
([Ca2+]i) in metabolic disorders associated with obesity by regulating adipocyte lipid
metabolism and triglyceride storage(14). Increased [Ca2+]i results in stimulation of
lipogenic gene expression and lipogenesis and suppression of lipolysis, resulting in
adipocyte lipid filling and increased adiposity. [Ca

2+

]i can clearly be modulated by the

calcitrophic hormone 1α, 25-dihydroxyvitamin D3 (1α, 25-(OH)2-D3), which appears to
have both genomic and non-genomic action in adipocytes. 1α, 25-(OH)2-D3 modulates
adipocyte Ca2+ signaling via a non-genomic action, resulting in increased lipogenesis and
decreased lipolysis (15-17). In addition, 1α, 25-(OH)2-D3 plays a genomic role in
regulating adipocyte UCP2 expression levels, indicating that the regulation of UCP2 and
the resulting increased core temperature may contribute to increased rates of energy
dissipation (18). Accordingly, we recently demonstrated that the increased 1α, 25-(OH)23

D3 produced in response to low-calcium diets stimulates adipocyte Ca2+ influx and,
consequently, promotes adiposity. In contrast, the suppression of 1α, 25-(OH)2-D3 by
increasing dietary calcium attenuates adiposity by decreasing triglyceride accumulation
in the adipocytes, resulting in a net reduction in fat mass in the absence of caloric
restriction, a marked augmentation of body weight and fat loss during energy restriction
(15-17). However, a key problem in the management of obesity is the maintenance of
reduced body weight and fat content following successful weight loss. How an individual
responses to changes of energy and nutrient status from fasting to refeeding may have
important long-term consequences with respect to the retention of body fat. Thus, the
effects of dietary calcium on prevention of weight regain needs to be explored.
Although the anti-obesity effects of dietary calcium are due, in part, to an
enhanced metabolic rate and thermogenic processes, it is also possible that a loss of
adipocytes would result in a deficit cells for lipid esterification as the body recovers from
energy restriction. Clinically, the duration of maintaining at a lower body weight after
dietary treatment of obese human seemed to be inversely proportional to the estimated
number of adipocytes in adipose tissue (19-20). Thus, there seems to be some association
with the severity of the obesity and with the cellular characteristics of adipose tissue.
Recent data indicate that [Ca2+]i may play a key role in modulating sensitivity to the
apoptotic stress (21). Several of the functional groups of molecules involved in apoptosis,
including caspases and the Bcl-2 family, are [Ca2+]i responsive (22-23). Given that
[Ca2+]i can be modulated by 1α, 25-(OH)2-D3, the role of 1α, 25-(OH)2-D3 in apoptosis
should be explored. In addition, UCP2 has been demonstrated to function as
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mitochondrial uncoupler of oxidative phosphorylation and thus reduce efficiency of ATP
synthesis. Consequently, it is reasonable to propose that UCP2 may stimulate apoptosis in
adipocytes. We have previously demonstrated that 1α, 25-(OH)2-D3 inhibits UCP2
expression in human adipocyte via a genomic mechanism (18), further implying that 1α,
25-(OH)2-D3 may play a role in adipocyte apoptosis. Although high doses of 1α, 25(OH)2-D3 have been reported to induce apoptosis in various tumor cells, the regulation of
apoptosis by physiological doses of 1α, 25-(OH)2-D3 remains unclear.
Accordingly, present studies expanded our previous observations by broadly
exploring the effect of dietary calcium on lipid metabolism and energy partitioning under
different nutritional status. I also investigated the direct effect and mechanisms of
mitochondrial uncoupling on lipogenesis and lipolysis as well as the role of [Ca2+]i in this
process. Finally, the effect and mechanism of 1α, 25-(OH)2-D3 and UCP2 on adipocyte
apoptosis were investigated in both in vivo and in vitro environments.

1.2 Obesity: General Aspects
1.2.1 Prevalence of Obesity
The prevalence of obesity in the United States has grown substantially over the
past decade. Currently, approximately 20% of males and 25% females are considered
obese based on a body mass index (BMI) of 30 or more. (24-28). Three percent of U.S.
adults have a BMI of 40 or more, equivalent to approximately 100 lbs overweight (24-26).
In 2000, approximately 44 million adults in the U.S. were overweight or obese, reflecting
5

an increase of 74 percent since 1991 (27). Overweight and obesity are significant and
growing problems in children as well. Over the past decade or so, the proportion of
children and adolescents who are overweight or obese in has increased significantly.
Results from the 1999-2000 National Health and Nutrition Examination Survey
(NHANES) (28), using measured heights and weights, indicate that an estimated 15
percent of children and adolescents ages 6-19 years are overweight, representing a 40
percent increase from the overweight estimates of 11 percent obtained from NHANES III
(1988-94) (29-30).
Overweight and obese individuals (BMI of 25 and above) are at increased risk for
physical ailments such as type II diabetes mellitus, insulin resistance/glucose intolerance,
heart disease and stroke, hypertension, cancer, obstructive sleep apnea, osteoarthritis, and
psychological disorders (31-32). Using relative hazards associated with elevated BMI in
six United States studies (Alameda Country Health Study, Framingham Heart Study,
Tecumseh Community Health Study, American Cancer Society Cancer protection Study
1, and Nurses Health Study,) the national distribution of adult BMI, and the estimates of
population size and total deaths from the same period, Mokdad et al calculated that the
annual number of deaths attributable to overweight in 2000 was over 490,000 (33).
Although obesity was rarely listed as the cause of death, it is now more frequently noted
as the associated comorbidity.
Overweight and obesity and their associated health problems have substantial
economic consequences for the U.S. health care system (34). The increasing prevalence
of overweight and obesity is associated with both direct and indirect costs. Direct health
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care costs refer to preventive, diagnostic, and treatment services related to overweight
and obesity (for example, physician visits and hospital and nursing home care). Indirect
costs refer to the value of wages lost by people unable to work because of illness or
disability, as well as the value of future earnings lost by premature death (35). In 1995,
the total (direct and indirect) costs attributable to obesity amounted to an estimated $99
billion (36-37). In 2000, the total cost of obesity was estimated to be $117 billion ($61
billion direct and $56 billion indirect) (36-37). Most of the cost associated with obesity is
due to type 2 diabetes, coronary heart disease, and hypertension (36-37).
1.2.2 Pathology of Obesity
1.2.2.1 Genetics of Obesity
Obesity is determined by genetic and environmental factors acting through the
physiological mediators of energy intake and energy expenditure. It is likely that genes
involved in weight gain increase the susceptibility of an individual to the development of
obesity when exposed to environmental conditions that favor a positive energy balance
(38).
Adoption, twin and family studies have shown that human obesity has a genetic
component (39-41). Body weight, however, is the archetypal polygenic trait, a
quantitative phenotype that usually fails to display a Mendelian pattern of inheritance
because it is influenced by many different loci, and this complex etiology makes the
search for obesity genes especially challenging (42). Until recently, the analysis of
candidate genes (known genes identified a priori on the basis of their effects in animal
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models or suspected physiological involvement in a particular disorder) was the primary
strategy used in the search for potential obesity genes (43-44). The ninth annual human
obesity gene map identifies more than 70 specific gene variants thought to cause a person
to become obese (45), including leptin gene and its receptor, pro-opiomelanocortine
(POMC), prohormone convertase 1 (PC1), mutations in the melanocortin receptor 4, and
more recently, lpin1. Genome scanning is an alternative but complex approach by
conducting linkage analysis using a series of anonymous polymorphisms over the entire
genome (46). This approach offers the potential of identifying genes previously
unsuspected of having an influence on the phenotype of interest. To date, the results of
two genome scans for obesity-related phenotypes have been reported, one in Mexican
Americans (47), and the other in Indians (48), but no obvious candidate genes have been
mapped to either chromosomal region. Results from reported genome-wide linkage
studies suggest that serum leptin levels are significant linked to chromosome 2p21 (49-51)
and this region of human chromosome 2 includes the POMC gene (52), in which loss-offunction mutations have been demonstrated as rare Mendelian causes of obesity in
humans. Other than the locus on 2p there are no other loci which have been highlighted
in more than one of the genome wide scans reported to date.

1.2.2.2 Endocrine Disorders of Obesity
Obesity is associated with multiple alterations in the endocrine system, including
abnormal circulating blood hormone concentrations, which can be due to changes in the
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pattern of their secretion and/or metabolism, altered hormone transport and/or action at
the level of target tissue. The following discussion focuses on cortisol, insulin and growth
hormone.
a.

Cortisol

Patients with Cushing's syndrome display a number of clinical features that
resemble those seen in patients with the metabolic syndrome (syndrome X) (53),
including abdominal obesity, insulin resistance, impaired glucose homeostasis,
hypertension, and lipid abnormalities. These similarities led to the hypothesis that a
dysregulation of the hypothalamic-pituitary adrenal (HPA) axis could potentially be a
cause for abdominal obesity and its different metabolic consequences. Adipose tissue is
involved in the metabolism of cortisol. The enzyme 11 beta-hydroxysteroid
dehydrogenase-1 (11β-HSD-1), which converts cortisone to cortisol, is expressed in
adipose tissue (54). It appears that in obesity more cortisol is derived from cortisone due
to the increased activity of this enzyme, which could simply be due to increased fat mass
(54). Urine studies in obesity also show an increase in the ratio of tetrahydrocortisol to
tetrahydrocortisone indicating a relative increase in the pathways leading to cortisol
formation (through the action of 11β-HSD-1) (55). Although the serum concentration of
cortisol and the 24 hour urine free cortisol excretion are essentially normal or slightly
elevated in obesity,, it is possible that there is an increase in the local production of
cortisol in the fat tissue and this in turn could lead to increased local action of cortisol
with the subsequent metabolic consequences known to occur in obesity. The cortisol
response to a variety of stimuli such as corticotropin releasing hormone (CRH), or meal
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ingestion is increased in obesity (56). An increase in cortisol response to ACTH has also
been seen in obese men and obese premenopausal women, but not in obese
postmenopausal women (57), indicating a possible role for estrogens in that response. A
decrease in the mineralocorticoid receptor response to circulating corticosteroids was
suggested by Jessop et al as an explanation for the decreased HPA axis to glucocorticoid
feedback in obesity (58).
b.

Insulin

Obesity is strongly associated with insulin resistance and is a risk factor for type 2
diabetes (59). Visceral abdominal fat is inversely correlated with insulin sensitivity, and
visceral hepatic glucose production and reduced peripheral glucose uptake are commonly
seen in abdominal obesity (60-61). Insulin levels are elevated in obese individuals and a
high correlation exists between insulin secretion and BMI (62). The hyperinsulinemia
seen in obese subjects is mainly due to increased insulin secretion. In some patients,
decreased insulin clearance can also contribute to the elevated insulin levels. When
impaired glucose tolerance develops, the insulin secretory dynamics are altered with a
progressive decrease in the ability of the pancreas to maintain normal glucose
homeostasis, initially in response to glucose load, and ultimately in the basal state.
The exact mechanism(s) by which obesity contributes to the development of
insulin resistance is the subject of extensive research. In human insulin resistance itself
and hyperinsulinemia can precede the development of obesity (63). Substances
originating in the adipose tissue and capable of exerting distant or local actions may
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explain the link between obesity and insulin resistance. Free fatty acids (FFA) are
released in excess by abdominal fat (64-66). Increased concentrations of FFA cause
insulin resistance and decreased glucose uptake by impairing insulin mediated glucose
transport. Impairment at the level of the insulin receptor and insulin receptor substrate-1
(IRS-1) are likely reasons for the impaired insulin mediated glucose uptake (67). Tumor
necrosis factor-alpha (TNF-α) is another potential link between obesity and insulin
resistance (68-69). TNF-α has been shown to alter basal and glucose stimulated insulin
secretion and to produce insulin resistance in isolated cell lines (70-71). Similar
conclusions can be drawn in regard to leptin. Leptin in vitro is capable of inhibiting
insulin release but its role in the pathogenesis of insulin resistance in humans has not
been confirmed (72). Resistin, a peptide isolated from the mouse, is produced by the
adipose tissue and its expression is decreased by peroxisome proliferator-activated
receptor gamma (PPARγ) agonists (73-74). Serum levels of resistin are elevated in obese
mice and immunoneutralization of this peptide improves insulin sensitivity in the mouse.
mRNA levels of resistin in freshly isolated human adipocytes are very low but the role of
resistin in human obesity and insulin resistance is unclear at this point. Ghrelin, a potent
growth hormone secretagogue, is produced mainly by the stomach. Administration of
ghrelin results in increased growth formone (GH) release, hyperglycemia, and decrease
insulin concentrations (75). Tschöp et al, found a negative correlation of circulating
ghrelin levels with insulin, leptin levels, and percent body fat (76). Thus, Ghrelin is yet
another peptide which may turn out to have a role in the pathogenesis of insulin
resistance accompanying obesity.
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c.

Growth Hormone

Obesity is typically accompanied by a decrease in GH levels and increase in
growth hormone binding protein (GHBP) levels (77-78). An inverse relation exists
between GH levels and percent fat mass. Another major determinant of GH level is age;
GH levels fall with increasing age and recombinant human growth hormone, rhGH, has
been studied as a supplement to counteract the effects of aging on body composition (79).
The reduction in GH levels in obesity is believed to result from decreased pituitary
release of the hormone. In animal models of genetic obesity there is a decrease in the
number of somatotroph cells in the pituitary gland. GH responses to a variety of stimuli,
including GHRH, arginine, and GHRPs (growth hormone releasing peptides) have been
shown to be reduced in obesity (80). Similarly it has been found that GHBP levels are
increased in obesity, suggesting a negative feedback mechanism on GH secretion. Other
possible mechanisms included in the altered GH response in obesity are FFA and leptin,
both of which are increased in obesity (81-82). Lee et al, showed that reduction in free
fatty acids concentrations in obese subjects through use of Acipimox leads to increased
GH response to GH-releasing hormone. In animals, leptin has an inhibitory role on GH
secretion from the pituitary gland through its effects on GHRH and neuropeptid Y (NPY)
at the hypothalamus level.
Most of GH promoting effects are mediated by insulin- like growth factor-1 (IGF1). GH also has effects independent of IGF-1. Serum IGF-1 concentration represents the
most accurate reflection of growth hormone biologic activity (83). In spite of the reduced
GH levels seen in obesity, IGF-1 levels do not appear to be significantly different
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between obese and non obese subjects (84). Individuals with visceral obesity, even in the
absence of total body obesity, may, on the other hand, have lower IGF-1 levels than
comparable individuals with no abdominal obesity. The serum concentration of unbound
or free IGF-1 is increased in obese subjects (85). Similarly it has been found that GHBP
levels are increased in obesity. This suggests that lower levels of GH are accompanied by
increased peripheral sensitivity to GH accounting for the normal IGF-1 levels. Insulin
could result in increased peripheral sensitivity to GH, reduced IGFBP-1 levels and
increased (to within normal range) IGF-1 in spite of decreased GH secretion by the
somatotroph (86). High free IGF-1 levels in this case exert a negative feedback
mechanism on GH secretion. This hypothesis supports a peripheral rather than a central
mechanism by which GH release is decreased in obesity.
1.2.3 Dietary Management of Obesity
Obesity results from the accumulation of excessive calories as body fat.
Accordingly, the goal for dietary management of obesity is to reduce calorie intake from
diet. In addition, once the obese individual has lost body fat, this healthier weight must be
maintained. Thus the energy deficit phase must be followed by a weight maintenance
phase. Paradoxically, the slimmer individual's energy needs are lower to stay in energy
balance than they were prior to weight reduction (87-89). The primary reason for this is
that some loss of lean as well as fat tissue inevitably occurs on reducing diets. Thus
metabolically active tissue is reduced and resting metabolism is decreased. Also, it takes
less effort to move the lighter body, and the energy cost of physical activity is thus
reduced. The implications are that a slight decrease in energy intake from prior levels and
13

an increase in energy output will be necessary during weight maintenance. Thus there is a
need for continued attention to these factors on the part of the physician and patient. All
too often the weight maintenance phase is neglected or ignored, and weight is regained
over the long term. Although the macronutrient composition of the diet does not appear
to play a major role in overall weight loss, there is much interest in the macronutrient
composition of reducing diets, as discussed in the next section (90).
1.2.3.1 Dietary Fat
Balanced deficit weight reduction diets that are moderate to low in fat (20-30%
calories) are so called because maintain a reasonable balance between macronutrients
similar to that recommended in the Food Group Pyramid and the Dietary Guidelines for
Americans (91). The introduction of low-fat diets (<30% fat calories) for the prevention
and treatment of obesity was based on the link established between dietary fat and body
fatness. Observational and mechanistic studies show that because fat possesses a lower
satiating power than carbohydrate and protein, a diet rich in fat can increase energy
intake (92-93). The propensity to gain weight is enhanced in susceptible persons,
particularly sedentary people who have a genetic predisposition to obesity. On the other
hand, empirical evidence from dietary intervention trial shows that increase in
carbohydrate: fat ratio achieved by low fat intervention is effective in producing
spontaneous weight loss (94). Meta-analyses of weight change occurring on ad libitum
low-fat diets in intervention trials consistently demonstrate a highly significant weight
loss of in normal-weight and overweight subjects (95). Very low fat diets (<10% fat
calories) such as the Pritikin diet (96) and the Ornish diet (97), are advocated not only for
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weight reduction but also for improving cardiovascular risk profiles. The Ornish diet,
which is very low in fat (13% of calories) and saturated fat, very high in carbohydrate
(81% of calories) and very high in fiber (38 gm) with a program that includes
nonsmoking, exercise and behavior modification was shown to reduce some
cardiovascular risk factors in a limited long term study. However, whether the percentage
of dietary fat in diet plays an important role in the rising prevalence of overweight and its
treatment has been repeatedly debated in recent years. Willett has argued that there is no
evidence that energy density has an important role on long-term weight control and thus
that the importance of fat-restriction in dietary treatment is unproven (98).
Even on reducing diets, needs for small amounts (e.g. 3-6 gm) of essential fatty
acid (linoleic or arachidonic acid) are present, and some fat is also necessary as a carrier
for the fat-soluble vitamins (99). Therefore the diet should not be devoid of fat. However,
because fat is calorically dense, it is usually decreased to increase bulk and reduce energy.
High fat reducing diets (55-65%) are usually also low or very low in carbohydrate
(<200 gm carbohydrate per day) (100). There is some evidence that free-living
overweight people who self-select high fat low carbohydrate diets which they eat ad
libitum consume fewer calories and lose weight. Also overweight people who consume
such diets under experimental conditions lose weight. When high fat low carbohydrate
reducing diets are fed they also tend to cause ketosis. They may also result in decreased
blood lipids, decreased blood glucose and insulin and decreased blood pressure, but only
if weight is lost. Over the short term (a few days or a week) high fat, low carbohydrate,
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ketogenic diets cause a greater loss of body water than body fat, but water balance is
restored when carbohydrate levels increase or when the diet ends (101).
1.2.3.2. Dietary Carbohydrate
Carbohydrate needs are at least 50 gm per day. At least 100 gm carbohydrate, and
preferably 55% or more of total energy intake should be provided for diets that are over
800 kcal per day (91). On reducing diets under experimental conditions with equicaloric
reducing diets, both diets very high in sugars and diets very high in complex
carbohydrates as starch have similar effects in bringing about weight loss (102). However,
from the practical standpoint, since many products that are high in sugar are also high in
fat and calories, sugars are usually limited on reducing diets.
Low-carbohydrate diets (<100mg carbohydrate) may be accompanied by greater
weight loss than other diets and this concept is supported by recent evidence. A recent
comparison of a low carbohydrate diet with a low fat diet in patients with severe obesity
found that patients on the low carbohydrate diet lost more weight than patients on a
calorie-restricted, fat-restricted diet, and had greater improvement in insulin sensitivity
and triglyceride levels (103). A second study also found a similarly greater weight loss
using a low carbohydrate diet without adverse effects on lipids, glucose, or insulin (104).
Both diets are associated with reduced caloric consumption. Futhermore, Foster et al
compared a low-carbohydrate, high-protein, high-fat diet with a low-calorie, highcarbohydrate, low-fat (conventional) diet in a recent clinical trial and they demonstrated
that the low-carbohydrate diet produced a greater weight loss than did the conventional
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diet for the first six months (105). In addition, the low-carbohydrate diet was associated
with a greater improvement in some risk factors for coronary heart disease. However,
these studies were conducted in a relatively short period of time and longer and larger
studies are required to determine the long-term safety and efficiency of low carbohydrate
diets.
Notably, the effect of low carbohydrate diets in promoting weight loss may be
partially attributable to the loss of water. Glycogen is hydrated with 2 to 3 grams of water
per gram of glycogen, while fat stores contain only 0.5 grams of water per gram of fat.
Thus, high fat, low-carbohydrate diets deplete muscle and liver glycogen stores rapidly
and facilitate rapid weight (water) loss (101). Also, some low carbohydrate diets are
ketogenic and may lead to excessive protein breakdown to maintain blood glucose levels
unless protein intakes are increased. When the body must rely on degradation of protein's
carbon skeletons to preserve blood glucose levels (via gluconeogenesis), the catabolism
of the protein is accompanied by loss of water. For every gram of protein (or glycogen)
that is broken down, 3 grams of water are released, causing rapid weight loss but also a
state of relative dehydration. This rapid weight loss may contribute to the popularity of
very low carbohydrate diets. Furthermore, initial weight loss on low carbohydrate diets
may be enhanced by an exaggerated diuresis related to decreased postprandial serum
insulin levels. Insulin promotes water retention through its antinatriuretic effects. Some
behavioral impact also contributes to the effect of weight loss. When individuals commit
themselves to a weight-loss program, they change usual patterns of eating and commit
themselves to paying attention to what they eat and avoiding unplanned eating episodes,
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and thereby decrease energy intake. Furthermore, although such diets produce rapid
weight loss due to polyuria in the short run, refeeding carbohydrates causes water
retention and weight gain (101). The effect low carbohydrate diets on blood cholesterol
remains controversial. A study conducted by LaRosa and colleagues examined the effect
of lipid changes after following the Atkins low-carbohydrate, high-fat diet for four weeks
(106). Despite a weight loss, total cholesterol insignificantly increased. Significant
changes in LDL cholesterol triglycerides, free fatty acids and uric acid were seen.
However, some evidence exhibited an opposite effect (107-108), with low carbohydrate
diets decreasing blood cholesterol.
The glycemic index (GI) is a dietary concept, originally developed for the therapy
of diabetes, which has recently become popular in weight management. The GI is a
property that describes the blood glucose response resulting from consumption of a
defined amount of carbohydrate (usually 50 grams) from a given food, relative to the
same amount of carbohydrate from a control food (usually white bread) (109). The basic
premise is that more moderate blood glucose and metabolic responses will sustain satiety
and energy balance to a greater extent than would larger metabolic shifts over the course
of the day (110). Physiological studies demonstrate that consumption of high GI meals
induce a sequence of hormonal changes that limit availability of metabolic fuels in the
postprandial period and cause overeating. Short-term feeding studies consistently show
less satiety or greater voluntary energy intake after consumption of high compared to low
GI meals (111). However, it is still unclear if the glycemic index offers sustained
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advantages to patients in planning menus and in learning to control food intake compared
to other weight reduction methods.
1.2.3.3. Dietary Protein
The Recommended Dietary Allowance for protein is 0.8 gm/kg/day, but most
Americans eat approximately 15% of their total caloric intake from protein, or about 1.2
gm/kg per day (91). Protein requirements do not decline and may actually rise on
hypocaloric diets, and especially on low carbohydrate diets, when protein needs sharply
increase above the levels needed for energy balance. When energy intakes are insufficient,
some amino acids are used to maintain blood glucose levels and others must be used for
energy, so overall protein requirements increase (112). High protein reducing diets are
those that provide more than 1.6 gm/kg/ideal body weight per day. Self-prescribed high
protein reducing diets varying in their composition from about 28-65% of energy,
providing 71-162 gm of protein per day, are currently popular as a strategy for losing
weight. They are usually quite low in their carbohydrate content (113). High protein diets
have been demonstrated to induce successful weight loss and other beneficial effects
(114-115).
There is emerging evidence that additional metabolic roles for some amino acids
require plasma intracellular levels above minimum needs for protein synthesis. Branched
chain amino acids (leucine, isoleucine, and valine), or BCAA's, are a group of essential
amino acids that play important roles in protein synthesis and energy production. In
humans, about 15-25% of total protein intake is BCAA's, and dairy products are
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particularly high in them (116). BCAA's make up 35-40% of the essential amino acids in
body protein and 14% of the total amino acids in skeletal muscle (117). One of the most
important BCAA's is leucine and estimates of dietary requirements for leucine range
from 1-12 g daily (118). Leucine stimulates skeletal muscle protein synthesis through
multiple independent mechanisms, including increasing insulin secretion as well as
stimulating mammalian target of rapamycin (mTOR) pathways (119-120). However, the
potential to participate in these additional metabolic processes of leucine is limited by its
availability and the first priority being provided to new protein synthesis (121).
Accordingly, only diets that provide BCAAs in general, and leucine specifically, at levels
that exceed requirements for protein synthesis can fully support the intracellular leucine
concentrations

required

to

support

additional

signaling

pathways

(122-124).

Consequently, the abundance of leucine in diet is of particular interest because it plays a
distinct role in protein metabolism and plays a pivotal role in the translation initiation of
protein synthesis.
However, whether a high protein diet is a safe approach for obesity management
is questionable. Many of these diets advocate very high intakes of protein from meat and
other foods that are also often high in saturated fat, cholesterol and sodium while they are
low in dietary fiber, potassium, calcium, and magnesium, increasing cardiovascular risk
(125). The purine content of meat, poultry, seafood, egg, seeds and nuts is high and
increases uric acid levels and risk of gout in susceptible persons. The effect of dietary
protein on calcium absorption remains controversial. Some studies demonstrate that high
protein load may increase urinary calcium loss if it is not buffered (126-127) while
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clinical trial conducted by Heaney suggests that dietary protein exerts no effect on
calcium absorption (128).
1.2.3.4 Dietary Calories
Low calorie diets of 1000-1200 calories for women and 1200-1600 calories per
day for men are currently recommended by the National Institutes of Health for weight
loss in most individuals (129). The rationale is that on such regimens a deficit of
approximately 500-1000 Calories per day will be created, which should result in slow,
progressive weight loss of 1-2 pounds per week. The dietary composition is similar in
macronutrients to that of the National Heart, Lung and Blood Institute's (NHLBI) Step 1
diet to decrease risks of high blood cholesterol and blood pressure. The National Institute
of Health's Obesity Initiative recently sponsored an evidence-based review of low calorie
diets. It found that on the average diets such as these reduced body weight by an average
of 8% over 3-12 months of treatment, and that the losses were accompanied by decreases
in abdominal fat (129).

1.3 Role of Intracellular Calcium in Obesity
1.3.1 Mouse Agouti and Obesity
Agouti originally referred to the wild-type pigmentation pattern of mouse hair,
with a predominately black hair shaft with a subapical yellow segment (130). The mouse
agouti gene, mapped to chromosome 2, encodes a 131 amino acid paracrine molecule that
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is secreted from cells of the hair follicle (131-132). Agouti protein functions as a
competitive antagonist of α-melanocyte-stimulating-hormone (α-MSH) binding to the
melanocaortin-1 receptor (MC-1R), causing melanocytes to switch from the synthesis of
black pigment (eumelanin) to yellow pigment (phaeomelanin), which in turn results in
the characteristic pigmentation pattern of wild-type mice (133). However, in the absence
of α-MSH, agouti also affects basal melanogenesis of melanoma cells in culture,
suggesting that agouti may have an additional physiological function (134). The human
homolog of the agouti gene is 85% identical to the mouse gene and encodes a protein of
132 amino acids with a consensus signal peptide (135). The major difference between
mouse and human agouti is the expression pattern. Whereas mouse agouti is only
transiently expressed in the hair follicle during neonatal development, human agouti is
expressed in diverse tissues; primarily adipose tissue followed by the testis, heart, liver,
kidney, ovary, and foreskin.
Dominant mutations in the mouse agouti gene confer a pleiotropic syndrome
characterized by obesity, mild hyperphagia, decreased thermogenesis, hyperinsulinemia,
peripheral insulin resistance, impaired glucose tolerance, hyperglycemia, increased
susceptibility to cancer and yellow hair (136). Molecular analysis of six dominant agouti
alleles (Ay, Asy, Avy, Aiapy, Ahvy and Aiy) demonstrated that mutations in promoter regions
result in ubiquitous expression of normal agouti protein (137-140). Expressing the wildtype agouti cDNA under the control of a ubiquitous promoter in mice resulted in the
dominant obesity syndrome, indicating ectopic overexpression of the wild-type agouti
gene is the cause of the obesity syndrome.
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The actual mechanism whereby the ubiquitous expression of agouti causes yellow
obese syndrome is not clear yet and both peripheral and central mechanism have been
proposed.
Ectopic expression of agouti may antagonize signal transduction cascades that are
mediated by melanocortin receptors present in tissues other than the skin (141). Agouti
modulation of pigmentation is mediated by MC-1R (142), which is primarily expressed
in melanocytes, leading to the hypothesis that melanocortin receptor antagonism may be
responsible for the metabolic effects of agouti in yellow obese syndrome. Four other
melanocortin receptors have been cloned: MC-2R is expressed in the adrenal cortex and
adipose tissue (143); MC-3R is expressed in the hypothalamus and limbic systems in the
brain (143), and in the placenta and gut; MC-4R is expressed throughout the brain (144),
and MC-5R is ubiquitously expressed (145). To test the hypothesis that agouti protein
may antagonize these other melanocortin receptors, the receptors were expressed in
human embryonic kidney cells and the ability of recombinant agouti protein to
antagonize alpha-melanocyte stimulating hormone (alpha-MSH) signaling was
determined by assaying for adenylyl cyclase activity (133). These experiments
demonstrated that the agouti protein is a high affinity antagonist of MC-1R, MC-2R and
MC-4R, but not of MC-3R or MC-5R. However, only disruption of MC-4R results in an
obesity syndrome that is markedly similar to that seen in mice with dominant agouti locus
mutations, suggesting that chronic antagonism of MC-4R by the agouti protein may be a
central mechanism of the agouti-induced obesity syndrome (146).
Recent studies demonstrate that melanocortin/MC-4R signaling play a key role in
the regulation of food intake and energy homostatsis (147). MC-4R is abundantly
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expressed in hypothalamic paraventricular nucleus (PVN), dorsomedial nucleus and
veentromedial nucleus, which are major hypothalamic regions involved in regulating feed
behavior, body weight and energy homeostasis (148). The importance of the central
melanocortin system in the regulation of energy balance is highlighted by studies in
transgenic animals and humans with defects in this system. Mice with a targeted
disruption of MC-4R exhibit an obesity syndrome that is remarkably similar to that seen
in mice with dominant agouti mutations, suggesting that chronic antagonism of MC-4R
by the agouti protein may be a central mechanism of the agouti-induced obesity
syndrome (146). In addition, agonist of MC-4R was shown to inhibit feeding in Ay/a mice,
whereas a melanocortin antagonist stimulated feeding (149). Furthermore, diet-induced
obesity in mice causes a down regulation of MC-4R while food restriction up-regulates
its expression (150). In humans, the obesity phenotype, including BMI, fat mass and
body fat content was highly associated with restriction fragment polymorphisms of MC4R in the Quebec family study (151). In addition, mutations in MC-4R gene have been
identified in severely obese human subjects (152). These recent experiments strongly
support a role for neural melanocortin receptor(s) in regulating nutrient intake and energy
balance;
Although agouti is not normally expressed in the central nervous system, the
melanocortin system may modulate energy homeostasis through the actions of two other
endogenous antagonist agouti related protein (AGRP) and α-MSH, POMC cleavage
product (153). POMC is expressed at only two locations in the brain: the arcuate nucleus
of the hypothalamus (ARC) and the nucleus of the tractus solitarius (NTS) of the
brainstem. AGRP has been identified primarily in the arcuate nucleus of the
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hypothalamus of the rat and primate with neuronal projections to the paraventricular
hypothalamic nucleus (154). AGRP exhibits high degree of homology to agouti, with the
highest degree of identity in the cysteine-rich carboxyl terminus (155). The AGRP
protein was demonstrated pharmacologically to competitively antagonize the MC-3R and
MC-4R brain melanocortin receptors, and when ectopically expressed or Central Nervous
System administration, resulted in an obese phenotype (156-157). AGRP is co-localized
in NPY containing neurons, and when administered centrally to NPY-/- knockout mice,
results in increased food intake (158). α-MSH is the endogenous ligand for MC-4R.
Previous studies demonstrate that MC-4R agonists or antagonists suppressed or
stimulated food intake, respectively. It has been shown that the blockade of MC-4R due
to the ectopic expression of agouti protein or the overexpression of AGRP induces
hyperphagia and obesity. The MC-4R and POMC knockout mice also express an obese
phenotype (159). Thus, the importance of the melanocortin system in the regulation of
feeding behavior and body weight is generally accepted.
Agouti also appears to exert significant peripheral effects by targeting ion
channels, thereby causing an increase in intracellular free calcium ([Ca2+]i) in multiple
peripheral tissues, particularly in adipose tissue and pancreatic β cells (160-161).
Agouti protein contains a cysteine-rich carboxyl terminus, with the number and
spacing of cysteine residues are extremely similar to those of toxins from snails (ωconotoxins) and spiders (plectoxins) that are known to function by targeting ion channels
(162-163). This cysteine-rich terminus appears to have functional activity equivalent to
the full-length agouti. Analysis of the three-dimensional structure formed by the Cterminus of the agouti protein also showed a high similarity to those toxins (164).
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Furthermore, recombinant agouti protein stimulates a significant increase in [Ca2+]i
influx in skeletal muscle myocytes and adipocytes and this effect was not mediated by
antagonizing MC-R, indicating a direct targeting of Ca2+ channel (160).
1.3.2 Intracellular Calcium and Obesity Related Metabolic Disorder
Agouti protein appears to stimulate lipogenesis in adipocytes (165). The mRNA
levels of fatty acid synthase (FAS) and stearoyl-CoA desaturase (SCD), two key enzymes
in de novo fatty acid synthesis and desaturation respectively, were dramatically increased
in obese (Avy) mice relative to lean (a/a) controls. Treatment of adipocytes with
recombinant agouti protein in vitro increased FAS and SCD expression and activity.
Strong correlation between the degree of agouti expression and both [Ca2+]i levels and
body weight have been demonstrated in mice, indicating that agouti may modulate
adiposity via a [Ca2+.]i dependent mechanism (166). Humans also have an agouti gene,
and the mouse and human agouti proteins are 87% identical over the cysteine rich Cterminus, suggesting that agouti may be functionally similar in both species. Unlike the
mouse, however, the human agouti gene is normally expressed primarily in adipose tissue.
The presence of human agouti in adipose tissue is intriguing in light of the fact that
recombinant murine agouti protein not only causes an increase in [Ca2+]i in cultured
adipocytes, but also increases fatty acid synthase expression and activity, and stimulates
the accumulation of triglycerides in a [Ca2+]i-dependent manner. Claycombe et al.
reported that FAS promoter contains an agouti response element that also responds to
KCl, a membrane depolarization agent (167). Furthermore, calcium channel inhibition
results in significant decreases in adipose tissue mass and adipocyte lipogenesis in obese
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transgenic mice that express the agouti gene in a ubiquitous manner (168). Moreover, the
human adipocyte agouti is up-regulated during differentiation (169). In addition, agouti
expression is highly correlated with FAS expression and activity in human adipose tissue
which stimulates Ca2+ influx (167). These results indicate that the agouti protein may
regulate fatty acid metabolism by acting directly on adipose tissue.
Agouti protein also plays a role in regulation of lipolysis via a Ca2+ dependent
mechanism (170-171). Recombinant agouti protein inhibits both basal and agonist
stimulated lipolysis in human adipocytes. Increasing Ca2+ influx through either voltageor receptor-operated Ca2+ channels also inhibits lipolysis and this effect is blocked by
Ca2+ channel antagonists, indicating that this anti-lipolytic effect is mediated by calcium
signaling. The mechanism underlying the anti-lipolytic effect of Ca2+ has recently been
demonstrated to be mediated by increased activation of phosphodiesterase 3B, resulting
in reduced cAMP levels and consequently, inhibition of hormone sensitive lipase activity.
However, considerable species variability exists in the lipolytic response to
melanocortins (172). Recent studies suggested that agouti may also inhibit lipolysis by
antagonisting ACTH. ACTH and

-MSH are potent lipolytic hormones (173). The

adipocyte MC-2R exhibits properties similar to the adrenocortiacal ACTH receptor and
couples to activation of adenylyl cyclase (174-175). Both ACTH and -MSH bind to
mouse adipocytes, but only ACTH elevates cAMP and stimulates lypolysis. Therefore,
agouti antagonism of ACTH to adipocytes may lead to an inhibition of lipolysis and/or
stimulation of lipogenesis.
Insulin resistance is of major pathogenic importance in several common human
disorders, including type 2 diabetes and obesity. The human homologue of agouti is
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expressed in both adipose tissue and pancreas, and may therefore exert important
peripheral effects. Administration of AGRP caused significant increases in plasma insulin
concentrations and fat pad mass, and transgenic mice expressing agouti exhibited
hyperinsulinemia and hyperglycemia (176), indicating an interaction between insulin and
agouti-induced obesity syndrome. Since agouti stimulates Ca2+ in several cell types and
Ca2+ is the proximal signal for insulin release, it is possible that agouti may exert effect
on pancreatic β-cells to modulate Ca2+ signaling and stimulates Ca2+ release. Indeed,
agouti is expressed in pancreas and potently stimulates insulin release via a Ca2+
dependent mechanism (177).
One of the potential factors that may account for or contribute to insulin
resistance is a sustained high level of [Ca2+]i in the insulin target cells. Draznin et al
demonstrated an optimal range of [Ca2+]i for the stimulatory effect of insulin on glucose
transport in isolated rat adipocytes, with the levels beyond this range causing marked
decrease in insulin sensitivity (178). Similarly, elevations of [Ca2+]i induced by
incubation of adipocytes with depolarizing concentrations of K+ or parathyroid hormone
resulted in diminished cellular responsiveness to insulin (179). High levels of the steady
state [Ca2+]i have been observed in adipocytes of patients with obesity, type 2 diabetes,
skeletal muscles of agouti rats, and hepatocytes of diabetic rats (180), and an inverse
correlation between the whole body insulin sensitivity and the [Ca2+]i of peripheral blood
cells has been observed in human studies (181). It has been postulated that high [Ca2+]i in
the insulin target cells may diminish cellular responsiveness to insulin and thus contribute
to the development of insulin resistance (182). The mechanism whereby the high levels
of [Ca2+]i interfere with insulin action on glucose metabolism remains largely unknown.
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Insulin-receptor binding is not affected, and receptor tyrosine kinase activity is only
minimally affected. Recruitment of glucose transporter, glucose transporter (GLUT) 4, is
also not influenced. Begum et al have demonstrated in isolated rat adipocytes that an
elevation in [Ca2+]i induces inhibition of phosphoserine phosphatase activity through an
activation of inhibitor 1 (183). Accordingly, sustained elevations in [Ca2+]i may result in
insulin resistance by preventing dephosphorylation of insulin-sensitive target protein(s)
within the cell. Reduction in insulin-induced dephosphorylation of glycogen synthase and
GLUT4 supports this possibility (184-185).
Alemzadeh et al. have reported that diazoxide, a drug that activates the ß cell
KATP channel and subsequently reduces [Ca2+]i and inhibits insulin release, exerts an
antiobesity effect in obese Zucker rats and hyperinsulinemic obese adults (186-187).
Sulfonylureas such as glibenclamide are insulin secretagogues widely used to stimulate
insulin secretion in the treatment of non-insulin-dependent diabetes mellitus.
Sulfonylurea interact with specific, high affinity receptors (SUR) on the pancreatic betacell to close ATP-sensitive K+ channels, depolarize the cell, activate Ca2+ influx through
voltage-dependent Ca2+ channels, and trigger insulin secretion (188). SUR agonists also
been demonstrated to exert direct effects on adipocytes. Draznin et al. reported that
glibenclamide increased [Ca2+]i in isolated rat adipocytes by promoting Ca2+ influx
through voltage-dependent Ca2+ channels, while this effect was blocked by a Ca2+
channels antagonist (182). Moreover, glibenclamide has been reported to potentate
peripheral insulin effects in isolated adipocytes (189). Consistent with this, human
adipocytes express SUR and exhibit a glibenclamide dose-responsive increase in [Ca2+]i
(190). Moreover, glibenclamide exerts lipogenic and antilipolytic effects in human
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adipocytes, whereas diazoxide completely blunts each of these effects. These data
demonstrate that SUR in adipocyte regulates [Ca2+]i and thereby exerts coordinated
control over lipogenesis and lipolysis (190).
Agouti may also participate in the regulation of adipogenesis. Mynatt et al
demonstrated substantial increases in PPAR-γ and signal transducer and activators of
transcription (STATs) expression in the fat pads of the aP2-agouti mice and in cultured
adipocytes that have been exposed to recombinant agouti protein (191-192). The major
transcription factors involved in adipocyte gene regulation include PPARγ, proteins
belonging to the CCAAT/enhancer-binding protein (CEBP) family, and adipocyte
determination and differentiation dependent factor 1, also known as sterol regulatory
element binding protein (193). Recent studies have also suggested that the STAT family
of transcription factors may also be important in fat cells (194). A STAT family member
shows a distinct pattern of activation by cytokines and, upon nuclear translocation, can
regulate the transcription of particular genes in cell- or tissue-specific manners. In fat
cells, the expression of STAT1, STAT5A, and STAT5B is highly induced during
differentiation and correlates with lipid accumulation. Agouti-induced regulation of
STAT1, STAT3, and PPAR-γ expression results in the regulation of various genes
associated with the adipocyte phenotype. [Ca2+]i also plays a regulatory role in
adipogenesis. [Ca2+]i appears to promote and accelerate preadipocyte differentiation
program(s), thereby inducing the adipocyte phenotype in the late stage of differentiation
(195-196). To achieve this, increasing [Ca2+]i causes a marked increase in the expression
of PPAR-γ, and subsequently accelerates adipocyte differentiation by directly acting
upon and eliciting late differentiation gene expression, such as aP2, steroyl-CoA
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desaturase (SCD-1), phosphoenolpyruvate carboxykinase (PEPCK), and FAS. On the
other hand, in late differentiation, preadipocytes become more committed to terminal
differentiation after the expression of several critical differentiation transcriptional factors,
such as CCAAT/enhancer binding protein beta and delta (C/EBP-ß and C/EBP-δ),
PPARγ, and sterol regulatory element binding protein-1/adipocyte determination and
differentiation factor-1 (SREBP-1/ADD-1). [Ca2+]i may synergize with these
transcriptional factors to promote the differentiation program by stimulating late
differentiation gene expression.
1.3.3 Dietary Calcium and Obesity
1.3.3.1 Dietary Calcium Intake and Obesity
Human studies show an inverse association between calcium intake and body
weight, body fat and the risk of becoming obese (197). The US Department of
Agriculture’s Nationwide Food Consumption Survey from 1987 to 1988 showed that the
average dietary calcium intake in the United States was far below the suggested optimal
calcium intake, and that persons with the lowest calcium intakes tended to have the
highest body weight (198-199). When stratified by ethnic group, the non-Hispanic black
population, which has one of the highest prevalence of obesity in the United States, was
also found to have a lower mean daily calcium intake than either the Hispanic white
population or the non-Hispanic white population. Using data from the first National
Health and Nutrition Examination Survey (NHANES I), McCarron found a statistically
significant inverse association between calcium intake and body weight (199). More
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recently, Zemel et al demonstrated a strong inverse association between the relative risk
of obesity and calcium intake for participants of NHANES III (200). The relative risk of
high body adiposity was found to be greatest in those with the lowest calcium intake and
was progressively lower as calcium intake increased. Animal models have provided
mechanistic insight as to how low calcium intakes could influence body fat stores.
Studies in the 1980s in spontaneous hypertensive rats found a lower net weight gain in
the rats fed a high-calcium diet than in the rats fed a low-calcium diet, respectively (201).
Shortly afterward, it was observed that diets high in both dietary calcium and sodium
induced favorable changes in the total body fat content of spontaneous hypertensive rats
and Wistar-Kyoto rats (202). More recently, we studied transgenic mice that
overexpression agouti gene, specifically in adipocytes under the control of the aP2
promoter. We examined the effects of various calcium intakes on weight gain and
acceleration of weight loss over 6 wk. Weight gain and fat-pad mass on obesitypromoting diets were significantly reduced by high calcium diets, and high calcium also
promoted weight loss during energy restriction (200). These data suggest that, an increase
in dietary calcium decreases body weight gain during ad libitum and accelerates weight
loss during energy restriction.
1.3.3.2 Mechanism of Dietary Calcium Intake in Regulation of Obesity
a. Dietary Calcium, 1, 25-(OH)2-D3 and Intracellular Calcium
Dietary calcium supplementation has been reported to decrease the [Ca2+]i
concentration in various cell types in rodents and human (203-204). Calcium supplements
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significantly increased the cell Ca-ATPase activity and decreased intracellular Na+
concentration (205-206). The decrease in Na+ results in an increased driving force for
Na+-Ca2+ and Na+-H+ exchange mechanisms, which have a central role in controlling the
[Ca2+]i level, and consequently reduce reduced free cytosolic Ca2+ concentration(207).
Dietary calcium reduces parathyroid secretion of parathyroid hormone (PTH) and
renal production of 1, 25-dihydroxyvitamin D3 (1, 25-(OH)2-D3). Petrov et al demonstrate
that oral calcium supplementation in man causes a reduction in plasma concentration of
PTH and 1, 25-(OH)2-D3 (208). According to Basile et al, increasing dietary calcium
intake increases urinary calcium excretion and reduces plasma 1, 25-(OH)2-D3, but total
and ionized serum Ca2+ and plasma 25-(OH)-D3 are unchanged (209). 1, 25-(OH)2-D3
also increases radio-labeled calcium uptake in various cell types. Accordingly, the
decrease in [Ca2+]i observed after dietary calcium supplement could be attributable to a
reduced cellular influx of Ca2+, resulting from suppression of circulating levels of 1, 25(OH)2-D3 and/or PTH. Indeed, 1, 25-(OH)2-D3 and PTH have both been shown to
stimulate a significant and sustained increase in [Ca2+]i concentrations in primary
cultures of adipocytes (210-211). Data from our laboratory recently demonstrated that 1α,
25-(OH)2-D3 increased [Ca2+]i whereas the specific membrane vitamin D receptor
antagonist 1ß-hydroxyvitamin D3 blocked vitamin D–stimulated increases in [Ca2+]i
(212), indicating that a non-genomic actions of 1α, 25-(OH)2-D3 via a putative membrane
vitamin D receptor plays a significant role in 1, 25-(OH)2-D3–induced increases in [Ca2+]i.
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b. Intracellular Calcium and Adipocyte Lipid Metabolism
High-calcium diets attenuate adipocyte lipid accretion and weight gain during
overconsumption of an energy-dense diet and increase lipolysis and preserve
thermogenesis during caloric restriction, thereby markedly accelerating weight loss (1516). Previous studies of the agouti gene demonstrate a key role for intracellular Ca2+ in
regulating adipocyte lipid metabolism and TG storage (213). The role of the increased
[Ca2+]i in stimulation of lipogenesis has been explored using fatty acid synthase, a key
enzyme of de novo lipogenesis (166-167). An agouti/Ca2+ response sequence has been
mapped to the -435 to -415 region of the FAS promoter and this sequence is upstream of
insulin response element. This location consistent with the observed additive effects of
agouti and insulin on FAS gene transcription (166, 214). Increasing [Ca2+]i in adipocytes
via either receptor- or voltage-mediated Ca2+ channel activation stimulated FAS gene and
expression and consequently resulted in stimulation of FAS activity. In contrast, [Ca2+]i
influx inhibition by a Ca2+ channel antagonist suppressed lipogenesis, indicating that
[Ca2+]i stimulates lipogenesis directly. In addition to activating lipogenesis, recent data
also indicate that increasing [Ca2+]i also contributes to increased triglyceride stores by
inhibiting lipolysis (170) as reviewed in the previous section.
Animal studies using aP2 transgenic mice confirmed these observations in vivo.
We recently demonstrated that the increased calcitriol produced in response to lowcalcium diets stimulates adipocyte Ca2+ influx and, consequently, promotes adiposity by
both inhibiting lipolysis and stimulating lipogenesis. Accordingly, suppressing calcitriol
levels by increasing dietary calcium is an attractive target for obesity interventions (1534

16). In support of this concept, transgenic mice expressing the agouti gene specifically in
adipocytes (a human-like pattern) respond to low-calcium diets with accelerated weight
gain and fat accretion, whereas high-calcium diets markedly inhibit lipogenesis,
accelerate lipolysis, increase thermogenesis, and suppress fat accretion and weight gain in
animals maintained at identical caloric intakes (15). Further, low-calcium diets impede
body fat loss whereas high-calcium diets markedly accelerate fat loss in transgenic mice
subjected to caloric restriction (16). Dairy sources of calcium exert markedly greater
effects in attenuating weight and fat gain and accelerating fat loss. This augmented effect
of dairy products is likely due to additional bioactive compounds in dairy that act
synergistically with calcium to attenuate adiposity (215). These concepts are confirmed
by both epidemiological and clinical data (216-217), which demonstrate that increasing
dietary calcium results in significant reductions in adipose tissue mass in obese humans
in the absence of caloric restriction and markedly accelerates the weight and body fat loss
secondary to caloric restriction, whereas dairy products exert significantly greater effects.
c. 1 α, 25-(OH)2-D3 and Adipocyte Energy Homeostasis
1α, 25-(OH)2-D3 appears to play an important role in modulating adipocyte lipid
metabolism and energy homeostasis via both genomic and non-genomic actions. 1α, 25(OH)2-D3 generates rapid, non-genomic signal transduction, including modulation of
calcium channels, via a putative membrane vitamin D receptor (mVDR) in adipocytes
and thereby participates in the regulation of lipid metabolism (17). Thus suppression of
1α, 25-(OH)2-D3 with high dietary calcium induces reduction in body fat (15-16).
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Although this anti-obesity effect of dietary calcium appears to be due, in part, to
effects on lipolysis and lipogenesis, it is also possible that a loss of adipocytes would
results in a cellular deficit lipid esterification as the body recovers from energy restriction.
Thus, a reduced number of available adipocytes may not be able to store excess energy
coming from rebound in food intake. Moreover, generating new cells would require extra
energy that would contribute to a further metabolic enhancement. Recent data also
indicate that [Ca2+]i may play a key role in modulating cell’s sensitivity to the apoptotic
stress (21). Several of the functional groups of molecules involved in apoptosis are
[Ca2+]i responsive. [Ca2+]i has been demonstrated to modulate the role of proteases,
including caspase-3, caspase-9 and Ca2+-dependent endonucleases (22-23). Scorrano et al.
also showed a key interaction occurs between Bcl-2 family protein and calcium signaling
in the execution of apoptosis (218). Their data demonstrated a critical role of BAX and
BAK in maintaining of homeostatic concentration of [Ca2+]i in endoplasmic endoreticulum (ER) and mitochondria, which control the apoptotic fate of cells responding to
[Ca2+]i dependent stimuli. Numerous studies also showed that thapsigargin, which can
induce sustained [Ca2+]i elevation by inhibiting sacro-endoplasmic reticulum Ca2+ATPase (SERCA), triggers apoptosis in various cell types (219-221). These data indicate
a key role of [Ca2+]i in the apoptosis process. Given that [Ca2+]i can be modulated by 1α,
25-(OH)2-D3, the role of 1α, 25-(OH)2-D3 in apoptosis should be explored. Although high
dose of 1α, 25-(OH)2-D3 has been reported to induce apoptosis in various tumor cells
(222-225), the regulation of apoptosis by physiological doses of 1α, 25-(OH)2-D3 remains
unclear.
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1α, 25-(OH)2-D3 also generates genomic actions via a nuclear receptor in a
manner similar to the other members of steroid hormone superfamily. Recent study
further demonstrated that 1α, 25-(OH)2-D3 exerts an inhibitory effect on basal,
isoproterenol, and fatty acid-stimulated UCP2 expression via a genomic action (226).
This inhibition is mediated by nVDR. The mVDR agonist and antagonist fail to exert
their actions to either mimic or prevent the 1α, 25-(OH)2-D3 inhibition of UCP2
expression, whereas nVDR knockout by antisense oligonucleotide prevented the
inhibitory effect of 1α,25-(OH)2-D3 on adipocyte UCP2 expression. UCP2 is ubiquitously
expressed, with the highest level in white adipose tissue, and has been shown to stimulate
mitochondria proton leak and therefore exhibit a potential role in thermogenesis, energy
metabolism, and obesity (12). In addition, considerable progress has been made in
elucidating a pivotal role of mitochondria playing in the coordination, initiation, and
execution of apoptotic cell death (227). Three general mechanisms have been proposed,
including 1) disruption of oxidative phosphorylation ATP production; 2) regulation of the
apoptotic proteases; and 3) alteration of cellular reduction-oxidation potential. Because
UCP2, which is highly expressed in white adipose tissue, has been demonstrated to
function as mitochondrial uncoupler of oxidative phosphorylation, it is reasonable to
propose that UCP2 may stimulate apoptosis in adipocytes. Accordingly, the obesitypromoting effect of 1α, 25-(OH)2-D3 may also attributable to its suppression of UCP2
expression. However, the effect and mechanism of 1α, 25-(OH)2-D3 and UCP2 in
regulation of adipocytes apoptosis is not yet well understood.
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1.4 Role of UCPs in Regulation of Obesity
1.4.1 Thermogenesis and Obesity
Obesity results from energy intake exceeding energy expenditure over time
(228). The biochemical mechanisms responsible for the regulation of energy expenditure
and the efficiency of energy utilization are poorly understood. Possible ways to increase
energy expenditure include increasing physical activity and energy dissipation as heat by
futile

metabolic

cycles.

Thermogenesis

in

mammals,

comprising

obligatory

thermogenesis and regulatory thermogenesis, is a spontaneous mechanism allowing body
temperature of most mammals to be maintained at around 370C in cold environments
(229-230). Obligatory thermogeneisis corresponds to resting energy expenditure and
minimal biological work essential for life in resting conditions, in absence of food intake,
and at thermoneutrality. Regulatory thermogenesis, also called adaptive thermogenesis,
corresponds to extra heat induced by exposure to the cold or food intake. Regulatory
thermogenesis can occur in muscle in the form of shivering thermogenesis, and in brown
adipose tissue and some other tissues too as non-shivering thermogenesis, such as
postprandial excess heat production. Rothwell et al postulated decades ago that nonshivering thermogenesis could be utilized by the organism not only to protect against
cold stress, but also to maintain energy homostatsis in response to caloric stress (231). It
followed that obesity could rise from abnormalities in this mechanism of regulation and
that pharmacological stimulation of non-shivering thermogenesis could be an effective
mechanism for reducing obesity (228). This hypothesis is very attractive because 1) the
production of heat is fundamental to the concepts of energy balance and the regulation of
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body weight; 2) non-shivering thermogenesis is a physiological system dedicated to heat
production; and 3) potential to develop agonists that are specific for non-shivering
thermogenesis exist.
The endocrine factors regulating basal thermogenesis are not well known,
although that it has been shown that thyroid hormones play a major role in modulating
resting energy expenditure (232). Such evidence comes from analysis of patients
exhibiting hypo- or hyperthyroid activity, and is confirmed by experimental work on
animals (233-234). The sympathetic nervous system and noradrenaline are the major
regulators of adaptive and cold induced thermogenesis (235-236). Recent data point out
the thermogenic effect of leptin, acting via the brain and activation of sympathetic fibers
(237).
1.4.2 UCP Family
At the cellular level, thermogenesis results from loss of energy during a number
of biochemical processes coupling endergonic and exergonic reactions, and linked in
particular to ATP hydrolysis and ion transport (232). Uncoupling of mitochondrial
respiration from ADP phosphorylation is a highly thermogenic mechanism existing in
brown adipose tissue (BAT) (238). Unlike white adipose tissue, BAT is characterized by
rich vascularization, which is responsible for its color, a network of sympathetic fibers
around every cell and numerous mitochondria with dense cristae (239). In response to
acute cold exposure, the sympathetic nerve-endings of BAT release noradrenaline (NA).
This NA binds to membrane β-adrenergic receptors, stimulating lipolysis and the release
of FFA. FFAs released in situ are used as substrates for the respiratory chain and they
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apparently also activate thermogenesis in BAT (240). The brown adipocytes are also rich
in the UCP1, which uncouples respiration from phosphorylation and leads to the
dissipation of energy as heat. Although in large mammals BAT is present in neonates and
hardly detectable in adults, the presence of large amounts of UCP has been shown in
perirenal adipose tissue of adult human in certain conditions. During the past 10y, the
interest of several pharmaceutical groups has focused on β3-adrenoceptor agonists, which
mimic the action of noradrenaline and could be useful in stimulating UCP1 and
increasing energy expenditure in obese patients (241). Unfortunately, these drugs often
proved to have undesirable side-effects on the cardiovascular system and other tissues
associated with agonist activity at β1 and β2- adrenoceptors, or have a poor bioactivity
(242). In addition to catecholamines, several hormones activate UCP1 gene transcription,
including thyroid hormones, retinoids and legends of PPARs (243-245).
It was known for a long time that only 70% of the energy released from
respiratory substrate oxidation was recovered as ATP and that respiring mitochondria
release heat (246). Measurement of proton leaks in liver and muscle mitochondria
favored a role for proton leak in the less than perfect coupling of O2 consumption to ATP
synthesis (247). Rolfe and Brown quantified various processes composing mammalian
resting metabolic rate (RMR). For the sum metabolism of various tissues, ~10% was
estimated as being attributable to non-mitochondrial oxygen consumption and ~20% to
oxygen consumption for maintaining the mitochondrial membrane potential against the
leak of protons (246). The existence of proton leak suggested that proteins leaked to
UCP1 might be involved (248). Despite a compelling rationale in support of a role for
UCP1 in the regulation of body weight (249-251), this idea has been viewed as
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questionable, because brown adipocytes are thought to be rare in adults human. Instead,
white adipose tissue (WAT) and skeletal muscle are the two major peripheral tissues that
regulate energy homostatsis and thermogenesis in adult mammals (252-253). However,
newly identified uncoupling protein homologs (UCP2, UCP3, UCP4, UCP5, avUCP,
HmUCP) have been found in various animal tissues (254-259). In particular, in both
rodents and human, UCP2 is expressed in a variety of tissues such as WAT, BAT,
skeletal muscle, heart, placenta, brain, stomach, kidney, lung and liver. UCP2 is 60%
homologous to UCP1. In contrast to the ubiquitous expression of UCP2, UCP3 is
dominantly expressed in skeletal muscles of human and rodents. The amino acid
sequence of human UCP3 is 57% identical to human UCP1 and 73% identical to human
UCP2. This high level of homology with UCP1 suggested a possible uncoupling activity
of UCP2 and UCP3. Several reports provide both direct and indirect evidence of a role of
UCP2 and UCP3 in the in vivo regulation of energy production and expenditure (260262). Such a role has been elucidated in vitro, where they both mediate mitochondrial
proton leak in an identical fashion, and their overexpression leads to reduction of
mitochondrial membrane potential (263-264).
Genetic strategies have also clarified the functional role of UCP2 and UCP3 in
modulation of energy metabolism. Markers encompassing the UCP2/3 locus have
revealed significant linkage to resting energy expenditure in a French-Canadian cohort
and in Pima Indians (265-266). A polymorphism in UCP2 exon 8 has demonstrated an
association with body mass index (BMI) and leptin in specific populations (267-268).
Numerous sequence variants have also identified in UCP3. Particular attention has

41

focused on a splice site mutation in UCP3 intron 6 detected in African-American subjects,
which results in reduced fatty acid oxidation (269).
So far two mechanisms have been proposed for the mitochondrial uncoupling
(270). The fatty acid protonophore model of UCP-mediated H+ flux was first introduced
by Skulachev and Garlid (271-272). In this mechanism, UCP doesn’t conduct protons but
catalyzes flip-flop of the anionic head group of fatty acid from the matrix leaflet to the
outer leaflet of the inner membrane. Transport of the anion is driven by the high, insidenegative membrane potential (∆ψ). After the carboxyl head group has crossed the
membrane, it picks up a proton, and the protonated fatty acid spontaneously and rapidly
flip-flops back to the matrix side, where deprotonation completes the cycle. The net result
of the cycle is delivery of protons with charge to the matrix. Thus, fatty acids behave as
cycling protonophores by virtue of the fact that UCP permits the anionic charge to move
across the inner membrane. The other model, however, assumes that UCP transports
proton directly (273). Winkler and Klingenberg demonstrate that fatty acids are buffering
cofactors that operate in conjunction with resident H+-conducting amino acids. Mutation
of two histidine residues in UCP1 causes loss of H+ transport. This model is supported by
the evidence that alkylsulfonates are competitive inhibitors of fatty acid induced proton
transport via UCP. In both models, fatty acids appear to be obligatory for UCP activity.
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1.4.3 UCPs and Obesity
1.4.3.1 UCPs and Thermogenesis
Thermogenesis appears to be a major function of UCP1, the uncoupling protein
homolog that is restricted to BAT (251). In rodents, neonatal, or hibernating mammals,
which have large amount of BAT associated UCP1 activity, energy substrate are used to
generate heat, limiting ATP production. Thus transgenic mice with brown fat ablation
have decreased metabolic rate and hypothermic and these mice are obese (274-275). In
addition, the elevated expression of both UCP2 and UCP3 in ground squirrels during
hibernation has been cited to advocate a role for these UCPs in mammalian nonshivering
thermoregulation (276).
Recent studies demonstrate that the synthesis of UCP2 and UCP3 is positively
controlled by hormonal regulators, including thyroid hormone and leptin (277-278).
These studies reinforce the putative role for UCP2 and UCP3 in energy expenditure and
are in agreement with the genetic linkage of the UCP2 and UCP3 locus to resting
metabolic rate in rodents and human (279). Early studies demonstrated T3 increases the
transcription of UCP1 by acting at thyroid hormone response elements (TREs) in the
enhancer located 2.3kb upstream of the promoter (280). However, in hyperthyroid
animals, BAT becomes inactive, with reduced UCP1 expression, suggesting that T3
induced thermogenesis in other tissues reduces the need for BAT thermogenesis (281).
Since UCP1 shares high sequence similarities with UCP2 and UCP3, it is reasonable to
propose that UCP2 and UCP3 have related function. Administration of T3 to rodents
leads to increases in the expressions of UCP2 and UCP3 in heart and skeletal muscle
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(282-283). In association with the alteration in the thyroid status, increases occur in
UCP3 mRNA expression in skeletal muscle and in mitochondrial uncoupling activity.
The latter result has been confirmed in vivo by a non-invasive method (nuclear magnetic
resonance spectroscopy) in both rats and humans (284-285). In hypothyroid rats given a
single injection of T3, a strict correlation in terms of time course has been shown among
the induced increase in UCP3 protein levels in gastrocnemius muscle, the decrease in
mitochondrial respiratory efficiency and the increase in the RMR of the whole animal
(286). In that study, the maximal increase in mitochondrial UCP3 density was reached at
65 h after the T3 injection, and the increase in RMR showed the same time course. At the
same time point, mitochondria isolated from gastrocnemius muscle showed a
significantly higher non-phosphorylating respiration rate, whereas the membrane
potential showed a decrease, clearly indicating the occurrence of uncoupling. In contrast,
chronic hypothyroidism decreases the UCP3 expression in skeletal muscle from rat.
These data provide in vivo evidence that UCP3 has the potential to act as a molecular
determinant in the influence of T3 over RMR. All these data support that T3-promoted
increase in thermogenesis via mitochondrial uncoupling in skeletal muscle.
In contrast to these observations, it has been reported that UCP3 null mice given a
4 day course of T3 (at 100 µg/100 g body weight/day) show the same increase in RMR as
wild-type controls, a finding that does not seem to support the involvement of UCP3 in
the T3-induced increase in metabolic rate (287). Among the possible reasons for the
discrepancy are the very high doses of T3 used in UCP3-knockout studies (which could
have overstimulated other thermogenetic mechanisms) and the possible conversion of T3
to other thermogenic iodothyronines, such as 3,5-diiodothyronine.
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Leptin is believed to play a role in regulation of UCPs as well. Exogenous leptin,
administered to rodents, results in reduced adipose mass, which is only in part explained
on the basis of decreased food intake, implying an effect of the peptide to increase energy
expenditure (288). Indeed, leptin has been demonstrated to increase core body
temperature, stimulate sympathetic nerve activity, and increase norepinephrine turnover
in BAT (289). Scarpace et al demonstrated that peripheral administration of leptin
induced both oxygen consumption and UCP1 expression (290). Chronic injection of
leptin in C57BL/6J was shown to induce UCP1 and UCP2 expression in brown and white
adipose tissue and lead to depletion of lipid from these fat depots (291). Using an
adenovirus expression vector to introduce leptin, Zhou et al observed similar effects in
rats (292). Furthermore, leptin prevents the decrease in UCP1 and UCP2 expression
caused by fasting and stimulates energy utilization in ob/ob mice by inducing UCP
activity (293). Consistent with these observations, lactation is a natural model of chronic
negative energy balance, and lactating rats have decreased adaptive thermogenesis, a
significant reduction in UCP1 and UCP3 protein levels as well as low circulating leptin
levels (294). Low circulating leptin levels during lactation could be the cause of the
decrease in UCP1 and UCP3 expression. Indeed, leptin replacement during mid-lactation
significantly increased UCP1 and UCP3 mRNA expression. One major difference
between fasted and lactating rats is that circulating FFA levels are elevated during fasting
but reduced during lactation due to the increased FFA uptake by mammary tissue. This
difference may be a reason for the divergent effects of fasting and lactation on UCP3
expression in skeletal muscle despite the low serum leptin levels in these conditions. The
remarkable increase in UCP3 expression during fasting agrees with previous reports
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(295). Skeletal muscle is the primary tissue responsible for the clearance of dietary
glucose and lipids from circulation. During fasting, when the overall strategy is to
conserve energy and to spare glucose for use by the brain, the fuel requirement of skeletal
muscle is diminished, and its predominant fuel is shifted toward lipids. UCP3 is likely to
be specifically involved in regulating the use of lipids as fuel substrates in skeletal muscle.
This hypothesis is supported by previous evidence showing an up-regulation of UCP3 in
skeletal muscle under conditions where the preference for fuel substrate is shifted toward
lipids, such as in fasting and high fat feeding (295). Furthermore, mice lacking UCP3
showed a tendency toward impairment in the starvation-induced shift in fatty acid
metabolism (296).
1.4.3.2 UCPs and Fatty Acid Metabolism
The function of UCPs may not be restricted to thermoregulation and there is now
a number of data linking UCP expression levels to fatty acid metabolism and fatty acid
flux into various tissues. A high fat diet increased UCP2 gene expression in adipose
tissue of mice (297). Starvation, which increases the level of circulation free fatty acids,
markedly increases the level UCP2 expression in both white adipose tissue and skeletal
muscle (298). In humans, the expression level of UCP2 is up-regulated during fasting in
skeletal muscle and white adipose tissue of lean and obese subjects and shows a positive
correlation with the percentage of body fat (299-300). Evidence of uncoupling, lower
mitochondrial potential, and increased mitochondrial volume has recently been observed
in rat pancreatic islets cultured for 1-2 days with palmitate (301). Similarly, long-term
exposure to free fatty acids increases UCP2 expression in hepatocytes (302). These data
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strongly support a regulation of UCP2 expression by fatty acids and also indicate that
UCP2 activity could be related to fatty acid oxidation. The regulatory effect of fatty acids
on UCP transcription may be attributable to PPARs, which can be activated upon binding
fatty acid ligands. A PPAR response element (PPRE) has been identified in the UCP
promoter region (303-304). In rats or lean and db/db mice, in vivo PPARγ activation can
induce expression of UCP-1, -2, and -3 in BAT (305), and chronic-intense PPARγ
activation may cause BAT to assume white adipose tissue-like phenotype with increased
UCP-2 levels (305). PPARα activation in mice is sufficient to induce liver UCP-2
expression (306). Since PPARs are also involved in the regulation of adipocyte
differentiation and lipid oxidation, it is possible that PPARs are the key regulators that
coordinate the activation of lipid metabolism and thermogenetic activity of adipocytes.
Furthermore, administration of pyretic compounds such as lipopolysaccharides to mice
induced significant increases in UCP2 expression in liver, indicating a potential role of
UCP2 in infection and inflammation, both which are also highly thermogenetic processes
(307).
However, several studies also show that UCP2 expression is up-regulated in obese
animals and humans. A higher level of UCP2 expression has been found in skeletal
muscle of obese versus lean individuals and UCP2 expression is positively correlated
with percentage of body fat (308). In ob/ob and db/db mice, which are well characterized
model of obesity associated with increased body weight and decreased energy
expenditure, up-regulation of UCP2 expression has been observed (309-310), suggesting
that enhanced UCP2 expression in obesity could be a compensatory response. In fact,
UCP2 appears to function as a free fatty acid transporter and thereby increases fatty acid
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utilization (311), as previously discussed. Indeed, impairment in the oxidation but not in
the uptake of free fatty acids by muscle has been found in obesity. An increased content
of UCP2, on the other hand, could function as a compensatory mechanism that could
favor the outward translocation of fatty acids. The export of the fatty acid anion thus
permits continued rapid fatty acid oxidation in the face of an oversupply. A similar
hypothesis has been proposed for that UCP3, suggesting that it may function as a fatty
acid anion exporter in muscle and brown adipose tissue when fatty acids are the
predominant fuel substrates (312).
Early studies indicate that lipogenesis is dependent on mitochondrial ATP
production. Therefore, mitochondrial uncoupling in adipocytes may have an inhibitory
effect on lipogenesis by stimulating energy dissipation and depressing ATP production.
Rognstad and Katz et al investigated the effect of chemical mitochondrial uncoupler, 2,
4-dinitripenol, on glucose metabolism in epididymal fat from rat (313). Addition of 2, 4dinitripenol resulted in depressed synthesis of fatty acids and increased lactate, indicating
that inhibition of fatty acid synthesis probably resulted from limited availability of
intramitochondrial ATP for the carboxylation of pyruvate. In addition, ATP/ADP ratio
has been demonstrated to affect pyruvate carboxylase activity (312). In agreement with
this hypothesis, overexpression of UCP2 in adipocyte and induction of UCP1 and UCP3
in adipose tissue by pharmacological treatments results in reduction of lipid accumulation
(314). Expression of UCP1 from the adipose specific promoter in aP2-UCP1 transgenic
mice attenuates both genetic and diet-induced obesity (315).
Lipolysis also depends on the energy status of adipocytes (316-317). Cold
temperature and high-calorie diets stimulate the sympathetic nervous system, leading to
48

the release of noradrenaline. The noradrenaline bound to adipocyte β3-adrenaline
receptors stimulates hormone sensitive lipase via phosphorylation by protein kinase A.
The receptor is not desensitized by noradrenaline, and thus delivers a sustained signal via
Gs-protein to stimulate adenylate cyclase (AC). The AC synthesizes cAMP (cyclic AMP)
and activates protein kinase (318). Protein kinase A also phosphorylates CREB (cAMP
responsive element-binding protein), the trans-element for transcription of the messenger
RNA for UCP1, UCP2 and UCP3 (319). A decrease of intracellular ATP, elicited in
white adipocytes in vitro by uncoupling inhibitors of the mitochondrial respiratory chain,
counteracted the stimulation of lipolysis by catecholamines. Incubation of isolated
adipocytes with lipolytic hormones resulted in an up to a decrease of their intracellular
ATP level and inhibition of lipolysis itself (320). More recently, ATP was shown to be
required for translocation of hormone sensitive lipase from cytoplasm to the surface of
lipid storage droplets and for phosphorylation of HSL and other proteins that are involved
in lipolysis in adipocytes (321-323).
1.4.3.3 Role of UCPs in Regulation of Insulin Secretion
ATP levels are also essential for insulin signaling (324-325). The signal is altered
at the level of the interaction of insulin with its receptor, as well as downstream from
receptor. Like other cells, pancreatic β cells metabolism of glucose yields ATP through
oxidative phosphorylation, and the generation of ATP is tightly coupled to the
metabolism of glucose. In pancreatic β cells, an increase in ATP/ADP ratio associated
with increased glucose metabolism promotes insulin release. The proposed mechanism
involves closure of the KATP channel in response to the increased ratio causing membrane
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deplorization, Ca2+ influx and insulin secretion (326). Defects in oxidative
phosphorylation would be expected to impair insulin release. Thus, UCP2 may be a
negative regulator of insulin secretion, in view of its high expression in this cell type and
its potential uncoupling action, as suggested by the decrease in glucose stimulated insulin
secretion that follows its overexpression in isolated rat pancreatic islets (327). Consistent
with this, mice lacking UCP2 had significantly lower glucose levels and higher insulin
secretion rates under basal conditions and intravenous glucose administration (328). In
contrast, in ob/ob mice, a model of type II diabetes, hyperinsulinemia, hyperglycemia,
exhibits a significant up-regulation of UCP2 (325). When mice lacking UCP2 were
crossed with ob/ob mice, the resulting reduction of UCP2 expression in the ob/ob animals
was associated with a marked improvement in glucose tolerance (329). These results
suggest that the level of UCP2 gene expression in the pancreatic beta cells is an important
determinant of the sensitivity of insulin secretion to changes in glucose.
1.4.3.4 Role of UCPs in Regulation of Intracellular Calcium
[Ca2+]i is a ubiquitous intracellular messenger involved in many cellular processes
(330-331). To generate such complex Ca2+ signals, cells rely on the rapid release of the
Ca2+ from storage as well as on the controlled Ca2+ influx from the extracellular
compartment. Ca2+ concentration is maintained at extremely low levels by expelling Ca2+
ions to the exterior and by compartmentalization of Ca2+ stores. Ca2+ accumulation and
protection of cells against Ca2+ overload has been considered a role of mitochondria.
When exposed to an elevated local cytosolic Ca2+, mitochondria will take up Ca2+
through an electrogenic uniporter, and this action is driven by the mitochondrial
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membrane potential generated by oxidative phosphorylation. This process causes a
depolarization of mitochondrial potential, providing a mechanism that serves to couple
energy supply and demand to cell function. For instance, increased work by the myocyte
is inextricably linked to an increase in [Ca2+]i, which in turn signals an increased ATP
requirement to the mitochondria (332).
Since mitochondria play a key role in regulation of [Ca2+]i homestatsis, alteration
of mitochondrial function may influence [Ca2+]i level. Pharmocological agents have been
useful in identifying mitochondrial contributions to depolarization-evoked [Ca2+]i
responses in intact cells. Proton ionophores, such as DNP, depolarize the inner
mitochondrial membrane and reduce the electrochemical driving force for calcium uptake,
suppressing mitochondrial calcium accumulation (333). In isolated cardiac myocytes,
metabolic inhibition, such as ischaemia, has generally been reported to induce an initial
increase in cytosolic Ca2+ concentration, which appears to be associated with the
depletion of intracellular ATP (334). Artificially suppression of ATP production using
DNP induced a biophasic increases in [Ca2+]i, with the initial increase resulting from
calcium release from mitochondria after deporlarization and the secondary increase
representing calcium release from SR. Although mitochondria will take up an imposed
calcium load, when the load is intense and prolonged, it may precipitate opening of a
large conductance pathway through the mitochondrial inner membrane known as the
permeability transition pore (PTP). This may be a catastrophic event for the cell, leading
to leakage of mitochondrial contents into cytosol, and possibly culminating in cell death,
either through mitochondrial uncoupling and ATP depletion or by release of apoptosisinducing factors (335).
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[Ca2+]i appears to regulate oxidative phosphorylation and various reactions of
oxidative phosphorylation are possible targets for calcium activation. Some intramitochondrial Krebs cycle enzymes such as pyruvate dehydrogenase and isocitrate
dehydrogenase are calcium-sensitive (336). Activation of these enzymes results in a
substantial stimulation of the substrate oxidation subsystem. In addition, calcium may
directly stimulate the respiratory chain and activation of calcium influx also result
activation of ATP synthase and adenine nucleotide translocase. (337-338). Previous
studies suggest that the increase in the cycling of calcium across the mitochondrial
membrane will result in an increase in proton leak (339). However, this effect appears not
to be mediated by direct up-regulation of UCP2 expression since increase in [Ca2+]i has
no effect on UCP2 expression.
1.4.3.5 Role of UCPs in Regulation of Reactive Oxygen Species
Reactive oxygen species (ROS) have been implicated in the pathogenesis of a
number of clinical conditions, including atherosclerosis and chronic complications of
diabetes mellitus (340-341). Recent data also indicate that manipulation of mitochondrial
UCPs may be of interest for controlling the level of ROS (342). Mitochondrial production
of ROS is modulated by mitochondrial potential, which is itself controlled by the level of
coupling of respiration to ADP phosphorylation. BPQ (benzo[a]pyrene-1,6-quinone),
which is a mitochondrial redox cycling agent that increases mitochondrial ROS
production, up-regulates UCP-2 mRNAs in primary cultures of normal rat hepatocytes.
Moreover, mild uncoupling of oxidative phosphorylation decreases mitochondrial ROS
production. Duval et al demonstrate that murine endothelial cells (CRL 2181) pretreated
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by antisense oligonucleotides directed against UCP-2 mRNA exhibited a significant and
specific increase in membrane potential and intracellular ROS level compared with
control scrambled or anti-UCP-1 and -UCP-3 antisense oligonucleotides (343). In
agreement with this, UCP-ablated mice show more resistance to infection by Toxoplasma
gondii, an intracellular parasite that may infect the brains of normal animal and cause
death (344). The tentative conclusion of this study is that the macrophages in the absent
of UCP2 have a greater capacity to produce ROS. There is also evidence of a role for
UCP1 and UCP3 in the protection of tissues against oxidative damage by decreasing in
the mitochondrial production of ROS (345). The superoxides themselves have been
demonstrated to produce proton leak in mitochondria (346). Since changes in oxidative
metabolism in cells and tissues provoke marked changes in free radical synthesis, the
UCPs could represent important mechanism of control and limitation of these ions which
have deleterious effects on cellular machinery.
TNFα may play a key role in regulation of ROS production. Tumor necrosis
factor α (TNFα) inhibits mitochondrial electron transport chain activity, increasing the
interaction of electrons with O2 to generate superoxide anion and other mitochondrial
ROS (347). In contrast, uncoupling proteins are known to increase mitochondrial electron
transport chain activity, limiting electron interactions with O2 and reducing O2 formation
during mitochondrial respiration (348). Accordingly, increases in UCP-2 might help
mitochondria in cells to compensate for the TNF-related inhibition of electron transport
chain activity. Indeed, in obese mice, rats, and humans, increased serum TNFα has been
demonstrated to correlate with adiposity UCP-2 mRNA levels increase in cardiac muscle,
fat and liver (337-338). In addition, normal rats treated with lipopolysaccharide, a potent
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inducer of TNFα, exhibited UCP2 expression increases and this effect is inhibited by
neutralizing anti- TNFα antisera (346). However, this adaptive mechanism may come at a
risk. By enhancing proton conductance across the inner mitochondrial membrane, UCP-2
partially depolarizes this membrane and decreases the efficiency of ATP synthesis.
Inefficient mitochondrial ATP synthesis could cause energy failure and cell death if ATP
requirements increase abruptly (349). Thus, increased UCP-2 activity could transform a
survival advantage into a cause of cell death.

1.5 Regulation of Adipocyte Cellularity
1.5.1. Regulation of Adipocyte Size
1.5.1.1. Lipogenesis
The plasticity of adipose tissue mass is a function of both adipocyte size and
number (350). An increase in adipose tissue mass can occur by hypertrophic growth. This
increase in size occurs primarily by lipid accumulation within the cell. Lipogenesis is
very responsive to the changes in diet (351). A diet rich in carbohydrates stimulates
lipogenesis in both liver and adipose tissue, leading to elevated postprandial plasma
triglyceride levels (352). Fasting reduces lipogenesis in adipose tissue, which, combined
with an increased rate of lipolysis, leads to net loss of triglycerides from fat cells. High
fat diets, in contrast, decreases lipogenesis by suppressing lipogenic gene expression in
liver and adipose tissue, including that of FAS and SCD (353). It has been proposed that
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the dietary nutrient may be translated into changes in hormonal secretion and altered
expression levels of lipogenic genes (354).
Insulin is probably the most important hormonal factor influencing lipogenesis.
By increasing the uptake of glucose in the adipose cell via recruitment of glucose
transporters to the plasma membrane, as well as activating lipogenic and glycolytic
enzymes via covalent modification, insulin potently stimulates lipogenesis (354). Insulin
also has long-term effects on the expression of lipogenic genes, probably via the
transcription factor sterol regulatory element binding protein-1 (SREBP-1) (355-357). In
addition, insulin causes SREBP-1 to induce the expression and activity of glucokinase,
thereby increasing the concentration of a glucose metabolite that supposedly mediates the
effects of glucose on lipogenic gene expression (358). Another endocrine/autocrine factor
connected with triglyceride synthesis is acylation stimulating protein (ASP) which is
produced by adipose tissue and appears to acts via an autocrine loop (359). Numerous in
vitro studies have shown that ASP stimulates triglyceride accumulation in adipose cells
(360-362). This is achieved by an increase in triglyceride synthesis, as well as by a
simultaneous decrease in adipose tissue lipolysis. Leptin is may also be involved in
lipogenesis. There is a growing consensus that leptin limits fat storage not only by
inhibiting food intake, but also by affecting specific metabolic pathways in adipose and
other tissues (363).
Evidence that has been gathered over the past few years indicates that the effects
of various nutrients and hormones on the expression of lipogenic genes are mediated by
the SREBPs (364). Studies in transgenic mice that overexpress SREBP-2 in the liver
suggested that SREBP-2 stimulates the expression of genes involved in cholesterol
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metabolism, such as the LDL receptor, farnesyl pyrophosphate synthase and HMG-CoA
reductase genes (365). Interestingly, mice that overexpress SREBP-1a or SREBP-1c in
liver exhibit a dramatic build-up of hepatic triglycerides and elevated expression levels of
lipogenic genes. This led to the conclusion that SREBP-1 activates genes connected with
lipogenesis in liver. SREBP-1 probably has a somewhat different role in adipose tissue.
In white adipose tissue of these mice, expression of genes implicated in cholesterol
metabolism were markedly elevated, whereas the expression of genes implicated in fatty
acid and triglyceride synthesis remained unchanged (366).
In vitro studies have clearly established the importance of the upstream
stimulatory factors (USFs) in the regulation of the fatty acid synthase promoter by insulin
(367). USFs are ubiquitous bHLH-leucine zipper transcription factors that are able to
interact as homo- and/or heterodimers with E boxes of CANNTG sequence (368). Such
an E box is present in the promoter of FAS (367). Mutations that weaken binding of
USF1 and USF2 to this E box abolish the insulin-dependent activation of the FAS
promoter (369). Recent studies with mice lacking USF1 and/or USF2 have provided
compelling evidence that USF1 and USF2 are involved in mediating the stimulatory
effect of insulin/glucose on fatty acid synthase expression (370). Finally, glucose may
regulate expression of lipogenic genes via a carbohydrate response transcription factor
(ChoRF), which has yet to be cloned. Specific response elements that bind this
transcription factor have been identified in the promoter of target genes, such as pyruvate
kinase (371).
An important transcription factor in adipose tissue is the nuclear hormone
receptor PPARγ (372). Despite its name, this protein is not endogenously activated by
56

peroxisome proliferators but by fatty acids and their eicosanoid derivatives, as well as by
drugs of the thiazolidinedione class. PPARγ is a part of the adipocyte differentiation
program. To date, only a limited number of genes are known to be regulated by PPARγ in
adipose tissue. These encode the adipocyte fatty acid binding protein, lipoprotein lipase,
fatty acid transport protein (FATP), acyl-CoA synthetase, phospho-enol pyruvate
carboxykinase and the fasting-induced adipose factor FIAF/PPARγ angiopoietin related
gene (PGAR) (373). Based on the identities of these genes, coupled with the observation
that PPARγ expression is stimulated by insulin and by SREBP-1 (374-375), one would
expect PPARγ to have not only an adipogenic effect, but also a lipogenic effect. This is
supported by clinical data, showing that patients taking synthetic PPARγ activators
frequently gain weight (376). Furthermore, heterozygous PPARγ mutant mice exhibit
smaller fat stores on a high fat diet (377).
Recent studies demonstrate that increased lipogenesis combined with reduced
oxidation is associated with lipotoxicity (378). When lipids accumulate in nonadipose
tissues during overnutrition, fatty acids enter deleterious pathways such as ceramide
production, which, through increased nitric oxide formation, causes apoptosis of lipidladen cells, such as pancreatic β-cells and cardiomyocytes (389-382). Lipotoxicity of
pancreatic β-cells, myocardium, and skeletal muscle leads to type 2 diabetes,
cardiomyopathy, and insulin resistance respectively (381).
1.5.1.2. Lipolysis
Lipolysis is the chemical decomposition and release of fat from adipose tissue
(382). This process predominates over lipogenesis when additional energy is required.
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The triglycerides within the adipocyte are acted upon by a multi-enzyme complex called
hormone sensitive lipase (HSL), which hydrolyzes the triglyceride into free fatty acids
and glycerol (383). These lipases act consecutively on triglycerides, diglycerides, and
monoglycerides. Once triglycerides are hydrolyzed to fatty acids and glycerol, fatty acids
enter the common free fatty acid pool where they may be re-esterified, undergo betaoxidation, or be released into the circulation as substrates for skeletal muscle, cardiac
muscle, and liver. HSL is expressed in both WAT and BAT, although more is known
about its function in WAT.
In WAT, hydrolysis of triacylglycerols occurs through three consecutive reactions
and is catalyzed by two enzymes: HSL catalyses the hydrolysis of triacylglycerols (TGs)
and diacylglycerols (DGs) and the participation of monoglyceride lipase is required to
hydrolyse monoglycerides (384). Although HSL is generally considered as the ratelimiting enzyme in lipolysis, this concept has recently been challenged. Disruption of the
HSL gene has shown that the overall rate of lipolysis was unaffected, suggesting that
there is another lipase with considerable activity towards TGs in WAT (385). However,
HSL appears to be rate-limiting for DGs, as loss of HSL in mice results in accumulation
of diglycerides (386). Paradoxically, in HSL-knockout mice, obesity is not a consequence.
In fact, it was seen that WAT mass decreases in most parts of the body (387). Both de
novo free fatty acid (FFA) synthesis and triacylglycerol synthesis were reduced in HSLknockout mice (388). In a separate experiment, HSL overexpression in mice resulted in a
decreased rate of lipolysis (389). Clearly, no simple relationship exists between HSL and
the WAT mass and the involvement of other molecules is essential to explain this part of
WAT metabolism (390). HSL is also the intracellular lipase in brown adipose tissue (391).
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Fatty acids mobilized from BAT through the action of HSL are used in non-shivering
thermogenesis. It has been interesting to note that HSL has been shown to retain high
enzyme activity at low temperatures, which is probably a critical property in hibernating
animals.
HSL activity is regulated by lipolytic (catecholamines, ACTH) and antilipolytic
(insulin, adenosine) hormones (392). Catecholamines (such as adrenaline and
noradrenaline) and ACTH (adrenocorticotrophic hormone), otherwise known as
corticotrophin, active lipolysis whereas insulin is exerts an anti-lipolytic effect.
Adrenaline, synthesized in the adrenal gland, binds to β-adrenergic receptors. This
binding induces conformational changes in the septa-spanning receptor, resulting in
activation of adenylate cyclase, which in turn, the hydrolysis of ATP to form cAMP
Cyclic AMP has various targets, one of which is protein kinase A (PKA). The two main
targets for PKA-mediated phosphorylation in the adipocyte are HSL and perilipins, which
result in a large increase in lipolysis. Perilipins (predominant isoform in adipocytes is
perilipin A) coat the surface of lipids, thereby interfering with the access of HSL to the
triglyceride substrate. PKA-mediated perilipin phosphorlyation removes the perilipin
from the lipid surface. Hormone-sensitive lipase, which is also phosphorylated by PKA,
can then access the TG and hydrolyse it to glycerol and FFAs. It was once thought that
Ser 563 is the regulatory site (phosphorlyation site) (393), although further study found
that mutation of Ser 563 didn’t abolish PKA-induced of HSL (394). Other serines (565,
659 and 660) have since been considered to be possible activation sites. To prevent the
accumulation of FFAs having a negative feedback inhibitory effect on HSL, compounds
such as adipocyte lipid binding protein (ALBP) is associated with HSL as part of a
59

“lipolytic complex” (395). ALBP sequesters FFAs and thereby increases the hydrolytic
activity of HSL.
Insulin, the most important inhibitor of catecholamine-induced lipolysis, induces
phosphorlyation and activation of phosphodiesterase type 3B (PDE 3B), leading to a
decrease in the cAMP levels and therefore a decrease in the PKA activity (396-397). The
signaling pathway leading to PDE 3B activation involves the insulin receptor, insulin
receptor substrates, phosphatidyl-3 kinase and probably protein kinase B as well. Specific
inhibition of PDE 3B blocks the antilipolytic effect of insulin, indicating that cAMP
degradation is the main mechanism by which insulin antagonizes catecholamine-induced
lipolysis. The phosphorlyation of PDE 3B is associated with the phosphorlyation of Ser302 in rat adipocyte, catalyzed by an insulin-stimulated protein serine kinase (PDE3IK)
(398). A molecule called lipotransin has been proposed to be involved in docking HSL to
the lipid droplet surface and to play a role in the arrest of lipolysis by insulin (399).
1.5.2. Regulation of Adipocyte Number
1.5.2.1. Adipogenesis
In mammals, WAT formation begins before birth (401). The chronology of WAT
appearance, however, is strictly dependent on the species as well as the adipose depot.
White adipose tissue expansion takes place rapidly after birth as a result of increased fat
cell size as well as an increase in fat cell number (402). Even at the adult stage, the
potential to generate new fat cells persists (403). It has been demonstrated that fat cell
number can increase when rats are fed a high-carbohydrate or high-fat diet (404). An
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increase in fat cell number is also observed in severe human obesity (405). Moreover,
early differentiation markers of adipocyte differentiation can be detected even in adipose
tissue derived from very old mice (406). Fat cell precursors isolated from adult WAT of
various species, including humans, can be differentiated in vitro into mature adipocytes
(407-408). Several studies on multipotent clonal cell lines have suggested that the
adipocyte lineage derives from an embryonic stem cell precursor with the capacity to
differentiate into the mesodermal cell types of adipocytes (409-410). That potential to
acquire new fat cells from fat cell precursors throughout the life span is now undisputed.
In vitro systems have been extensively used to study adipocyte differentiation,
leading to a dissection of the molecular and cellular events taking place during the
transition from undifferentiated fibroblast-like preadipocytes into mature round fat cells
(411). The committed preadipocyte maintains the capacity for growth but has to withdraw
from the cell cycle before conversion to adipose. In preadipose cell lines as well as in
primary preadipocytes, growth arrest but not cell confluence or cell-cell contact appears
to be required for adipocyte differentiation. After growth arrest at confluence,
preadipocytes must receive an appropriate combination of mitogenic and adipogenic
signals to continue through subsequent differentiation steps. Studies on preadipose cell
lines have shown that growth-arrested cells undergo at least one round of DNA
replication and cell doubling. This has been proposed to lead to the clonal amplification
of committed cells. Growth arrest and clonal expansion accompanied by complex
changes in the pattern of gene expression (401).
Expression of lipoprotein lipase (LPL) mRNA has often been cited as an early
sign of adipocyte differentiation (412). Lipoprotein lipase is secreted by mature
61

adipocytes and plays a central role in controlling lipid accumulation (413). At least two
families of transcription factors, C/EBP and PPARγ, are induced early during adipocyte
differentiation (415). PPARγ is largely adipocyte specific and is expressed at low but
detectable levels in preadipocytes (373). Its expression rapidly increases after hormonal
induction of differentiation. The subsequent decrease of C/EBP- β and C/EBP-δ in early
to mid stages of differentiation is concomitant with the induction of C/EBP-α mRNA
(416). This increase in C/EBP-α expression occurs slightly before the expression of
adipocyte-specific genes. Another transcription factor induced very early during
adipocyte

differentiation

is SREBP-1c/

ADD1

(adipocyte determination

and

differentiation factor 1), a bHLH-leucine zipper protein that is involved in cholesterol
metabolism and may also participate in adipocyte gene expression (417). During the
terminal phase of differentiation, adipocytes in culture markedly increase de novo
lipogenesis and acquire sensitivity to insulin (418). The activity, protein, and mRNA
levels for enzymes involved in triacylglycerol metabolism including ATP citrate lyase,
malic enzyme, acetyl-CoA carboxylase, SCD1, glycerol-3-phosphate acyltransferase,
glycerol-3-phosphate

dehydrogenase,

FAS,

and

glyceraldehyde-3-phosphate

dehydrogenase increase (407). Glucose transporters, insulin receptor number, and insulin
sensitivity increase (407). During adipocyte differentiation, there is a loss of

β1-

adrenergic receptors and an increase in the β2- and the β3-subtypes, resulting in an
increase in total adrenergic receptor number. In addition to increases in mRNAs for
proteins directly related to lipid metabolism, adipocytes also synthesize other adipose
tissue-specific products. These include aP2, an adipocyte-specific fatty acid binding
protein (419); FAT/CD36, a putative fatty acid transporter (420); and perilipin, a lipid
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droplet-associated protein (421). In addition, adipocytes produce a number of secreted
products, including monobutyrin, an angiogenic agent; adipsin, a homolog of the serine
protease complement factor D; Acrp30/AdipoQ; PAI-1; angiotensinogen II; and leptin
(422-423).
In mammals, adipose tissue is a multi-depot organ made of two tissue types, the
white and brown adipose tissues, which collaborate in partitioning the energy contained
in lipids between thermogenesis and the other metabolic functions (424). Recent data
have stressed the plasticity of the adipose organ in adult animals (349). Indeed, under
peculiar conditions fully differentiated, white adipocytes can transdifferentiate into brown
adipocytes, and vice versa (425-426). The ability of the adipose organ to interconvert its
main cytotypes in order to meet changing metabolic needs may be pertinent to the
physiopathology of obesity and related to therapeutic strategies.
The adipose tissue expansion that occurs during the development of obesity is
initially characterized by fat cell hypertrophy (427-428). However, adipocytes do not
have an unlimited capacity for expansion, and increases in fat cell number do occur. The
development of hyperplastic adipose tissue noted in both genetic and diet-induced obesity
is associated with the most severe forms of obesity and has the poorest prognosis for
treatment (428-429). Understanding the mechanisms that regulate the growth of adipose
tissue may enhance efforts to develop successful prevention and treatment strategies to
limit accumulation of excess body fat. Chumlea et al estimated adipocyte number and
adipocyte size in nonobese adults 20 to 50 yr of age (430). Women had greater
percentage body fat and larger adipocytes than men in every age group except the oldest
(45-50 yr). Adipocyte number, total body fat, and percentage body fat are each positively
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correlated with age in both sexes. Adipocyte size is not correlated with age but is
positively correlated with total and percent body fat in men and women irrespective of
age. These cross-sectional data suggest that adipocyte number, rather than being stable
during adulthood, increases with age and is associated with corresponding increases in
total and percentage body fat. Noppa et al. demonstrated a significant relation between
body build in childhood and prevalence and degree of obesity in adulthood in women
(431). In addition, there was a significant relationship between the degree of obesity and
total fat cell number when age of onset was kept constant, but not between age of onset
and total fat cell number when degree of obesity was kept constant indicating that
adipocyte number is attributable to obesity. Animal studies also confirmed that adipocyte
hyperplasia is associated with obesity. Obst et al. assessed fat depot cellularity and cell
number and lipid per cell for three fat depots in overfed dietary obesity resistant S 5B/Pl
(S) and susceptible Osborne-Mendel (OM) rats (432). They found that both the size and
the number of adipocytes was associated with overfeeding-induced obesity. However,
other studies have the opposite observation. One study demonstrated that, when put obese
woman underwent controlled 1000 kcal diets for 6-month, weight gaining patients
showed a significantly higher mean fat cell number than while weight losing patients had
a higher mean adipose cell weight than the weight gaining and weight stable patients
(433).
The processes involved in adipocyte hypertrophy are relatively well understood,
but much less is known about adipocyte hyperplasia. The mature adipocyte has little
capacity for cell division and the hyperplastic capacity of adipose tissue resides in a
population of fibroblast-like adipocyte precursor cells (434). The origin of these cells and
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the processes involved in their commitment to the adipocyte lineage is not known.
Growth factors, in particular the bone morphogenetic proteins (BMP), are likely to be
involved in regulating commitment to the adipocyte lineage. In vitro studies have shown
that once committed to the adipocyte lineage, the proliferation and differentiation of
adipocyte precursor cells is regulated by a number of different growth factors (435-436).
A number of these growth factors are expressed in adipocyte precursor cells in vitro and
may have an autocrine-paracrine role (437). Others, such as epidermal growth factor
(EGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) are
more likely to have an endocrine role (438). The precise role that each growth factor
plays in regulating adipocyte development in vivo is poorly understood. It is likely that
adipocyte hyperplasia occurs in a localized fashion; adipocytes are not randomly
distributed in mammals but are organized in identifiable depots. In addition, adipose
tissue growth appears to occur within these depots through local recruitment of
pluripotent precursors rather than through generation of new loci.
The hypothesis that a critical fat cell size precedes adipocyte hyperplasia is not a
new one. Increases in mean fat cell size have been noted in mice and several strains of
rats fed high-fat diets. Studies of adipose tissue cellularity in the genetically obese Zucker
rat also indicated that hypertrophy develops before hyperplasia (428,439). Based on these
observations, Faust proposed that attainment of a critical fat cell size initiated the events
that lead to proliferation of adipocytes (440). A more recent study conducted by Brenda
et al demonstrated that proliferative activity of conditioned medium obtained from all
depots in obese Zucker rats was positively correlated to subsequent changes in fat cell
number, indicating that enlarged adipocytes secrete growth factors that induce
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preadipocyte proliferation (441). Considine et al report that mature adipocytes from both
lean and obese subjects release a factor that stimulates the growth of preadipocyteenriched and dedifferentiated adipocyte-enriched cell cultures (442). They demonstrate
that mature adipocytes from obese patients stimulate the growth of preadipocyte-enriched
cultures to a greater extent than those from lean individuals. There is now a
preponderance of evidence that adipose tissue is a source of growth factors such as IGF-I,
IGF binding proteins (443), TNFα (444), angiotensin II (445), and macrophage colonystimulating factor (MCSF) (446) that are capable of stimulating proliferation. The relative
importance of these autocrine/paracrine factors in the normal control of preadipocyte
proliferation is unknown. In addition, the proliferative response of preadipocytes to the
paracrine milieu is undoubtedly modulated by neural inputs to fat tissue and/or serum
factors (447). Together, these multiple regulatory controls orchestrate overall and regionspecific adipose tissue cellularity responses associated with the development of
hyperplastic obesity.
1.5.2.2. Adipocyte Depletion
Large increases in fat stores involve an increase in adipocyte number via the
replication and differentiation of preadipocytes, with the resultant cell gain widely
regarded as irreversible. A reduction in fat tissue mass generally involves the loss of
stored lipids by lipolytic processes (448). However, there is now growing evidence that
decreases in adipose tissue mass in humans may also result from a loss of fat cells
through programmed cell death, especially in condition when large amounts of fat are lost
(449). In cultured adipocytes, apoptosis may be induced by serum deprivation or
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exposure to TNF-α and HIV protease inhibitors (450-453). Studies in rodents
demonstrate that induced weight and fat loss such as starvation, dietary conjugated
linoleic acid (CLA), injection of neuropeptide Y-Y5 receptor antisense oligo or
intracerebroventricular administration of leptin results in apoptosis of fat cells (454-459).
Prins et al reported that human adipocytes undergo apoptosis following growth factor
deprivation or mild heat injury in vitro, thus suggesting a cellular mechanism by which
normal adipocyte loss could occur in vivo (460). Fat cell apoptosis was demonstrated in
patients with tumor cachexia (461) and in HIV-patients during treatment with protease
inhibitors (462). Patients with acquired forms of lipodystrophy (Lawrence Syndrome,
Barraquer-Simons Syndrome) show an immunologically mediated loss of fat cells
probably by apoptosis (463).
Up to now, general mechanisms for apoptosis induction in human adipocytes have
not been intensively investigated. Little is known about either the physiologic regulators
of cell death or the apoptotic sensitivity of preadipocytes versus adipocytes. Using the
well-established immortalized murine 3T3-L1 cell line model of adipogenesis, Papineau
et al reported that as adipogenesis ensues, these cells acquire resistance to apoptosis
induced by growth factor deprivation (464). Expression of 2 cell survival genes, neuronal
apoptosis inhibitor protein (NAIP) and Bcl-2, increased, consistent with the
differentiation-dependent effect on survival (465). Others have confirmed the apoptotic
sensitivity of 3T3-L1 preadipocytes (466-468). Although 3T3-L1 preadipocytes are a
valuable experimental model, they do have distinctive attributes compared with human
preadipocytes in primary culture, beyond the obvious species difference. 3T3-L1
preadipocytes are aneuploid, as well as embryonal in origin, and such features could
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influence cell survival pathways. Death receptors (CD95, TRAIL-R1 and R2, and TNFR1)
are expressed in human fat cells and that apoptosis can be induced by specific ligands
(469). In addition, inhibition of the auto-/ paracrine actions of IGF-1 dramatically
sensitizes human adipocytes for death-ligand induced apoptosis. Qian et al demonstrated
that injection of leptin could dramatically up-regulate the expression of PPARγ but
decrease TNFα in young rat (470). Lower TNFα levels were probably a secondary effect
of reduced fat mass and increased PPARγ maybe attributable to leptin induced apoptosis,
as PPARγ is associated with apoptosis in cancer cells and in white adipose tissue from
rodents treated with thiazolidinediones (471-472). Since PPARγ is a powerful promoter
of preadipocyte differentiation, the minor change of the WAT weight may be the
combined results of increased adipocyte recruitment and adipocyte apoptosis.
Supplementing mature adipocytes in culture with leptin induced expression of
angiopoietin-2(Ang-2), which antagonizes angiogenesis, and caused apoptosis of adipose
tissue endothelial cells (473). The apoptotic process also is modulated by energy states.
Mitochondrial dysfunction causes ATP depletion, ion dysregulation, mitochondrial and
cellular swelling, activation of degradative enzymes, plasma membrane failure, and cell
death (474). Augmentation of cellular ATP by manipulation of the glucose content in the
cultures led to an increase in survival from death signaling. In vitro experiments indicated
the dependence of both lipogenesis and lipolysis on ATP levels in adipocytes (475). Thus,
respiratory uncoupling in adipocytes that results in stimulation of energy dissipation and
depression of ATP synthesis may contribute to the control of lipid metabolism, adiposity,
and insulin sensitivity. This notion is supported by the observation that the expression of
UCPs in adipocytes as well as some protonophoric anion transporters reduce adiposity
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(476-477). Consistent with this, recent studies demonstrated a negative correlation
between expression of UCPs in adipocytes and accumulation of white fat (478). These
data suggested that energy status may also play a role in regulation of adiposity via
apoptosis.
Based on the preceding literature review, the research described in this
dissertation was designed to a) determine the role of dietary calcium and dairy on
adipocyte metabolism and energy modulation during energy restriction and energy
repletion; b) determine the role of mitochondrial uncoupling on adipocyte lipid
metabolism; c) determine the role and mechanism of dietary calcium and 1, 25 (OH)2-D3
in modulating adipocyte deletion via apoptosis.
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Part Two
Interactive Effects of Calcium-Fortified Breakfast Cereal and of Milk
on Adiposity and Weight Loss in a Transgenic Mouse Model of Obesity
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2.1 Abstract

We previously demonstrated a regulatory role for intracellular Ca2+([Ca2+]i) in
adipocyte metabolism. Recently, we reported that increasing dietary calcium, by
suppressing calcitriol-mediated increases in [Ca2+]i attenuates adipocyte lipid accretion
and weight gain during over-consumption and accelerates fat loss during energy
restriction. Notably, dairy sources of calcium exert consistently greater effects. The
present study was conducted to extend these observations by determining the efficacy of
a calcium-fortified cereal, alone or with a small amount of milk, in attenuation of weight
and fat gain in the aP2-agouti transgenic mouse. Male mice placed on a basal low
calcium (0.4%)/high fat (25 energy %)/high sucrose diet for six weeks exhibited ~2-fold
increases in [Ca2+]i and both visceral and subcutaneous fat mass. However, addition of a
calcium-fortified breakfast cereal sufficient to increase dietary calcium to 1.2% with
macronutrient adjustments to ensure identical carbohydrate, protein and fat levels with
the basal diet resulted in a 41% decrease in adipocyte [Ca2+]i (p<0.001) and 25- 30%
decreases in weight gain (p<0.03) and total fat pad mass compared to the basal diet
(p<0.001), while food consumption was unaffected. Interestingly, addition of sufficient
non-fat dried milk to bring the calcium content of the Ca-fortified cereal diet to from 1.2
to 1.3% (with macronutrient adjustment) resulted in substantially greater reductions in
adipocyte [Ca2+]i (63%, p<0.001), weight gain (45%, p<0.002) and fat pad mass (39%,
p<0.0001). In a follow-up study, both the calcium-fortified cereal and cereal plus milk
diets significantly accelerated weight and fat loss secondary to a fixed level of energy
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restriction, with the cereal plus milk diet exerting markedly greater effects. Thus, a
calcium-fortified breakfast cereal is effective in reducing adiposity in this model of
obesity, while addition of a small amount of milk significantly amplifies this effect.

2.2 Introduction
A substantial body of evidence has emerged over the last three years in support of
an “anti-obesity” effect of dietary calcium and calcium-rich foods (1-3). Increasing
dietary calcium in the absence of caloric restriction appears to result in a re-partitioning
of dietary energy from adipose tissue to lean body mass, resulting in a net reduction in fat
mass in both mice and humans (1-2), while increasing dietary calcium intake during
energy restriction results in a marked augmentation of body weight and fat loss in both
mice and humans (1). These observations are supported by epidemiological observations
from NHANES III (2), the Quebec Family Study (4) and the CARDIA study (5). Data
from NHANES III demonstrate an 84% reduction in the probability of being in the
highest quartile of body fat in those in the highest quartile versus those in the lowest
quartile of calcium and dairy intake (2).

Similarly, data from the CARDIA study

demonstrate a significant inverse relationship between dairy consumption and each of the
components of the Insulin Resistance Syndrome (IRS), including obesity, during a 10year follow-up of young adults who were overweight (body mass index > 25 kg/m2) at
baseline, with the odds of developing IRS 72% lower among overweight individuals in
the highest (>35 times per week) versus the lowest (<10 times per week) category of
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dairy consumption; the cumulative incidence of obesity was reduced from 64.8% in the
lowest dairy consuming group to 45.1% in the highest dairy consuming group
(p<0.001)(5).
Interestingly, the source of dietary calcium has a substantial impact on the
magnitude of calcium’s effect on adiposity, with dairy sources of calcium producing 5070% greater effects on fat loss during energy restriction in both mice and humans.
Consistent with this observation, analysis of NHANES III demonstrates a significantly
stronger inverse relationship between dietary calcium and adiposity when the number of
dairy servings is included in addition to the level of calcium consumption (2). Moreover,
the inverse relationship between dietary calcium and IRS in the CARDIA study was
explained solely by dairy intake, whereas the inverse association between dairy
consumption and IRS was not altered by adjustment for calcium, indicating an effect of
dairy consumption independent of calcium intake (5).
A compelling mechanism for the anti-obesity effect of dietary calcium was
provided by studies of the mechanism of action of the agouti gene in regulating murine
and human adipocyte metabolism (6-11). These studies demonstrated a key role for
intracellular Ca2+ in the regulation of adipocyte metabolism, resulting in modulation of
adipocyte triglyceride stores (7-10). Since intracellular Ca2+ can clearly be regulated by
calcitrophic hormones, including 1,25-(OH)2-D3 and parathyroid hormone, suppression
of these hormones by increasing dietary calcium may facilitate re-partitioning of dietary
energy from adipose tissue to lean body mass and thermogenesis. In support of this
concept, we have demonstrated that human adipocytes possess membrane (non-genomic)
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vitamin D receptors which transduce a rapid intracellular Ca2+ response to 1,25-(OH)2-D3
(12); consequently, 1,25-(OH)2-D3 treatment of human adipocytes results in coordinated
activation of fatty acid synthase expression and activity and suppression of lipolysis,
leading to an expansion of adipocyte lipid storage (2). Moreover, 1,25-(OH)2-D3 acts via
the adipocyte nuclear vitamin D receptor to inhibit the expression of uncoupling protein 2
(UCP2) (13), while suppression of 1,25-(OH)2-D3 levels by feeding high calcium diets to
mice results in increased adipose tissue UCP2 expression and increased thermogenesis
(14), suggesting that high calcium diets may also affect energy partitioning by
suppressing 1,25-(OH)2-D3-mediated inhibition of adipocyte UCP2 expression.
Although the foregoing mechanism provides a plausible explanation for an antiobesity effect of dietary calcium, there is as of yet no compelling mechanism to explain
the differential effects between dairy and non-dairy sources of calcium. Accordingly, the
present study was conducted to further explore the interaction between dairy and nondairy sources of calcium in modulating adiposity in a previous established transgenic
mouse model of diet-induced obesity.

2.3 Materials and Methods
2.3.1 Animals and Diets
We utilized transgenic mice which express agouti specifically in adipose tissue
under the control of the aP2 promoter (15), similar to the human pattern of agouti
signaling protein (ASIP) expression. These mice are not obese when fed standard rodent
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chow, but develop mild to moderate obesity when fed high sucrose and/or high fat diets
(16).
Phase I
40 Six-week-old male aP2-agouti transgenic mice from our colony were
randomized to four groups, as follows. The basal group were placed on a modified AIN
93-G diet with suboptimal calcium (0.4%), sucrose as the sole carbohydrate source, and
fat increased to 25% of energy with lard; a Ca-fortified cereal diet group, using both
sucrose and fortified cereal as carbohydrate sources, increased dietary calcium three-fold
to 1.2%, with macronutrient adjustments to ensure identical carbohydrate, protein and fat
levels with the basal diet; a Ca-fortified cereal plus non-fat milk diet group, in which 25%
of the protein was replaced by skim fat dry milk and dietary calcium was increased to
1.3%; a cereal control group utilized the same amount of a non-calcium fortified cereal as
used in the Ca-fortified cereal group with macronutrients adjusted. Food intake and
spillage were measured daily while body weight, core temperature and blood glucose
were measured weekly. At the conclusion of the 6 wk feeding period, animals were killed
by exsanguination under pentobarbitol (65mg/kg body weight) anesthesia, and blood was
collected via cardiac puncture for glucose and insulin measurements. Fat pads
(epididymal, perirenal, abdominal, and subscapular) and liver were dissected immediately,
weighed, frozen in liquid nitrogen and stored at -80°C for later analysis. [Ca2+]i was
measured immediately in abdominal adipocytes obtained as described below. Fatty acid
synthase activity and mRNA levels were measured in abdominal fat, and lipolysis was
measured in freshly obtained perirenal fat as described below.
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Phase II
This study was divided into two 6-week stages. In the first 6-week stage, 50 Six-week-old
aP2-agouti transgenic mice were place on the basal diet described above to induce
obesity. At the end of this stage, five representative mice were killed for measurement of
fat pad mass, adipocyte [Ca2+]i, fatty acid synthase activity and mRNA levels, and
lipolysis in abdominal fat. The remaining 45 diet-induced obese transgenic mice were
assigned to five groups as follows. One group was continued ad lib on the same lowcalcium (0.4%) basal diet with no modification, while the other four groups received the
four diets used in phase I (basal, Ca-fortified cereal, Ca-fortified cereal plus milk, cereal
control) at 70% of the energy level of the ad lib four groups using a pair-feeding protocol.
Diets were administered daily, and body weight, core temperature and blood glucose was
monitored every 5 days. At the end of second stage, all mice were killed by
exsanguinations under pentobarbitol anesthesia (65mg/kg body weight). Blood obtained
via cardiac puncture was used for insulin and glucose measurements. Fat pads were
collected for intracellular Ca2+, fatty acid synthase activity and mRNA levels, lipolysis as
indicated for phase I.
2.3.2 Core Temperature
Core temperature was used as an indirect metabolic index to determine the effect
of dietary calcium on thermogenesis. Temperature was measured via a thermocouple
(Columbus Instruments, Columbus, Ohio) weekly. The probe was inserted a constant
distance (1.8 cm) into the rectum of each mouse. After stabilization (10 s), the
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temperature was recorded every 5 s for 30 s. All core temperature measurements were
performed between 8:00 and 9:00 A.M.
2.3.3 Adipocyte Intracellular Ca 2+ ([Ca 2+]i) Measurement
Adipose tissue was first washed several times with Hank’s Balanced Salt Solution
(HBBS), minced into small pieces, and digested with 0.8 mg/ml type I collagenase in a
shaking water bath at 37o C for 30 min. Adipocytes were then filtered through sterile 500µm nylon mesh and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 1% fetal bovine serum (FBS). Cells were cultured in suspension and
maintained in a thin layer at the top of culture media for 2 h for cell recovery. [Ca2+]i in
isolated mouse adipocytes was measured by using a fura-2 dual wavelength fluorescence
imaging system Prior to [Ca2+]i measurement, adipocytes were pre-incubated in serumfree medium for 2 h and rinsed with HBSS containing the following components (in
mmol/L): NaCl 138, CaCl2 1.8, MgSO4 0.8, NaH2PO4 0.9, NaHCO3 4, glucose 5,
glutamine 6, Hepes 20, and bovine serum albumin 1%. Adipocytes were loaded with
fura-2 acetoxymethyl ester (AM) (10μmol/L) in the same buffer in dark for 1 h at 37o C.
Adipocytes were rinsed with HBSS three times To remove extracellular dye and then
post-incubated at room temperature for an additional 30 min to permit complete
hydrolysis of cytoplasmic fura-2 AM. A thin layer of adipocytes was plated in 35 mm
dishes with glass coverslips (P35G-0-14-C, MatTek Corporation, Ashland, Mass.). The
dishes with dye-loaded cells were mounted on the stage of Nikon TMS-F fluorescence
inverted microscope with a Cohu 4915 CCD camera. Fluorescent images were captured
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alternatively at excitation wavelength of 340 and 380 nM with an emission wavelength of
520 nM. [Ca2+]i was calculated by using a ratio equation.
2.3.4 Fatty Acid Synthase (FAS) Activity Assay
FAS activity was determined spectrophotometrically in crude cytosolic extracts of
mouse adipose tissue. Mouse abdominal fat pads were homogenized in 250 mmol/L
sucrose solution containing 1 mmol/L ethylenediamine-tetraacticacid (EDTA), 1mmol/L
dithiothreitol (DTT), and 100μmol/L phenylmethylsulfonyl fluoride (PMSF) (pH 7.4).
The homogenate was centrifuged at 18,500 X g for 1 h, and the infranatant was used for
measuring oxidation rate of NADPH. The final FAS activity was normalized to DNA,
which was measured by CyQUANT cell proliferation assay kit according to
manufacturer’s instruction (Parkard instrument Company, Inc., Downers Grove, IL).
2.3.5 Lipolysis Assay
Perirenal adipose tissue was immediately dissected and incubated for 4h. Glycerol
released into the culture medium was used to measure lipolysis, as described previously
(17). Glycerol was measured using a one-step enzymatic fluorametric method (18). The
final lipolysis was normalized by DNA, as described above.
2.3.6 Northern Blot Analysis
Total RNA from mouse abdominal adipose tissue was extracted by using CsCl2
density centrifugation, run in 1% agarose gel, and transferred to nylon membrane (New
England Nuclear, Boston, Mass.). The membrane was hybridized with FAS and β-actin
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(as a loading control) cDNA probes that were radiolabeled by using a random primer
method. Unbound probe was removed by rinsing the membrane with 2X SSC / 0.1% SDS
for 30 min at room temperature and 0.1X SSC / 0.1% SDS for 45 min at 55 0C. Finally,
the membrane was exposed to X-ray film (New England Nuclear) at –80

0

C.

Autoradiographs were quantitated densitometrically, and all blots were stripped and
reprobed with ß-actin as a loading control.
2.3.7 Statistical Analysis
All data are presented expressed as mean + SE. Data were evaluated for statistical
significance by one- way analysis of variance (ANOVA), and significantly different
group means were then separated by the least significant difference (LSD) test by using
SPSS (SPSS Inc, Chicago, IL).

2.4 Results
We first investigated the effect of high calcium diet on attenuation of weight gain.
There were no significant differences in food intake among the ad libitum-fed groups.
Nonetheless, weight gain was reduced by 20% and 37% in the animals fed the Cafortified cereal and fortified cereal plus milk diets, respectively, when compared to those
fed the basal low calcium diet (P<0.015) (Figure 2-1). Consistent with this, fat pad mass
was reduced by 24% and 41% by the calcium-fortified cereal and cereal plus milk diets,
respectively (P<0.01) (Figure 2-2). Figure 2-3 demonstrates that the high calcium diet
groups exhibited significant decreases in adipocyte [Ca2+]i, with decreases of 44% and
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Figure 2-1. Effects of high calcium diets on weight gain in aP2-agouti transgenic
mice. Diet and animal administration was conducted as described in Materials and
Methods. Data are expressed as mean ± SE (n =8). Different letters above the bars
indicate a significant difference at level of p<0.05.
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Figure 2-2. Effects of high calcium diets on fat pad weight (sum of four fat fads) in
aP2-agouti transgenic mice. Diet and animal administration was conducted as described
in Materials and Methods. Data are expressed as mean ± SE (n =8). Different letters
above the bars indicate a significant difference at level of p<0.05.
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Figure 2-3. Effects of high calcium diets on adipocyte [Ca2+]i in aP2-agouti
transgenic mice. Diet and animal administration was conducted as described in Materials
and Methods. Data are expressed as mean ± SE (n =8). Different letters above the bars
indicate a significant difference at level of p<0.05.
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63% induced by the calcium-fortified cereal and cereal plus milk diets, respectively
(p<0.001).
To study the effect of the high calcium diets on acceleration of weight loss, aP2agouti mice were first placed on the ad lib basal low calcium / high fat / high sucrose diet
to induce mild to moderate obesity and then randomized to the same dietary treatments
used in Phase I, with energy restricted to 70% of an additional group maintained on the
basal diet ad libitum using a pair-feeding protocol. Energy restriction on the low calcium
diet resulted in a 6% body weight loss. However, greater weight reductions of 14% and
19% were observed in the Ca-fortified cereal group and fortified cereal plus milk groups,
respectively (p<0.05) (Figure 2-4). A similar pattern was noted for fat loss during energy
restriction, with a 21% decrease in fat pad mass on the low calcium diet, versus a 43%
decrease on the Ca fortified cereal diet and a 64% decrease on the fortified cereal plus
milk diet (p<0.01) (Figure 2-5).
Figure 2-6 shows that Ca-fortified cereal diet and fortified cereal plus non-fat
milk diet caused 28% and 47% decreases, respectively, in FAS activity (p<0.05 vs. basal
energy-restricted group). Similarly, the two high calcium diets caused corresponding
decreases in adipocyte FAS mRNA, with 67% and 84% decreases on the Ca-fortified
cereal diet and fortified cereal plus non-fat milk diet, respectively (Figure 2-7).
Increasing dietary calcium on the energy-restricted diets caused a corresponding increase
in lipolysis. The basal energy-restricted diet increased basal lipolysis by only 5% (NS)
while the Ca-fortified cereal and fortified cereal plus non-fat dry milk diet stimulated
lipolysis by 34% and 57%, respectively (p<0.05) (Figure 2-8).
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Figure 2-4. High calcium diets accelerate body weight loss in energy restricted aP2agouti transgenic mice. Diet and animal administration was conducted as described in
Materials and Methods. Data are expressed as mean ± SE (n =8). Different letters above
the bars indicate a significant difference at level of p<0.05.
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Figure 2-5. Effects of high calcium diets on fat pad mass (sum of four fat fads) in
energy restricted aP2-agouti transgenic mice. Diet and animal administration was
conducted as described in Materials and Methods. Data are expressed as mean ± SE (n
=8). Different letters above the bars indicate a significant difference at level of p<0.05.
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Figure 2-6. Effects of high calcium diets on fatty acid synthase activity in energy
restricted aP2-agouti transgenic mice. Diet and animal administration was conducted
as described in Materials and Methods. Data are expressed as mean ± SE (n =8).
Different letters above the bars indicate a significant difference at level of p<0.05.
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Figure 2-7. Effects of high calcium diets on fatty acid synthase mRNA in energy
restricted aP2-agouti transgenic mice. Data are expressed as fatty acid synthase (FAS):
actin ratio. Diet and animal administration was conducted as described in Materials and
Methods. Data are expressed as mean ± SE (n =8). Different letters above the bars
indicate a significant difference at level of p<0.05.
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Figure 2-8. Effects of high calcium diets on basal lipolysis in energy restricted aP2agouti transgenic mice. Glycerol release was used to measure lipolysis, as described in
Material and Methods. Diet and animal administration was conducted as described in
Materialsand Methods. Data are expressed as mean ± SE (n =8). Different letters above
the bars indicate a significant difference at level of p<0.05.
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This apparent shift in the efficiency of energy utilization was reflected in the
effects of the dietary treatments on core temperature. As expected, energy restriction
significantly reduced core temperature (Figure 2-9). However, the Ca-fortified cereal
diet and fortified cereal plus milk diets caused significant increases in core temperature
compared to the animals fed the basal low calcium diet during energy restriction (Figure
2-9).

2.5 Discussion
Consistent with our previous reports, administration of basal low calcium diet
caused a significant increase in body weight, fat pad mass and basal adipocyte [Ca2+]i in
aP2-agouti transgenic mice. In contrast, high-calcium diets caused a significant reduction
in body weight, fat-pad mass, and basal adipocyte [Ca2+]i in energy-restricted aP2 mice.
Further, administration of high-calcium diets suppressed lipogenesis and stimulated
lipolysis and thermogenesis in energy-restricted aP2 mice. Notably, inclusion of non-fat
dry milk in the diet markedly amplified the effect.
We have previously shown that agouti stimulates Ca2+ influx (7, 19) and promotes
energy storage in human adipocytes by coordinately stimulating the expression and
activity of fatty acid synthase, a key enzyme in de novo lipogenesis and inhibiting
lipolysis in a Ca2+-dependent fashion (7, 8, 20). Thus, adipocyte [Ca2+]i modulates energy
storage, suggesting that adipocyte [Ca2+]i is a logical target for modulation of adiposity.

159

* p<0.001 vs. basal ad lib
** p<0.01 vs. basal restricted

37.4
37.2
37

**
b
*

36.6

o

C

36.8

36.4
36.2

a

**
b
*

*

a*

36
35.8
35.6

Basal
Basal
(ad lib)

Ca-Fortified Ca-Cereal Cereal
Cereal
+ milk
Control
Restricted (70% of ad lib)

Figure 2-9. Effects of high calcium diets on core temperature in energy restricted
aP2-agouti transgenic mice.Diet and animal administration was conducted as described
in Materials and Methods. Data are expressed as mean ± SE (n =8). Different letters
above the bars indicate a significant difference at level of p<0.05.
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We have recently demonstrated that 1,25-dihydroxyvitamin D3 (1,25-(OH)2-D3)
exerts a rapid action on human adipocytes to cause a sustained increase in [Ca2+]i and a
corresponding marked inhibition of lipolysis and stimulation of fatty acid synthase
expression as well as activity (1, 2, 12). Further, increased circulating level of 1, 25(OH)2-D3 was found in obese humans(21-25). In present study, we sought to decrease
[Ca2+]i by utilizing an increase in dietary calcium to suppress 1, 25-(OH)2-D3 level. This
approach has previously been demonstrated to suppress 1, 25-(OH)2-D3 levels in multiple
studies (26-28). Accordingly, we proposed that dietary calcium suppression of 1, 25(OH)2-D3 would reduce adipocyte [Ca2+]i and thereby inhibit triglyceride accumulation.
Increasing dietary calcium resulted in increased adipocyte lipolysis and suppression of
lipogenesis, similar to our previous observations (1-3). Moreover, these data extend our
previous observations by demonstrating that dietary calcium not only attenuates dietinduced obesity but also accelerates weight loss and fat mass reduction secondary to
caloric restriction in established obesity.
It is noteworthy that dairy and elemental calcium exerted qualitatively comparable
effects; however, quantitatively, the effects were significantly different. Calcium in the
form of dairy exerted a markedly greater effect on lipid metabolism and corresponding
body-weight/adipose tissue mass reduction compared with a like quantity of elemental
calcium. The effects of the high calcium cereal were similar to those described previously
for calcium carbonate, producing significant attenuation of diet-induced obesity and
accelerating body weight and fat loss during caloric restriction (1). However, the increase
in dietary calcium from 1.2% to 1.3% by adding small amount of non-fat dry milk
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doubled the rate of fat loss. Similar results were reported from utilization of yogurt as a
calcium source to increase dietary calcium from 0.4% to 1.2% (29).
Thus, it is clear that dairy contains additional factors which augment the antiobesity effect of calcium. This is consistent with the recent report from the CARDIA
study, in which the inverse relationship between dairy consumption and each of the
components of the insulin resistance syndrome, including obesity, was explained solely
by dairy intake, and was not altered by adjustment fro calcium, indicating an effect of
dairy consumption independent of calcium intake (5).
Although the anti-obesity effect of dairy is clearly attributable to other factor(s) in
addition to calcium, the identity of these factors is not yet clear. Although conjugated
linoleic acid (CLA) has been demonstrated to attenuate adiposity (30-33), these effects
are primarily attributable to the trans-10, cis-12 isomer of CLA, while the predominant
isomer present in dairy is cis-9, trans-11 (30). Moreover, since non-fat dry milk was the
source of dairy used in present study, as well as in our previous studies (1,2), no
appreciable CLA could have been present in this fat-free product.
Alternatively, it is possible that one or more of the compounds in whey may
contribute to the observed anti-obesity effect. Indeed, whey is a rich source of bioactive
compounds (34) which may act independently or synergistically with calcium to
attenuate lipogenesis, accelerate lipolysis and /or affect nutrient partitioning between
adipose tissue and skeletal muscle. Notably, milk proteins have been reported to contain
significant angiotensin converting enzyme (ACE) activity (35, 36). Furthermore, recent
data demonstrated that adipocytes have an autocrine/paracrine rennin-angiotensin system
and that adipocyte lipogenesis is regulated partially by angiotensin II (37). Indeed,
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inhibition of the rennin-angiotensin system mildly attenuates obesity in rodents, and
limited clinical observations support this concept in hypertensive patients treated with
ACE inhibitors (37, 38).
In summary, high-calcium diets exert potent effects in enhancing reduction of
body weight and fat pad mass in both ad lib fed and energy-restricted aP2-agouti
transgenic mice. High-calcium diets suppressed adipocyte [Ca2+]i, stimulated lipolysis,
inhibited lipogenesis and caused a corresponding increase in core temperature.
Consequently, dietary calcium facilitates reduction of fat tissue mass and body weight by
modulating energy partitioning. Moreover, dairy products contain other bioactive
components which markedly amplify this effect, although the identity of this
component(s) is not yet clear.
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Part Three
Calcium and Dairy Inhibit of Weight and Fat Regain during Ad
Libitum Feeding Following Energy Restriction in Ap2-Agouti
Transgenic Mice
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3.1 Abstract

We have previously demonstrated that dietary calcium suppression of calcitriol
reduces adipocyte Ca2+, suppresses lipogenesis and increases lipid utilization during
energy restriction. Notably, dairy calcium sources exert markedly greater effects. To
determine the effects of dietary calcium and dairy on energy partitioning during
subsequent re-feeding, we induced obesity in aP2-agouti transgenic mice with a high
fat/high sucrose diet, then restricted energy intake on a high calcium (1.3%) diet for 6weeks to induce fat loss, and then provided ad libitum access to the low calcium (0.4%)
diet or to high (1.3%) calcium diets which utilized either calcium-fortified foods or dairy
(milk or yogurt) for 6-weeks. Re-feeding the low calcium diet caused re-gain of all
weight and fat, while all high calcium diets reduced weight gain by 53% (p<0.01). All
high calcium diets stimulated adipose tissue UCP2 and skeletal muscle UCP3 expression
and increased core temperature, but only the dairy diets elicited a marked (>10-fold,
p<0.001) increase in skeletal muscle PPARα expression. The high calcium diet produced
a 50% increase in lipolysis, a 63% decrease in fatty acid synthase (FAS) and prevented
55% of the fat regain (p<0.001), while the high dairy diets stimulated lipolysis by 271%,
decreased FAS by 81% and prevented 85% of total fat regain (p<0.01).Thus, high Ca
diets elicit a shift in energy partitioning and reduction of weight gain during re-feeding,
with dairy Ca sources exerting markedly greater effects.
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3.2 Introduction
Although obesity results from chronic energy imbalance, the energy status of an
individual influences the partitioning of ingested food energy between oxidation and
storage (1-3). Since energy balance in humans is a dynamic state, often characterized by
substantial fluctuations in energy intake and expenditure, individual responses to such
changes in energy and nutrient status may have important long-term consequences with
respect to the retention of body fat. Long-term weight maintenance following successful
weight loss may be considered an example of such adaptation, and is clearly a greater
challenge than successful short-term weight loss (4).
Previous data from this laboratory demonstrate that adipocyte intracellular Ca2+
([Ca2+]i) plays a key role in disorders associated with obesity (5-9). Our understanding of
the effects of [Ca2+]i derives from studies of the mechanism of action agouti, an obesity
gene expressed in rodent and human adipocytes (5,9). We have demonstrated that
recombinant agouti protein stimulates the expression and activity of fatty acid synthase
(FAS)(10-11), and inhibits lipolysis in both human and murine adipocytes (12-13). We
have also demonstrated that agouti is expressed in human pancreas, and stimulates both
Ca2+-signaling and insulin release in human pancreatic islets, thereby contributing to
hyperinsulinemia (14-15). This coordinated regulation of lipid metabolism by agouti
appears to be responsible for the accumulation of triglyceride in adipose tissue. Further,
these effects of agouti can be mimicked by stimulation of Ca2+ influx with KCl and
blocked by [Ca2+]i channel antagonists (16-17), indicating that strategies directed at
reducing adipocyte intracellular [Ca2+]i would also be expected to reduce triglyceride
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accumulation in adipose tissue. Recent data from our laboratory demonstrates that
calcitrophic hormones, such as 1, 25-(OH)2-D3, cause a significant, sustained increase in
[Ca2+]i in primary cultured human adipocytes and a corresponding inhibition of lipolysis
(18). Consistent with this, we also reported that suppression of 1, 25-(OH)2-D3 by feeding
high calcium diets inhibits [Ca2+]i influx and subsequently attenuates diet-induced
adiposity by simultaneously stimulating lipolysis and inhibiting lipogenesis (19-20),
suggesting that dietary calcium may not only attenuate the diet-induced development of
adiposity but also promote weight loss in established obesity. We also demonstrated that
dairy sources of calcium exert substantially greater anti-obesity effects than calcium
carbonate (19-20). Compared with calcium carbonate, using dairy as a calcium source
induces a significantly greater attenuation of diet-induced obesity and acceleration of
weight and fat loss during energy restriction in both mice and humans (9, 19-21). Thus
dairy appears to contain additional bioactive compounds which provide an attenuation of
adiposity beyond that food with calcium (5).
We have now used an experimental model to further investigate the effect of
[Ca2+]i in regulating lipid metabolism in aP2 transgenic mice under conditions of varying
nutrient status: ad libitum, energy restriction and refeeding. The purpose of this study was
to investigate the effect of dietary calcium content and sources in regulating lipid
metabolism and energy partitioning in response to energy repletion following deprivation.
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3.3 Materials and Methods
3.3.1 Animals and Diets
This study was divided into three phases. The first phase was designed to induce
weight gain and fat accretion, the second phase to induce weight and fat loss, and the
third phase to determine the role of calcium and dairy in attenuating weight and fat gain
during re-feeding. We utilized aP2-agouti transgenic mice as a model of diet-induced
obesity, as previously described (19, 20). These mice are useful models for diet-induced
obesity in a genetically susceptible human population in that they are not obese on a
standard AIN-93G diet, but develop mild to moderate obesity when fed high sucrose
and/or high fat diets (19-20). Indeed, it is applicable that some individuals have
manifested a much greater increase of weight fat than others, strongly suggesting the
possibility that there is a subgroup that is genetically susceptible to obesity and a different
subgroup that is relatively resistant.
Phase I
Six-week old aP2 transgenic mice were studied in a six-week obesity induction
period on the basal low calcium/high sucrose/high fat diet, as follows.
60 aP2-agouti transgenic mice from our colony were placed at 6 weeks of age on a
modified AIN 93 G diet with suboptimal calcium ( calcium carbonate, 0.4%), sucrose as
the sole carbohydrate source and providing 64% of energy, fat increased to 25% of
energy with lard and protein(casein purified high nitrogen) provided 11% of energy.
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Animals were studied for six weeks, during which food intake and spillage were
measured daily and body weight, fasting blood glucose, food consumption and core
temperature were assessed weekly. At the end of phase I, five representative animals
were sacrificed to collect blood, fat pads, liver and muscle.
Phase II
At the end of the phase one, the 55 animals remaining from phase I were placed on
a high calcium diet with energy intake limited to 70% of that found during ad libitum
consumption. The high calcium diet used in this phase consisted of the basal diet with the
addition of sufficient calcium-fortified cereal to bring the calcium content of the diet to
1.3%, with the macronutrients adjustments as described previously (19, 20). Animals
were then studied for six weeks, during which food intake and spillage were measured
daily and body weight, fasting blood glucose, food consumption and core temperature
were assessed weekly. At the end of phase II, five animals were sacrificed as following to
collect blood, fat pads, liver and muscle.
Phase III
At the end of the phase II, the 50 animals remaining from phase II were further
randomized into five ad libitum-fed groups, as follows: 1) basal: modified AIN 93 G diet
with suboptimal calcium (0.4%), as described in phase I, 2) high-Ca cereal: the high-Ca(1.3%) cereal diet described in phase II; 3) high-Ca-cereal plus dry milk: a high
calcium cereal plus non fat milk diet. 1.2% calcium was derived from calcium fortified
cereal and an additional 0.1% calcium content was derived from non-fat dry milk, with
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20% protein was replaced by non-fat dry milk 4)yogurt: a high calcium (1.3 %) diet in
which sufficient spary-dried non-fat yogurt was added to the basal diet to increase
calcium to 1.3%, with 100% protein was replaced by non-fat dry yogurt 5) cereal control:
the basal diet with a calcium-free control cereal (identical to the calcium-fortified cereal
used in diet 3, but without the calcium fortification) with a final calcium concentration of
0.4% and macronutrients adjusted to match the other diets. 10 animals /group were
studied for six weeks, during which food intake and spillage were measured daily and
body weight, fasting blood glucose, food consumption and core temperature were
assessed weekly. At the conclusion of the study, all mice were sacrificed under
isofluorane anaesthesia and blood collected via cardiac puncture, and fat pads, soleus and
gastrocnemius muscles were immediately excised, weighed and used for further study, as
described below.
This study was approved from an ethical standpoint by the Institutional Care and
Use Committee of The University of Tennessee.
3.3.2 Core Temperature
Core temperature was used as an indirect metabolic index to determine the effect
of the diets on thermogenesis. Temperature was measured via a thermocouple (Columbus
Instruments, Columbus, Ohio) weekly. The probe was inserted a constant distance (1.8
cm) into the rectum of each mouse. After stabilization (10s), the temperature was
recorded every 5 s for 30 s. All core temperature measurements were performed between
8:00 and 9:00 A.M.
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3.3.3 Adipocyte [Ca 2+]i Measurement
Adipose tissue was first washed several times with Hank’s Balanced Salt Solution
(HBBS), minced into small pieces, and digested with 0.8 mg/ml type I collagenase in a
shaking water bath at 37o C for 30 min. Adipocytes were then filtered through sterile 500µm nylon mesh and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 1% fetal bovine serum (FBS). Cells were cultured in suspension and
maintained in a thin layer at the top of culture media for 2 h for cell recovery. [Ca 2+]i in
isolated mouse adipocytes was measured by using a fura-2 dual wavelength fluorescence
imaging system Prior to [Ca2+ ]i measurement, adipocytes were pre-incubated in serumfree medium for 2 h and rinsed with HBSS containing the following components (in
mmol/L): NaCl 138, CaCl2 1.8, MgSO4 0.8, NaH2PO4 0.9, NaHCO3 4, glucose 5,
glutamine 6,Hepes 20, and bovine serum albumin 1%. Adipocytes were loaded with fura2 acetoxymethyl ester (AM) (10µmol/L) in the same buffer in dark for 1 h at 37o C.
Adipocytes were rinsed with HBSS three times to remove extracellular dye and then
post-incubated at room temperature for an additional 30 min to permit complete
hydrolysis of cytoplasmic fura-2 AM. A thin layer of adipocytes was plated in 35 mm
dishes with glass coverslips (P35G-0-14-C, MatTek Corporation, Ashland, Mass.). The
dishes with dye-loaded cells were mounted on the stage of Nikon TMS-F fluorescence
inverted microscope with a Cohu 4915 CCD camera. Fluorescent images were captured
alternatively at excitation wavelength of 340 and 380 nm with an emission wavelength of
520 nm. [Ca2+]i was calculated by using a ratio equation.
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3.3.4 Fatty Acid Synthase (FAS) Activity Assay
FAS activity was determined spectrophotometrically in crude cytosolic extracts of
mouse adipose tissue. Mouse abdominal fat pads were homogenized in 250 mmol/L
sucrose solution containing 1 mmol/L ethylenediamine-tetraacticacid (EDTA), 1mmol/L
dithiothreitol (DTT), and 100µmol/L phenylmethylsulfonyl fluoride (PMSF) (pH 7.4).
The homogenate was centrifuged at 18,500 X g for 1 h, and the infranatant was used for
measuring oxidation rate of NADPH. The final FAS activity was normalized to DNA,
which was measured by CyQUANT cell proliferation assay kit according to
manufacturer’s instruction (Parkard instrument Company, Inc., Downers Grove, IL).
3.3.5 Lipolysis Assay
Perirenal adipose tissue was immediately dissected and incubated for 4h. Glycerol
released into the culture medium was used to measure lipolysis, as described previously
(4). Glycerol was measured using a one-step enzymatic fluorametric method. The final
lipolysis was normalized by DNA, as described above.
3.3.6 Total RNA Extraction
Total cellular RNA isolation kit (Ambion Inc., Austin, TX) was used to extract
total RNA from mouse abdominal adipose tissue and soleus muscle according to
manufacturer’s instruction.
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3.3.7 Quantitative Real-time PCR
Mouse abdominal adipose tissue FAS, PPAR gamma, UCP2 mRNA, and mouse
soleus muscle UCP3 and PPAR alpha mRNA were quantitatively measured using a
Smart Cycler Real Time PCR System (Cepheid, Sunnyvale, CA) with a TaqMan 1000
Core Reagent Kit (Applied Biosystems, Branchburg, NJ). The primers and probes for
mouse genes are as follows. FAS: forward primer: 5’-CCCAGAGGCTTGTGCTGACT3’,

reverse

primer:

5’-CGAATGTGCTTGGCTTGGT-3’,

CCGATCTGGAATCCGCACCGG-3’;

PPAR

CGATACTGTCCTCCTTGATGA-3’,

alpha:

forward

reverse

probe:

5’-

primer:

5’-

primer:

5’-

CGCGTGTGATAAAGCCATTG-3’, probe: 5’-ACGCGATCAGCATCCCGTCTTTG-3’;
PPAR garma forward primer: 5’-GCCTATGAGCACTTCACAAGAAATT-3’, reverse
primer:

5’-TGCGAGTGGTCTTCCATCAC-3’,

TCTGCCCCACCAACTTCGGAATCAG-3’;

UCP2

GCGTTCTGGGTACCATCCTAAC-3’,

reverse

GCGACCAGCCCATTGTAGA-3’,

probe:
forward

primer:

primer:

probe:

GCCTATGAGCACTTCACAAGAAATT-3’;
CCTCTACGACTCTGTCAAGCAGTTCTAC-3’,

UCP3

forward
reverse

5’5’5’5’-

primer:
primer:

5’5’-

CAGCCTGCCAGAATCCTGAT-3’, probe: 5’-CGCTGGAGTGGTCCGCTCCCT-3’.
Pooled mouse abdominal adipose tissue total RNA was serial-diluted in the
range of 1.5625-25 ng and used to establish a a standard curve of desired gene; total
RNAs for unknown samples were also diluted in this range. Reactions of quantitative RTPCR for standards and unknown samples were also performed according to
theinstructions of Smart Cycler System (Cepheid, Sunnyvale, CA) and TaqMan Real
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Time PCR Core Kit (Applied Biosystems, Branchburg, NJ). The mRNA quatitation for
each sample was further normalized using the corresponding 18s or cyclophilin
quantitation, with 18S forward primer: 5’-AGTCCCTGCCCTTTGTACACA-3’, reverse
primer:

5’-GATCCGAGGGCCTCACTAAAC-3’,

CGCCCGTCGCTACTACCGATTGG-3’;

Cyclophilin

GGTGGAGAGCACCAAGACAGA-3’,

reverse

probe:
forward

primer:

primer:

5’5’5’-

GCCGGAGTCGACAATGATG-3’, probe: 5’-AGCCGGGACAAGCCACTGAAGGAT3’.
3.3.8 Carnitine Palmitoyltransferase (CPT) Assay
Liver samples were first homogenized in 10 volumes (wt/vol) of 0.25M
sucrose/0.2mM EDTA (PH 7.5) in a glass tissue grinder to isolate heptocyte
mitochondria. The tissue homogenates were then centrifuged for 12minutes at 750g to
collect the supernatant, which was further centrifuged for 12 min at 6,700g. These
centrifugations were repeated twice and the pellet was then suspended in 4 ml of
mitochondrial suspension buffer (70 mM sucrose, 220mM mannitol, 2mM HEPES buffer,
1mM EDTA, PH 7.4). CPT activity was determined by measuring the initial rates of total
CoASH formation by the DTNB reaction from palmitoyl CoA by mitochondria
individually with l (-)-carnitine and d (+)-carnitine using a spectrophotometry method.
Final data were normalized to cytosolic protein, which was assayed by the method of
Bradford.
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3.3.9 Statistical Analysis
All data were evaluated for normality of distribution and equality of variance prior
to statistical analysis. Variables with skewed distribution were ln-transformed. Outcomes
are shown as means and SD and were evaluated for statistical significance by one- way
analysis of variance (ANOVA), and significantly different group means were then
separated by the least significant difference (LSD) test by using SPSS (SPSS Inc,
Chicago, IL.).

3.4 Results
Body weight, weight regain and fat pad weight data are summarized in figure 1.
Although we did not observe significant difference in food consumption among the five
group of mice during the refeeding following energy restriction(average daily food intake
per mice during ad libitum refeeding: basal group:3.5+0.3g/day, high-Ca cereal group:
3.7+0.3g/day, high-Ca cereal plus dry milk: 3.8+0.3 3 g/day, yogurt group: 3.9+0.4 g/day
and cereal control group: 3.7+0.3 g/day, p>0.05), there was a striking effect of diet on
weight gain (p<0.05) (Figure 3-1 A) and fat pad weight (Figure 3-1 B) (p<0.04). Mice
re-fed the low calcium diets exhibited weight gain and an increase in fat pad mass. In
contrast, mice on the high calcium diets exhibited approximately 50% of this regain, with
increases of body weight and fat pad mass. Further, the dairy-based high calcium diets
were more effective in preventing fat gain, as the high dairy diets prevented 85% of the
fat gain while the high calcium diet prevented 55% of the fat gain.
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Figure 3-1. Effect of dietary calcium and dairy on weight and fat mass regain in aP2
transgenic mice. (A) body weight and (B) fat pads weight. Data are expressed as mean ±
SEM (n=5 for phase I and phase II, n =8 for phase III). Different letters above the bars
indicate a significant difference at level of p<0.05.
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Figure 3-2 shows adipose tissue lipolysis, FAS expression and FAS activity. We
found a slight decrease (20%, p<0.05) in lipolysis in mice on 70% restricted high calcium
cereal diet compared to the high sucrose, high fat, low calcium diet fed ad libitum
(Figure 3-2 A). Upon refeeding after energy restriction, the mice on the high calcium
diets exhibited a significantly higher level of lipolysis than mice on the low calcium diets
(p<0.05), and the dairy-based high calcium diets exhibited a significantly greater effect
than the non-dairy source (p<0.001). Adipose tissue FAS activity and expression
responded to dietary manipulations in an inverse fashion to lipolysis responses. Figure 32 B show that energy restriction with high-Ca fortified cereal diet decreased FAS
expression and activity by 99% and 91% respectively (FAS activity data not shown).
Upon refeeding, the low calcium diets restored FAS activity and expression back to the
basal level (cereal control diet) or higher (low calcium basal diet, p<0.03). In contrast, the
groups on high calcium diets exhibited marked lower level of adipose FAS activity and
expression. Furthermore, the mice re-fed the dairy-based high calcium diets exhibited a
significantly lower level of FAS expression than those fed the non-dairy-based high
calcium diet (p<0.001).
Energy restriction in aP2 mice for 6 wks using high calcium diet resulted in a
79% decrease in adipocyte [Ca2+]i (380 + 43nM vs. 79 + 10nM). Upon refeeding, the low
calcium diets induced a 4 to 5-fold (p<0.001) increase in adipocyte [Ca2+]i, (Figure 3-3),
while there was no significant increase on the high calcium diets, suggesting that dietinduced dysregulation of adipocyte [Ca2+]i is associated with diet-induced adiposity in
aP2-agouti transgenic mice.
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Figure 3-2. Effect of dietary calcium and dairy refeeding on lipid metabolism in aP2
transgenic mice. (A) adipose basal lipolysis, (B) FAS expression. Data are expressed as
mean ± SEM (n=5 for phase I and phase II, n =8 for phase III). Different letters above the
bars indicate a significant difference at level of p<0.05.
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difference at level of p<0.05.
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To determine if shifts in liver fat oxidation potentially contributed to changes in
adiposity, we also examined liver CPT activity (Figure 3-4). Upon refeeding, treatment
of aP2-transgenic mice with the low calcium diets resulted in a slight increase in liver
CPT activity by 44% and 56% while the high calcium diets increase CPT activity by
150%. However, there was no significant effect of the source of calcium on liver CPT
activity.
The shift in energy metabolism in refeeding was also confirmed further by
dietary-induced increase in UCP2 expression in adipose tissue (Figure 3-5) and UCP3
(Figure 3-6) expression in skeletal muscle. Upon refeeding, the high calcium diets
induced 8 to 19-fold increases in UCP2 expression in white adipose tissue and 30 to 34fold increases in UCP3 expression in solues muscle, compared with the low calcium diets
(p<0.001). Furthermore, the dairy-based high calcium diets exerted greater effects on
adipose tissueUCP2 expression than the non-dairy based high calcium diet, although a
comparable difference between calcium sources was not found for skeletal muscle UCP3
expression.
We also found dietary-calcium induced increases in core temperature, with
increases on refeeding the high-calcium, high-calcium plus milk and yogurt respectively
(Figure 3-7). This increase, coupled with the lack of difference in food intake in
refeeding, suggests a shift in efficiency of energy metabolism from energy storage to
thermogenesis.
This shift in energy metabolism was also evident in studies of the peroxisome
proliferator-activated receptor alpha (PPARα), a transcriptional factor which regulates

186

CoASH (nmol) / min.protein(ml)

5.E-05

b

4.E-05
4.E-05

b

3.E-05

b

3.E-05
2.E-05

a

a

2.E-05
1.E-05
5.E-06
0.E+00

Basal diet
(Ca 0.4%)

High-Ca cereal
(Ca 1.3%)

Milk
+
high-Ca cereal
(Ca 1.3%)

Yogurt
(Ca 1.3%)

Cereal
control
(Ca 0.4%)

Phase III
(ad lib)

Figure 3-4. Effect of dietary calcium and dairy refeeding on liver CPT activity in
aP2 transgenic mice. Data are expressed as mean ± SE (n=5 for phase I and phase II, n
=8 for phase III ). Different letters above the bars indicate a significant difference at level
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cellular lipid catabolism Refeeding with the dairy-based high calcium diets resulted in a
marked (> 10-fold) increase in skeletal muscle PPARα compared to the low calcium
diets (Figure 3-8, p<0.03), while the non-dairy calcium-enriched diet exerted no effect
on PPARα expression. Figure 3-9 indicates that mice refed high calcium diets exhibited
significant lower level of PPARγ expression, suggesting dietary calcium may also inhibit
fat mass regain by suppressing adipogenesis.
Serial measurements of plasma glucose and insulin demonstrate a diabetogenic
effect of the basal high fat, high sucrose and low calcium diet, with an increase in fasting
glucose from 121+23 to 169+16 mg/dl and a corresponding degree of compensatory
hyperinsulinemia and hyperleptinemia. On refeeding after fasting, hyperglycemia,
hyperleptinemia and hyperinsulinemia were observed in mice on low calcium diet but not
in mice on high calcium diets (Table 3-1).

3.5 Discussion
It is well accepted that energy balance are core factor involved in the obesity
epidemic, with increases in energy intake contribute to a net positive energy balance and
progressive weight gain. However, it is also well known that obesity is a complex genetic
trait, with multiple genes interacting to confer relative resistance or susceptibility to
positive energy balance. Similarly, specific micro- or macronutrients, dietary patterns, or
both may modulate the same metabolic pathways affected by these genetic factors and
thereby alter nutrient and energy partitioning. This concept is supported a potential body
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Figure 3-8. Effect of dietary calcium and dairy refeeding on PPARα expression in
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Table 3-1. Effect of dietary calcium and dairy refeeding on serum insulin, leptin and glucose concentrations of aP2-agouti
transgenic mice.

Groups

Insulin (ng/ml)

Leptin (ng/ml)

Glucose (mg/dl)

I:G ratio(x10-6)

9.12 + 3.21

13.15 + 4.18

169.42 + 16.98

0.07 + 0.19

II-Calcium Cereal

1.20 + 0.46ab

4.38 + 3.39ab

127.93 + 18.61ab

0.01 + 0.02 ab

III-Basal

12.12 + 7.43

17.12 + 6.13

145.30 + 19.32b

0.12 + 0.38

III-Calcium Cereal

3.28 + 0.20ab

8.77 + 0.86ab

131.00 + 15.07b

0.03 + 0.01 ab

III-Clacium Cereal+Milk

2.86 + 0.25ab

6.33 + 1.13ab

112.9 + 10.59ab

0.03 + 0.02 ab

III-Yogurt

2.20 + 0.34ab

6.40 + 2.21ab

129.8 + 17.12ab

0.02 + 0.02 ab

III-Cereal Control

4.46 + 0.84ab

14.07 + 4.46

151.4 + 20.10b

0.04 + 0.04 ab

I-Basal

a

p<0.05 vs. III-Basal ad lib.

b

p<0.05 vs. I-Basal ad lib

*

Diet and animal administration was conducted as described in Materials and Methods. Data are expressed as mean ± SE (n =10).

Statistical significance is as indicated in each panel.

194

of evidence emerged in recent years which indicated that dietary calcium and dairy
products may play a role in modulation of adiposity independent of energy restriction,
with high dietary calcium and addition of dairy products attenuate weight and fat gain
without energy restriction and stimulates weight and fat loss during energy restriction.
However, the effect of dietary calcium and dairy products on prevention of fat and weight
regain is not yet clear.
The present study demonstrates that dietary calcium exerts marked effects in the
regulation of weight and fat regain in aP2-agouti transgenic mice, as the high calcium
diets inhibited weight and fat regain while the low calcium diets promoted fat and weight
regain. Notably, dairy source of calcium appears to exert greater effects than elemental
calcium. Although there were no significant diet related difference in energy intake
during ad libitum refeeding following energy-restriction, the mice refed the low calcium
diets showed a rapid, pronounced regain of weight and fat which exceeded that lost
during energy restriction. In contrast, the mice refed the high calcium diets regained only
50% of the weight lost during energy restriction period, suggesting that dietary calcium
inhibits weight and fat regain by decreasing efficiency of energy utilization during
rebound food ingestion.
We also observed that dietary calcium levels are inversely associated with [Ca2+]i
levels in white adipocyte tissue, with mice refed low calcium diets exhibiting high
adipocyte [Ca2+]i while those refed high calcium exhibiting low adipocytes [Ca2+]i.
Adipocyte [Ca2+]i has been determined to regulate human and murine adipocyte
metabolism, as recently reviewed (5). Accordingly, manipulation of [Ca2+]i is an
attractive and logical approach for development of therapeutic interventions in obesity. 1,
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25-(OH)2-D3 has been previously shown to stimulate [Ca2+]i in multiple cell types,
including vascular smooth muscle cells, pancreatic ß cells and adipocytes (15, 17, 18, 20).
We demonstrated that 1,25-(OH)2-D3 also acts on human adipocytes to cause a rapid
sustained increase in [Ca2+]i and a coordinated activation of FAS and inhibition of
lipolysis (5, 18, 20). Increased 1,25-(OH)2-D3 has also been observed in obese humans,
further suggesting that 1,25-(OH)2-D3 may exert effects in human energy metabolism(20).
Consistent with this concept, we recently demonstrated that dietary calcium not only
attenuates diet-induced obesity but also accelerates weight loss and fat mass reduction
secondary to caloric restriction in established obesity in both mice (19) and human (9). In
present study, antagonism of [Ca2+]i was again achieved through a dietary intervention by
increasing dietary calcium. We proposed that suppression of 1, 25-(OH)2-D3 dietary
calcium would reduce adipocyte [Ca2+]i and thereby regulates lipid metabolism in
response to different energy status. Indeed, the present study extended our previous
observations by demonstrating that dietary calcium not only attenuates diet-induced
obesity and accelerates weight loss and fat mass reduction in energy restriction in
established obesity, but also inhibit weight and fat mass regain during refeeding
secondary to energy restriction.
Notably, increasing dietary calcium not only modulates energy petitioning by
inhibiting lipogenesis and stimulating lipolysis, but also stimulates UCP2 and UCP3
expression and causes an increase in core temperature, an indirect metabolic index
associated with thermogenesis during refeeding after energy restriction. This may further
contribute to the observed attenuation of weight and fat pad regain during refeeding. This
concept is supported by our previous observation that 1, 25-(OH)2-D3 inhibits UCP2
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expression in human adipocytes, indicating that suppression of 1, 25-(OH)2-D3 by
increasing dietary calcium may stimulate UCP2 induced thermogenesis and fat oxidation
and thereby result in decreased energy efficiency.
The function of UCPs is not restricted to thermoregulation, as a growing body of
evidence links UCP expression to fatty acid metabolism and fatty acid flux in various
tissues (23-24). Previous studies have demonstrated that free fatty acids increase UCP2
and UCP3 expression in adipocytes, pancreatic beta cells and myocytes (25-28). These
data strongly support a regulation of UCP2 and UCP3 expression by fatty acids and also
indicate that UCPs activity could be related to fatty acid oxidation. In fact, UCP2 and
UCP3 may function as free fatty acid transporter and thereby increases fatty acid
utilization (29-30).
The regulation of UCP transcription is attributable a group of ligand-regulatedtranscription factors such as peroxisome-peroliferation-activted factors, which can be
activated upon binding fatty acid ligand (31). Since PPARs are also involved in the
regulation of adipocyte differentiation and lipid oxidation (31), it is possible that PPARs
are the key regulators which coordinate the activation of lipid metabolism and oxidation
in adipocytes. In fact, a PPAR response element (PPRE) has been identified in the UCP
promoter region (32-33), and PPARα activation in mice is sufficient to induce liver UCP2 expression (34). Consistent with this, our data showed that high calcium diets induced
increases in UCP2 and UCP3 expression were accompanied by marked increases in
PPARα expression during refeeding, indicating that high dietary calcium may stimulates
UCPs via a PPARα-dependent mechanism. Consistent with the effect of dietary calcium
on stimulating thermogenesis and energy partitioning via up-regulation of UCPs, we also
197

observed high calcium diets caused a significant increase in hepatic activity of CPT
during refeeding, suggesting that dietary calcium may stimulate a diversion of hepatic
fatty acid metabolism towards oxidation pathway during ad libitum refeeding. These data
suggest that dietary calcium reduces lipid accumulation via energy repartitioning and
dissipation, resulting in less regain of fat during ad libitum refeeding.
We also found that refeeding high calcium diets caused a significant decrease in
PPARγexpression in white adipose tissue. Unlike PPARα, which is highly expressed in
liver and skeletal muscle and modulates fatty acid oxidation, PPARγis mainly restricted
to white and brown adipose tissue and regulates adipogenesis (35). Accordingly, these
present data suggest the possibility that dietary calcium may also inhibit adiposity by
decreasing adipogenesis during food re-administration.
It is also noteworthy that although dairy and elemental calcium exerted
qualitatively comparable effects, the magnitude of these effects was significantly
different. Although all three high calcium diets exerted similar effect on inhibition of
body weight regain during refeeding, the inclusion of dairy resulted in significantly less
regain of fat and weight compared to mice fed elemental calcium. Consistent with this,
calcium derived from dairy exerted a markedly greater inhibitory effect on lipogensis and
greater stimulatory effect of lipolysis compared with the non-dairy-calcium source.
Previous data demonstrated that the increase in dietary calcium from 1.2% to 1.3% by
adding small amount of non-fat dry milk doubled the rate of fat loss (unpublished data
from this lab) and data from present study are consistent with these observations. Thus,
utilizing a dairy source of calcium is maximizing the anti-obesity effects of calcium.
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Additional factors in dairy responsible for this effect besides calcium have been
recently discussed. Several investigators have reported that conjugated linoleic acid
(CLA), a component in dairy product and meat is an effective regulator of body fat
accumulation and retention (36). However, the dairy diet utilized in this study was from
non-fat dry milk and fat-free yogurt, which does not contain CLA, indicating that
additional effect cannot be attributed to CLA. Other components of dairy which may
contribute to these anti-obesity effects include branch chain amino acids and small
bioactive peptides. Our preliminary data in mice isolated most of the additional
bioactivity of dairy products to the whey fraction (unpublished data), which containing
high proportion of branch chain amino acids (BCAAs, leucine, isoleucine, and valine).
BCAAs, especially leucine, play a specific metabolic role in regulation of energy
metabolism and muscle protein synthesis (37-38). In skeletal muscle, leucine stimulates
protein synthesis and inhibits protein catabolism through multiple independent
mechanisms (39-40). Leucine stimulates protein synthesis through the mammalian target
of rapamycin (mTOR) pathways, 70-kDa ribosomal protein S6 kinase activity, and
enhances eIF4E-binding protein phosphorylation and the association of eukaryotic
initiation factor eIF4E with eIF4G (41-42). Accordingly, dairy products provide
sufficient BCAAs to be able to maintain the high concentration of intracellular leucine
required by these signaling pathways. Milk proteins have also been reported to contain
significant angiotensin converting enzyme (ACE) activity (43-44). Furthermore, recent
data demonstrate that adipocytes have an autocrine/paracrine rennin-angiotensin system
and that adipocyte lipogenesis is regulated partially by angiotensin II (45). Moreover,
inhibition of the rein-angiotensin system mildly attenuates obesity in rodents and clinical
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observations in hypertensive patients treated with ACE inhibitors support this concept
(21). In addition, our recent data demonstrate that dairy-derived ACE inhibitor augments
the anti-obesity effects of calcium in aP2 transgenic mice.
In summary, high-calcium diets exert potent effects in weight maintenance during
refeeding following energy-restriction in aP2-agouti transgenic mice. High-calcium diets
suppressed adipocyte [Ca2+]i, stimulated lipolysis, inhibited lipogenesis and a
corresponding increase in core temperature. Consequently, dietary calcium facilitates
reduction of fat tissue mass and body weight in refeeding by modulating energy
metabolism, which serves to reduce energy storage and increase beta-oxidation. This
concept that calcium modulation of adiposity is consistent with the observations obtained
epidemiologically in the NHANES III data set , Quebec Family Study; CARDIA and a
recent clinical trial (20, 46, 47, 9). Moreover, dairy source of calcium exerts greater
effects o preventing regain compared to supplementary calcium carbonate.
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Part Four
Effects of Mitochondrial Uncoupling on Adipocyte Intracellular Ca2+
and Lipid Metabolism
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This part is a slightly revised version of a paper by the same name published in
the Journal of Nutritional Biochemistry in 2003 by Xiaocun Sun, Michael B. Zemel:
Xiaocun Sun, Michael B. Zemel. Effect of mitochondrial uncoupling on adipocyte
intracellular Ca2+ and lipid metabolism, Journal of Nutritional Biochemistry 14 (2003)
219-226.

4.1 Abstract

Previous data from this laboratory demonstrate that increased intracellular Ca2+
([Ca2+]i) coordinately regulates human and murine adipocyte lipid metabolism by
stimulating lipogenesis and inhibiting lipolysis. However, recent data demonstrate
metabolic uncoupling increase [Ca2+]i but inhibit lipogenesis by suppressing fatty acid
synthase (FAS) activity. Accordingly, we have evaluated the interaction between
mitochondrial uncoupling, adipocyte [Ca2+]i, and adipocyte lipid metabolism.
Pretreatment of 3T3-L1 cells with mitochondrial uncouplers (DNP or FCCP) amplified
the [Ca2+]i response to depolarization with KCl by 2-4 fold (p<0.001), while this increase
was prevented by [Ca2+]i channel antagonism with lanthanum. Mitochondrial uncouplers
caused rapid (within 4hr) dose-dependent inhibition of FAS activity (p<0.001), while
lanthanum caused a further additive inhibition. The suppression on FAS activity induced
by uncoupler DNP was reversed by addition of ATP. Mitochondrial uncouplers increased
FAS expression significantly while [Ca2+]i antagonism with lanthanum decreased FAS
expression (P<0.001). In contrast, mitochondrial uncouplers independently inhibited
basal and isoproterenol-stimulated lipolysis (20-40%, p<0.001), while this inhibition was
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fully reversed by lanthanum. Thus, mitochondrial uncoupling exerted short-term
regulatory effects on adipocyte [Ca2+]i and lipogenic and lipolytic systems, serving to
suppress lipolysis via a Ca2+ -dependent mechanism and FAS activity via a Ca2+independent mechanism.

4.2 Introduction
The discovery of novel homologues of the brown adipose tissue mitochondrial
uncoupling protein (UCP), such as UCP2, has provoked intensive study of these
mitochondrial proteins and the role that they may play in energy metabolism (1). Since
lipogenesis is dependent upon mitochondrial ATP production (2), mitochondrial
uncoupling in adipocytes may contribute to control of lipid metabolism.
Previous data from our laboratory demonstrates that intracellular calcium ([Ca2+]i)
plays a key role in the regulation of adipocyte energy metabolism (3). Increased [Ca2+]i
stimulates the expression and activity of fatty acid synthase (FAS), a key enzyme in de
novo lipogenesis, and inhibits basal and agonist-stimulated lipolysis in both human and
murine adipocytes(4-5). However, little is known of the mitochondrial regulation of
[Ca2+]i and lipid metabolism in adipose tissue. Accordingly, in the present study, the role
of mitochondrial uncoupling in regulating lipolysis and lipogenesis as well as
intracellular calcium have been examined in differentiated 3T3-L1 adipocytes. We used
two different mitochondrial uncouplers to induce uncoupling effect on adipocytes
mitochondria (6-7). We report that mitochondrial uncoupling increases [Ca2+]i and downregulates lipolysis via a calcium-dependent mechanism. In contrast, the effect of
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mitochondrial uncoupling on fatty acid synthase is more complex, with up-regulation of
FAS expression via a calcium-dependent mechanism, and suppression of FAS activity via
a Ca2+-independent mechanism.

4.3 Materials and Methods
4.3.1 Culture and Differentiation of 3T3-L1 Adipocytes
3T3-L1 preadipocytes were incubated at a density of 8000 cells/cm2 (10 cm2 dish)
and grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS and
antibiotics at 37°C in 5% CO2 in air. Confluent preadipocytes were induced to
differentiate with a standard differentiation medium consisting of DMEM-F10 (1:1,
vol/vol) medium supplemented with 1% FBS, 1µM dexamethasone, IBMX (0.5 mM) and
antibiotics (1% BSA). Preadipocytes were maintained in this differentiation medium for 3
days and subsequently cultured in adipocyte medium. Cultures were refed every 2–3 days.
Cell viability was measured via trypan blue exclusion.
4.3.2 Fatty Acid Synthase (FAS) Activity Assay
Adipocytes were incubated for 4 h in the presence of 0-50 µM 2,4-dinitrophenol
(DNP) or 0-5 µM carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP) (Sigma,
St Louis, MO) with or without insulin (30nM) and with or without lanthanum(1mM)
(Sigma, St Louis, MO) . Subsequently, the cells were returned to serum free medium
(containing 1% BSA) for 48 hours. Fatty acid synthase activity was measured in cytosolic
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extracts by measuring the oxidation rate of NADPH, as described previously (8-10).
Adipocytes were then homogenized in 250 mmol/L sucrose solution containing 1
mmol/L ethylenediamine-tetraacticacid (EDTA), 1mmol/L dithiothreitol (DTT), and 100
μ mol/L phenylmethylsulfonyl fluoride (PMSF) (pH 7.4). The homogenates were
centrifuged at 18,500 X g for 1h and then incubated in phosphate buffer and acetyl-CoA,
with or without ATP (10nM) (Sigma, St Louis, MO), for 15 minutes, and the infranatant
was used for measuring oxidation of NADPH right after adding malonyl-CoA. The final
FAS activity was normalized to nucleic acids, which was measured by CyQUANT cell
proliferation assay kit (Parkard instrument Company, Inc., Downers Grove, IL) according
to manufacturer’s instruction.
4.3.3 Lipolysis Assay
Adipocytes were incubated for 2 h in the presence of 0-50 µM DNP or 0-5 µM
FCCP with or without insulin (30nM) and with or without lanthanum (1mM), and with or
without isoproterenol (50nM). Glycerol released into the culture medium was determined
as an indicator for lipolysis, using a one-step enzymatic fluorometric method (11).
Glycerol release data was normalized for cellular nucleic acids as described above.
4.3.4 [Ca2+]i Measurement
[Ca2+]i in 3T3-L1 adipocytes was measured using a fura-2 dual-wavelength
fluorescence imaging system. Preadipocytes were plated in 35-mm dishes (P35G-0-14-C,
MatTek). Prior to [Ca2+]i measurement, cells were preincubated with or without different
concentration 0-50 µM DNP or 0-5 µM FCCP with or with or without lanthanum(1mM)
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for one hour. Cells were then put in serum-free medium overnight and rinsed with
HEPES balanced salt solution (HBSS) containing the following components (in mM):
138 NaCl, 1.8 CaCl2, 0.8 MgSO4, 0.9 NaH2PO4, 4 NaHCO3, 5 glucose, 6 glutamine, 20
HEPES, and 1% bovine serum albumin. Cells were loaded with fura-2 acetoxymethyl
ester (fura-2 AM) (10 µM) in the same buffer for 2 h at 37°C in a dark incubator with 5%
CO2. To remove extracellular dye, cells were rinsed with HBSS three times and then
postincubated at room temperature for an additional 1 h for complete hydrolysis of
cytoplasmic fura-2 AM. The dishes with dye-loaded cells were mounted on the stage of
Nikon TMS-F fluorescence inverted microscope with a Cohu model 4915 charge-coupled
device (CCD) camera. Fluorescent images were captured alternatively at excitation
wavelength of 340 and 380 nm with an emission wavelength of 520 nm. After
establishment of a stable baseline, the response to 40mM KCl was determined. [Ca2+]i
was calculated using a ratio equation as described previously(12). Each analysis
evaluated responses of 5 representative whole cells. Images were analyzed with InCyt
Im2 version 4.62 imaging software (Intracellular Imaging, Cincinnati, OH). Images were
calibrated using a fura-2 calcium imaging calibration kit (Molecular Probes, Eugene, OR)
to create a calibration curve in solution, and cellular calibration was accomplished using
digitonin (25 µM) and pH 8.7 Tris-EGTA (100 mM) to measure maximal and minimal
[Ca2+]i levels respectively.
4.3.5 Total RNA Extraction
Total cellular RNA isolation kit (Ambion Inc., Austin, TX) was used to extract
total RNA from 3T3-L1 cells according to manufacturer’s instruction.
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4.3.6 Quantitative Real-time PCR
3T3-L1 adipocyte FAS mRNA was quantitatively measured using a Smart Cycler
Real Time PCR System (Cepheid, Sunnyvale, CA) with a TaqMan 1000 Core Reagent
Kit (Applied Biosystems, Branchburg, NJ). The primers for mouse FAS are as follows.
Forward

primer:

5’-CCCAGAGGCTTGTGCTGACT-3’

reverse

primer:

5’-

CGAATGTGCTTGGCTTGGT-3’. Pooled 3T3-L1 adipocyte total RNA was serialdiluted in the range of 1.5625-25 ng and used to establish a FAS standard curve; total
RNAs for unknown samples were also diluted in this range. Reactions of quantitative RTPCR for standards and unknown samples were also performed according to the
instructions of Smart Cycler System (Cepheid, Sunnyvale, CA) and TaqMan Real Time
PCR Core Kit (Applied Biosystems, Branchburg, NJ). The FAS mRNA quantitation for
each sample was further normalized using the corresponding 18s quantitation, with a
forward primer: 5’-AGTCCCTGCCCTTTGTACACA-3’ and a reverse primer: 5’GATCCGAGGGCCTCACTAAAC-3’.
4.3.7 Statistical Analysis
All data are expressed as mean ± SE. Data were evaluated for statistical
significance by one-way analysis of variance (ANOVA), and significantly different group
means were then be separated by the least significant difference test by using SPSS
(SPSS Inc, Chicago, IL).
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4.4 Results
Both mitochondrial uncouplers increased KCl-stimulated [Ca2+]i (p<0.001).
Antagonism of calcium channels with the non-specific inhibitor lanthanum decreased
both basal and stimulated [Ca2+]i significantly (p<0.001) and reversed the stimulation of
[Ca2+]i induced by mitochondrial uncouplers (Figures 4-1 and 4-2).
Mitochondrial uncoupling with DNP or FCCP significantly inhibited lipolysis
(Figures 4-3 and 4-4). This effect was attenuated by insulin while lanthanum completely
reversed the suppression by mitochondrial uncouplers or/and insulin. These results
indicate that metabolic uncouplers suppress lipolysis via a calcium dependent mechanism.
In short-term (4 hours) treatment with DNP, FAS activity was decreased significantly by
mitochondrial uncoupling (p<0.001) (Figure 4-5). However, lanthanum was unable to
reverse this short-term suppression, indicating that this short-term suppression of FAS
activity by DNP was calcium-independent. Similar results were observed with a longterm (48hours) treatment with both mitochondrial uncouplers, with lanthanum causing a
further suppression (Figures 4-5 and 4-6). However, both mitochondrial uncouplers
significantly increased FAS expression and this effect was reversed by lanthanum
(Figure 4-7). Thus, metabolic uncoupling has a dual effect on FAS: to decrease activity
via a Ca2+-independent mechanism and to increase FAS expression via a Ca2+-dependent
mechanism. The addition of ATP reversed the DNP-induced suppression of FAS activity,
indicating that this effect is secondary to ATP depletion (Figure 4-8).
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Figure 4-1. Effect of DNP on intracellular calcium in 3T3-L1 adipocytes.
Differentiated 3T3-L1 adipocytes were treated with or without DNP (25µM, 50µM),
DNP plus KCl (40mM) or DNP plus lanthanum(1mM). Data are expressed as mean ± SE
(n=12). Difference letters above the bars indicate a significant difference at level of
p<0.05.
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Figure 4-2. Effect of FCCP on intracellular calcium in 3T3-L1 adipocytes.
Differentiated 3T3-L1 adipocytes were treated with or without FCCP (1µM, 5µM),
FCCP plus KCl (40mM) or FCCP plus lanthanum (1mM). Data are expressed as mean ±
SE (n =12). Difference letters above the bars indicate a significant difference at level of
p<0.05.
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Figure 4-3. Effect of DNP on lipolysis in 3T3-L1 adipocytes. Differentiated 3T3-L1
adipocytes were treated with or without DNP (25µM), DNP plus insulin (30nM), DNP
plus isoproterenol (50nM) or DNP plus lanthanum (1mM). Lipolysis was determined as
glycerol release by enzymatic fluorescence method, which was conducted as described in
Materials and Methods. Data are expressed as mean ± SE (n =12). Difference letters
above the bars indicate a significant difference at level of p<0.05.
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Figure 4-4. Effect of FCCP on lipolysis in 3T3-L1 adipocytes. Differentiated 3T3-L1
adipocytes were treated with or without FCCP (1µM, 5µM), FCCP plus insulin (30nM),
FCCP plus isoproterenol (50nM) or FCCP plus lanthanum (1mM). Lipolysis was
determined as glycerol release by enzymatic fluorescence method, which was conducted
as described in Materials and Methods. Data are expressed as mean ± SE (n =12).
Difference letters above the bars indicate a significant difference at level of p<0.05.
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Figure 4-5. Effect of DNP on fatty acid synthase (FAS) activity in 3T3-L1 adipocytes.
Differentiated 3T3-L1 adipocytes were treated with or without DNP (25µM), Insulin
(30nM), Lanthanum(1mM), DNP plus insulin or DNP plus lanthanum. FAS activity was
measured as the oxidative rate of NADPH, which was conducted as described in
Materials and Methods. Data are expressed as mean ± SE (n =12). Difference letters
above the bars indicate a significant difference at level of p<0.05.
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Figure 4-6. Effect of FCCP on fatty acid synthase (FAS) activity in 3T3-L1
adipocytes. Differentiated 3T3-L1 adipocytes were treated with or without FCCP (1µM,
5µM), Insulin (30nM), Lanthanum (1mM), FCCP plus insulin or FCCP plus lanthanum.
FAS activity was measured as the oxidative rate of NADPH, which was conducted as
described in Materials and Methods.

Data are expressed as mean ± SE (n =12).

Difference letters above the bars indicate a significant difference at level of p<0.05.
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Figure 4-7. Effect of DNP on fatty acid synthase (FAS) expression in 3T3-L1
adipocytes. Differentiated 3T3-L1 adipocytes were treated with or without DNP (25µM),
Insulin (30nM), Lanthanum (1mM), DNP plus insulin or DNP plus lanthanum. FAS
mRNA was measured by real time PCR, which was conducted as described in Materials
and Methods. Data are expressed as mean ± SE (n =6). Difference letters above the bars
indicate a significant difference at level of p<0.05.
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Figure 4-8. Effect of DNP on fatty acid synthase (FAS) activity in 3T3-L1 adipocytes.
Differentiated 3T3-L1 adipocytes were treated with or without DNP (25µM), ATP
(10nM), Lanthanum(1mM), DNP plus ATP, DNP plus lanthanum or Lanthanum plus
ATP. FAS activity was measured as the oxidative rate of NADPH, which was conducted
as described in Materials and Methods. Data are expressed as mean ± SE (n =6).
Difference letters above the bars indicate a significant difference at level of p<0.05.
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4.5 Discussion

Several studies have reported that mitochondrial uncoupling regulates lipid
metabolism both in vivo and in vitro (13-15). However, the mechanism mediating this
effect remains unclear. Our previous data suggested intracellular calcium is an important
regulator of both lipogenesis and lipolysis. Accordingly, We investigated whether there is
an effect of mitochondrial uncoupling on intracellular calcium level and whether [Ca2+]i
is the mediator for the regulation of lipid metabolism by mitochondrial uncoupling.
The role of the mitochondria in regulation of [Ca2+]i homeostasis has been
widely investigated. Several observations suggest that [Ca2+]i is regulated by
mitochondria in an energy-linked process (16-18). In addition, experimental evidence
indicates a positive association between mitochondrial calcium and mitochondrial ATP
production (19-22). Our results suggest that mitochndrial uncoupling contributes to the
control of membrane calcium channel activity in differentiated 3T3-L1 adipocytes. We
report that mitochondrial uncouplers dose-responsively increase [Ca2+]i in adipocytes.
This regulation of [Ca2+]i level by mitochondrial uncouplers in adipocytes appears to
involve membrane calcium channels, as this effect can be completely blocked by nonspecific calcium channel antagonist (lanthanum). Although Makowska et al. previously
reported that mitochondrial uncoupler depressed the rate of calcium influx in vitro (23),
this inhibitory effect of uncoupler on intracellular calcium was observed on storeoperated calcium channel rather than voltage-gated calcium channel (VGCC). However,
an important relevant role of VGCCs is to serve as highly regulated mechanisms to
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deliver calcium ions into specific intracellular locales for a variety of calcium-dependent
processes (24), Thus, the observation from present work demonstrated that mitochondrial
uncoupler regulates VGCC by increasing the calcium influx. Additionally, Lynch et al
have shown that calcium was released from mitochondrial as a result of DNP dissipation
of the H+ gradient (25). Consequently, we reasoned that intracellular calcium may be a
trigger in the effect of mitochondrial uncoupling on lipid metabolism.
Previous studies have demonstrated that lipolysis depends on the energy status of
adipocytes (26-27). A decrease in intracellular ATP elicited in white adipocytes in vitro
by inhibitors of the mitochondrial respiratory chain reversed the stimulation of lipolysis
by catecholamines (28). More recently, ATP was shown to be required for translocation
of HSL from cytoplasm to the surface of lipid storage droplets and for phosphorylation of
HSL and other proteins that are involved in lipolysis in adipocytes (29). Incubation of
isolated adipocytes with lipolytic hormones resulted in up to 50% decrease of their
intracellular ATP level and in inhibition of lipolysis itself (29). In addition, The
intracellular ATP is also essential for insulin signaling (30-31), which is altered at the
level of the interaction of insulin with its receptor (32). In present study, we also showed
that mitochondrial uncoupling inhibits lipolysis and this effect is via a calcium dependent
mechanism. Previous data from our laboratory demonstrate that increasing [Ca2+]i
inhibits adipocyte lipolysis. This effect is primarily mediated by activation of adipocyte
phosphodiesterase 3B and a reduction of cAMP levels, leading to a decrease in hormone
sensitive lipase phosphorylation and, consequently, an inhibition of lipolysis (32). In the
present study, increased [Ca2+]i and decreased lipolysis were observed concomitantly
with two individual mitochondrial uncouplers, while inhibition of Ca2+ influx prevented
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the suppression of lipolysis. Therefore, [Ca2+]i appears to mediate the effect of
mitochondrial uncouplers on lipolysis. In addition, the mitochondrial uncoupling results
in reduced adipocytes lipolysis in response to isoproterenal or insulin, suggesting a
reduction in adipocytes cAMP levels.
We also found that mitochondrial uncoupling has dual effects on a key lipogenic
system, fatty acid synthase. The suppression of FAS activity induced by short-term
treatment with mitochondrial uncouplers indicates a non-genomic effect of mitochondrial
uncoupling on FAS. This effect is a calcium-independent since lanthanum is unable to
reverse the suppression. The stimulation of FAS expression was induced by long-term
treatment with mitochondrial uncouplers and this stimulation of FAS expression can be
fully reversed by lanthanum, indicating that a genomic effect of mitochondrial
uncoupling on FAS expression is [Ca2+]i-dependent, consistent with our previous reports
of [Ca2+]i regulation of FAS expression(8-9). To our surprise, FAS activity was
suppressed by long-term treatment with mitochondrial uncouplers and addition of
lanthanum induced a further suppression on FAS activity, which suggests that there is
both a calcium dependent and a non-genomic, Ca2+-independent effect similar to that
observed in the short-term treatment. This non-genomic effect of suppression on FAS
activity by mitochondrial uncoupling may result from the shortage of the substrates (e.g.
NADPH and ATP) secondary to reduced mitochondrial energy with mitochondrial
uncouplers (33). For each molecule of acetate incorporated into long-chain FA, two
molecules of NADPH are necessary in the reaction catalyzed by FA synthase. Moreover,
mitochondrial production of ATP is required for synthesis of oxalacetate by carboxylation
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of pyruvate and subsequent synthesis of citrate in mitochondria and for FA synthesis and
esterification in cytoplasm (34-35). The ATP/ADP ratio has been demonstrated to affect
pyruvate carboxylase activity directly (35-36). Although the in vitro assay system used in
this study provides acetyl-CoA, malonyl -CoA and NADPH, it does not provide
exogenous ATP. Therefore, reduced availability of intramitochondrial ATP and the a
reduced ATP: ADP ratio secondary to uncoupling may be responsible for the observed
reduction in activity (37-38). To further test this hypothesis, we found that addition of
ATP reversed the uncoupler-induced suppression on FAS activity, indicating that
inhibition of FA synthesis by uncouplers probably resulted from limited availability of
intramitochondrial ATP.
In conclusion, mitochondrial uncoupling participates in the regulation in lipid
metabolism and [Ca2+]i. Figure 4-9 depicts a proposed scheme for the integration of this
regulation, as follows. Mitochondrial uncoupling increases [Ca2+]i by activating
membrane calcium channels and thereby inhibits lipolysis via a Ca2+-dependent pathway.
Mitochondrial uncoupling has dual effects on lipogenesis: it inhibits FAS activity via a
Ca2+-independent mechanism and stimulates of FAS expression via a Ca2+-dependent
metabolism.
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Figure 4-9. A proposed scheme for the integration of the regulation of lipid
metabolism by mitochondrial uncoupling. Mitochondrial uncoupling increases [Ca2+]i
by activating membrane calcium channels and thereby inhibits lipolysis via a Ca2+dependent pathway. Mitochondrial uncoupling has dual effects on lipogenesis: it inhibits
FAS activity via a Ca2+-independent mechanism and stimulates of FAS expression via a
Ca2+-dependent metabolism.
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Part Five
Role of Uncoupling Protein 2 (UCP2) Expression and 1α, 25
Dihydroxyvitamin D3 (1 α, 25-(OH)2-D3) in Modulating Adipocyte
Apoptosis
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This part is a slightly revised version of a paper by the same name published in
the FASEB Journal in 2004 by Xiaocun Sun, Michael B. Zemel:
Xiaocun Sun, Michael B. Zemel. Role of uncoupling protein 2 (UCP2) expression
and 1alpha, 25 -dihydroxyvitamin D3 in modulating adipocyte apoptosis, FASEB Journal
(2004) [Epublication ahead of print]

5.1 Abstract

We previously found that 1α,25-(OH)2-D3 modulates adipocyte lipid
metabolism via a Ca2+-dependent mechanism and inhibits adipocyte UCP2 expression,
indicating that the anti-obesity effects of dietary calcium are mediated by suppression of
1α, 25-(OH)2-D3 levels. However, because UCP2 reduces mitochondrial potential, we
have evaluated the roles of UCP2, mitochondrial uncoupling and 1α, 25-(OH)2-D3 in
adipocyte apoptosis. Overexpressing UCP2 in 3T3-L1 cells induced marked reductions in
mitochondrial potential (∆ψ) and ATP production (p<0.01), increases in the expression of
caspases (p<0.05) and a decrease in Bcl-2/Bax expression ratio (p<0.01). Physiological
doses of 1α, 25-(OH)2-D3 (0.1-10 nM) restored mitochondrial ∆ψ in LI-UCP2 cells and
protected against UCP2 overexpression-induced apoptosis (p<0.01), while a high dose
(100 nM) stimulated apoptosis in 3T3-L1 and L1-UCP2 cells (p<0.05). 1α, 25-(OH)2-D3
stimulated cytosolic Ca2+ dose-dependently in both 3T3-L1 and L1-UCP2 cells. However,
physiological doses suppressed mitochondrial Ca2+ levels by ~50% while the high-dose
increased mitochondrial Ca2+ by 25% (p<0.05); this explains stimulation of apoptosis by
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the high dose of 1α, 25-(OH)2-D3. Using high calcium diets to suppress 1α, 25-(OH)2-D3
stimulated adipose tissue apoptosis in aP2 transgenic mice (p<0.01), suggesting that
increasing dietary calcium stimulates adipose apoptosis and thereby further contributes to
an anti-obesity effect of dietary calcium.

5.2 Introduction
Previous data from this laboratory demonstrate a key role for intracellular Ca2+
([Ca2+]i) in the regulation of adipocyte metabolism and lipid storage(1-3). Because [Ca
2+

]i can clearly be modulated by calcitrophic hormones, including 1α, 25-

dihydroxyvitamin D3 (1α, 25-(OH)2-D3), these data provide a theoretical framework to
explain an anti-obesity effect of high calcium diet (4). Indeed, increasing dietary calcium
in the absence of caloric restriction appears to result in a re-partitioning of dietary energy
from adipose tissue to lean body mass, resulting in a net reduction in fat mass in both
mice and humans, while increasing dietary calcium intake during energy restriction
results in a marked augmentation of body weight and fat loss in both mice and humans(46).
We have also found that high calcium diets attenuate the decreases in core
temperature which otherwise occur with energy restriction in mice(4), and that dietary
calcium up-regulates uncoupling protein 2(UCP2) expression in white adipose tissue(7).
We recently extended this concept by demonstrating that 1α, 25-(OH)2-D3 directly
suppresses UCP2 expression in isolated human adipocytes (8), indicating that the up237

regulation of UCP2 induced by dietary calcium may result from the loss of inhibition of
UCP2 expression by 1α, 25-(OH)2-D3.
Recent data also indicate that [Ca

2+

]i may play a key role in modulating

sensitivity to the apoptotic stress(9-12). Several of the functional groups of molecules
involved in apoptosis, including caspases and the Bcl-2 family, are [Ca
responsive(15-18). [Ca

2+

]i

2+

]i has been demonstrated to modulate the role of proteases,

including caspase-3, caspase-9 and Ca2+-dependent endonucleases(9,19-22). Scorrano et
al. also showed a key interaction occurs between Bcl-2 family protein and calcium
signaling in the execution of apoptosis (23). Their data demonstrate a critical role of
BAX and BAK in maintaining of homeostatic concentration of [Ca2+]i in endoplasmic
endo-reticulum(ER) and mitochondria, which control the apoptotic fate of cells
responding to [Ca2+]i dependent stimuli. Several studies have also shown that
thapsigargin, which can induce sustained [Ca2+]i elevation by inhibiting sacroendoplasmic reticulum Ca2+-ATPase(SERCA), triggers apoptosis in various cell
types(24-26). These data indicate a key role of [Ca2+]i in the apoptosis process. Given
that [Ca2+]i can be modulated by 1α, 25-(OH)2-D3, the role of 1α, 25-(OH)2-D3 in
apoptosis should be explored. Although high dose of 1α, 25-(OH)2-D3 has been reported
to induce apoptosis in various tumor cells (27-30), the regulation of apoptosis by
physiological doses of 1α, 25-(OH)2-D3 remains unclear.
Considerable progress has been made in elucidating a pivotal role of mitochondria
playing in the coordination, initiation, and execution of apoptotic cell death (31-33).
Three general mechanisms have been proposed, including 1) disruption of oxidative
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phosphorylation ATP production; 2) regulation of the apoptotic proteases; and 3)
alteration of cellular reduction-oxidation potential. Because UCP2, which is highly
expressed in white adipose tissue, has been demonstrated to function as mitochondrial
uncoupler of oxidative phosphorylation thus reduce efficiency of ATP synthesis, it is
reasonable to propose that UCP2 may stimulate apoptosis in adipocytes. Accordingly, in
the present study, the effect and mechanisms of mitochondrial uncoupling and 1α, 25(OH)2-D3 on apoptosis in adipocytes were examined. We report here that 1)
mitochondrial uncoupling induces apoptosis in differentiated 3T3-L1 cells; 2) low-doses
of 1α, 25-(OH)2-D3 inhibit apoptosis in differentiated 3T3-L1 cells in a dose-dependent
manner while high-dose of 1α, 25-(OH)2-D3 stimulates apoptosis; and 3)high calcium
diets, which suppress 1α, 25-(OH)2-D3 levels in vivo, stimulate adipose tissue apoptosis
in aP2 transgenic mice.

5.3 Materials and Methods
5.3.1 Culture and Differentiation of 3T3-L1 Adipocytes
3T3-L1 preadipocytes were incubated at a density of 8000 cells/cm2 (10 cm2 dish)
and grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS and
antibiotics (adipocyte medium) at 37°C in 5% CO2 in air. Confluent preadipocytes were
induced to differentiate with a standard differentiation medium consisting of DMEM-F10
(1:1, vol/vol) medium supplemented with 1% FBS, 1µM dexamethasone, IBMX (0.5 mM)
and antibiotics (1% Penicillin-Streptomycin). Preadipocytes were maintained in this
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differentiation medium for 3 days and subsequently cultured in adipocyte medium.
Cultures were re-fed every 2–3 days to allow 90% cells to reach fully differentiation
before conducting chemical treatment. Chemicals were freshly diluted in adipocyte
medium before treatment. Cells were washed with fresh adipocyte medium, re-fed with
medium containing the different treatments, and incubated at 37°C in 5% CO2 in air
before analysis. Cell viability was measured via trypan blue exclusion.
5.3.2 UCP2 Transfection
UCP2 full-length cDNAs was amplified by RT-PCR using mRNAs isolated
from mouse white adipose tissues. The PCR primers for this amplification are shown as
follows:

UCP2

forward,

5’-GCTAGCATGGTTGGTTTCAAG-3’,

reverse,

5’-

GCTAGCTCAGAAAGGTGAATC-3’. The PCR products were then subcloned into
pcDNA4/His expression vectors. The linearized constructs were transfected into 3T3-L1
preadipocytes using lipofectamine plus standard protocol (Invitrogen, Carlsbad, CA).
After 48 hrs of transfection, cells were split and cultured in selective medium containing
400 ug/ml zeocin for the selection of resistant colonies. Cells were fed with selective
medium every 3 days until resistant colonies could be identified. These resistant foci
were picked, expanded, tested for expression, and frozen for future experiments.
5.3.3 Determination of Mitochondrial Membrane Potential
Adipocytes were incubated with adipocyte medium for 4h with or without 1α,
25-(OH)2-D3. Mitochondrial membrane potential was analyzed fluorometrically with a
lipophilic

cationic

dye

JC-1

(5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazol
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carbocyanine iodide) using a mitochondrial potential detection kit (Biocarta, San Diego,
CA). Mitochondrial potential was determined as the ratio of red fluorescence (excitation
550 nm, emission 600 nm) and green fluorescence (excitation 485 nm, emission 535 nm)
using a fluorescence microplate reader.
5.3.4 ATP Measurement
Adipocytes were incubated with adipocyte medium for 4h with or without 1α, 25(OH)2-D3. ATP levels were measured using ENLITEN® Total ATP Rapid
Biocontamination

Detection

Kit

(Promega,

Madison,

MI)

according

to

the

manufacturer’s instruction. Cellular ATP was extracted as described previously (34), and
was using a microplate luminometer (Labsystem, Helsinki, Finland). The integration time
of the luminometer was set at 1s with normal gain.
5.3.5 Measurement of Cytosolic Ca2+([Ca2+]c) and Mitochondrial Calcium([Ca2+]m)
[Ca2+]c in adipocytes was measured using a fura-2 dual-wavelength fluorescence
imaging system. Cells were plated in 35-mm dishes (P35G-0-14-C, MatTek). Prior to
[Ca2+]c measurement, cells were put in serum-free medium overnight and rinsed with
HEPES balanced salt solution (HBSS) containing the following components (in mM):
138 NaCl, 1.8 CaCl2, 0.8 MgSO4, 0.9 NaH2PO4, 4 NaHCO3, 5 glucose, 6 glutamine, 20
HEPES, and 1% bovine serum albumin. Cells were loaded with fura-2 acetoxymethyl
ester (fura-2 AM) (10 µM) in the same buffer for 2 h at 37°C in a dark incubator with 5%
CO2. To remove extracellular dye, cells were rinsed with HBSS three times and then
post-incubated at room temperature for an additional 1h for complete hydrolysis of
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cytoplasmic fura-2 AM. The dishes with dye-loaded cells were mounted on the stage of
Nikon TMS-F fluorescence inverted microscope with a Cohu model 4915 charge-coupled
device (CCD) camera. Fluorescent images were captured alternatively at excitation
wavelengths of 340 and 380 nm with an emission wavelength of 520 nm. After
establishment of a stable baseline, the responses to 1α, 25-(OH)2-D3 was determined.
[Ca2+]c was calculated using a ratio equation as described previously. Each analysis
evaluated responses of 5 representative whole cells. Images were analyzed with InCyt
Im2 version 4.62 imaging software (Intracellular Imaging, Cincinnati, OH). Images were
calibrated using a fura-2 calcium imaging calibration kit (Molecular Probes, Eugene, OR)
to create a calibration curve in solution, and cellular calibration was accomplished using
digitonin (25 µM) and pH 8.7 Tris-EGTA (100 mM) to measure maximal and minimal
[Ca2+]c levels respectively.
Rhod-2/AM was used for qualitative measurement of [Ca2+]m(35). Cells were
incubated with the Ca2+ sensitive fluorescent indicator rhod-2 AM (1-1·5 µM), for at least
1 h at 370C in 5% CO2 in humidified air. Since rhod-2 AM consists of a cationic
rhodamine molecule, it accumulates preferentially inside the mitochondria due to their
negative membrane potential. After loading, the cells were kept in rhod-2 AM-free
standard solution for at least 1 h to allow conversion of the dye to its Ca2+-sensitive, free
acid form. Images of [Ca2+]m were acquired at the wavelength of 552nm excitation and
590nm emission using the intracellular imaging system described above. Since rhod-2 is
not a ratiometric dye, its fluorescence intensity was not calibrated to obtain absolute
values of [Ca2+]m. Instead, only relative values were recorded as fluorescence signal (F)
relative to the control value (F0). After baseline calcium concentration was measured, the
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1, 25(OH)2 D3 was immediately applied to the cells and the calcium concentration was
measured again.
5.3.6 Total RNA Extraction
A total cellular RNA isolation kit (Ambion, Austin, TX) was used to extract total
RNA from 3T3-L1 cells according to manufacturer’s instruction.
5.3.7 Quantitative Real-time PCR
Adipocyte caspase-1, caspase-3, Bcl-2 and Bax mRNA were quantitatively
measured using a Smart Cycler Real Time PCR System (Cepheid, Sunnyvale, CA) with a
TaqMan 1000 Core Reagent Kit (Applied Biosystems, Branchburg, NJ). The primers and
probe sets were ordered from Applied Biosystems TaqMan® Assays-on-Demand™ Gene
Expression primers and probe set collection according to manufacture’s instruction.
Pooled 3T3-L1 adipocyte total RNA was serial-diluted in the range of 1.5625-25 ng and
used to establish a standard curve; total RNAs for unknown samples were also diluted in
this range. Reactions of quantitative RT-PCR for standards and unknown samples were
also performed according to the instructions of Smart Cycler System (Cepheid,
Sunnyvale, CA) and TaqMan Real Time PCR Core Kit (Applied Biosystems, Branchburg,
NJ). The mRNA quantitation for each sample was further normalized using the
corresponding

18s

quantitation,

AGTCCCTGCCCTTTGTACACA-3’

with
and

GATCCGAGGGCCTCACTAAAC-3’.

243

a
a

forward
reverse

primer:
primer:

5’5’-

5.3.8 Animals and Diets
This study was divided into three phases. The first phase was designed to induce
weight gain and fat accretion, the second phase studied acceleration of weight and fat lass
on the obese animals induced by phase one, and the third phase determined attenuation of
graining back of weight and fat. The study was conducted in the aP2 transgenic mice
used in the studies described previously. These mice exhibit a normal pattern of leptin
gene expression and activity as well as a pattern of agouti gene expression similar to that
found in humans. Therefore, these mice are useful models for diet-induced obesity in a
genetically susceptible human population in that they are not obese on a standard AIN93G diet, but develop mild to moderate obesity when fed high sucrose and/or high fat
diets (4).
Phase I
Six-week old aP2 transgenic mice were studied in a six-week obesity induction
period on a basal low Calcium/high sucrose/high fat diet.
60 aP2 transgenic mice from our colony were placed at 6 weeks of age on a
modified AIN 93 G diet with suboptimal calcium (0.4%), sucrose as the sole
carbohydrate source, and fat increased to 25% of energy with lard. Animals were studied
for six weeks, during which food intake and spillage were measured daily, and body
weight and food consumption were assessed weekly. At the end of phase I, five
representative animals were sacrificed as following to collect fat pads.
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Phase II
At the end of the phase one, the 55 animals remaining from phase I were put into
high calcium diet but the energy intake was limited to 70% of that found in the ad libitum
fed during phase I. The high calcium diet used in this phase was made of the basal diet
with the addition of sufficient calcium to bring the calcium content of the diet to 1.3%.
Animals were maintained on this diet for six weeks, during which food intake and
spillage were measured daily and body weight as well as food consumption were
assessed weekly. At the end of phase II, five animals were sacrificed as following to
collect fat pads.
Phase III
At the end of the phase II, the 50 animals remaining from phase II were further
randomized into five groups, as following: 1) Basal-refed group were put on high
sucrose/high fat/low calcium basal diet ad lib 2) High-Ca cereal-refed group were put on
high-Ca-(1.3%)cereal diet ad lib. 3) High-Ca-cereal plus dry milk group were put on high
calcium cereal plus non fat milk diet ad lib, in which 1.2% calcium content comes from
fortified cereal and 0.1% calcium content comes from non fat milk; 4)Yogurt refed group
were put on high calcium (1.3 %)-yogurt diet ad lib. 5) Cereal control refed group were
put on low calcium (0.4%)-cereal diet ad lib. 10 animals /group were studied for six
weeks, during which food intake and spillage were measured daily and body weight and
food consumption were assessed weekly. At the conclusion of the study, all mice were
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sacrificed under isofluorane anaesthesia and fat pads were immediately excised, weighed
and snap-frozen in liquid nitrogen for subsequential assessment of gene expression.
The animal portion of this study was approved from an ethnical standpoint by the
University of Tennessee, Institutional Animal Care and Use Committee.
5.3.9 Statistical Analysis
All data are expressed as mean ± SE. Data were evaluated for statistical
significance by one-way analysis of variance (ANOVA), and significantly different group
means were then separated by the least significant difference test by using SPSS (SPSS
Inc, Chicago, IL.).

5.4 Results
All apoptosis signaling pathways converge on a common pathway of cell
destruction that is activated by a family of cysteine proteases (caspases) that cleave
protein at aspartate residues. Accordingly, we first studied the effect of 1α, 25-(OH)2-D3
and DNP on caspase-1 and caspase-3 expression in differentiated 3T3-L1(control) and
UCP2 transfected 3T3-L1 cells. Figures 5-1 and 5-2 demonstrate that physiological lowdoses of 1α, 25-(OH)2-D3 (0.1nM, 1nM, 5nM and 10nM) inhibited Caspase-1 and
caspase-3 expression respectively (p<0.05), indicating reduced apoptosis in both control
and UCP2 transfected 3T3-L1 cells. In contrast, a high-dose of 1α, 25-(OH)2-D3(100nM)
stimulated both caspase-1 and caspase-3 expression in both control and UCP2 transfected
3T3 L1 cells (p<0.01), indicating a pro-apoptotic effect. Although 1α, 25-(OH)2-D3
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Figure 5-1. Caspase-1 expression in 3T3 L1 and UCP2 transfected 3T3-L1
adipocytes. Primary-cultured adipocytes were treated with or without 1α, 25-(OH)2-D3
(0.1nM, 1nM, 5Nm, 10nM, and 100nM) and DNP (25µM and 50µM) for 24 h for mRNA
levels. Caspase-1 mRNA levels were measured by real-time PCR and these
measurements were conducted as described in Materials and Methods. Data are expressed
as mean ± SE (n =6). Different letters above the bars indicate a significant difference at
level of p<0.05.
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Figure 5-2. Caspase-3 expression in 3T3-L1 and UCP2 transfected 3T3-L1
adipocytes. Primary-cultured adipocytes were treated with or without 1α, 25-(OH)2-D3
(0.1nM, 1nM, 5Nm, 10nM, and 100nM) and DNP (25µM and 50µM) for 24 h for mRNA
levels. Caspase-1 mRNA levels were measured by real-time PCR and these
measurements were conducted as described in Materials and Methods. Data are expressed
as mean ± SE (n =6). Different letters above the bars indicate a significant difference at
level of p<0.05.

248

exerted similar effects on caspases-1 and 3 expression in 3T3-L1 and UCP2 transfectd
3T3-L1 cells, the basal expression levels of these two caspases were significantly higher
in the DNP treated and UCP2 transfected cells in compared to control cells(p<0.05),
suggesting that mitochondrial uncoupling stimulates apoptosis in cultured 3T3-L1 cells.
Both Bcl-2 and Bax are apoptotic proteins belonging to Bcl-2 family. Due to their
completely different roles in apoptotic signaling pathway, the ratio of protective Bcl-2 to
apoptotic Bax is widely used to determine the susceptibility to apoptosis by regulating
mitochondrial function following an apoptotic stimuli. Figure 5-3 shows the effect of 1α,
25-(OH)2-D3 on Bcl-2/ Bax expression ratio. We found that the lower levels of 1α, 25(OH)2-D3 induced a dose-dependent increase in Bcl-2/Bax ratio(p<0.01), indicating a
protective role of lower level of 1α, 25-(OH)2-D3 against apoptosis. In contrast, the high
dose of 1α, 25-(OH)2-D3 resulted in a significant decrease in the Bcl-2/Bax ratio in
control and UCP2 transfected 3T3-L1 cells(p<0.01). In addition, the DNP treated and
UCP2 transfected cells showed significantly lower ratio of Bcl-2/Bax than nontransfected 3T3-L1 cells (p<0.02), indicating mitochondrial uncoupling induced a
decrease in protection from apoptotic death.
Since physiological low-dose of 1α, 25-(OH)2-D3 appears to inhibit adipocyte
apoptosis, suppression of 1α, 25-(OH)2-D3 with high calcium diet may stimulate
apoptosis. Accordingly, we compared caspase-1 and caspase-3 expression as well as Bcl2/Bax expression ratio in aP2 transgenic mice fed diets with different calcium content
after energy restriction. As shown in the Figure 5-4, 5-5 and 5-6, we found significant
higher increases in caspase-1 and caspase-3 expression (p<0.001), and decreases in Bcl2/Bax ratio in mice fed high calcium diets(Ca 1.3%) than mice fed low calcium diets(Ca
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Figure 5-3. Bcl-2/Bax expression ratio in 3T3-L1 and UCP2 transfected 3T3-L1
adipocytes. Primary-cultured adipocytes were treated with or without 1α, 25-(OH)2-D3
(0.1nM, 1nM, 10nM, and 100nM) and DNP (25µM and 50µM) for 24 h for mRNA levels.
Caspase-1 mRNA levels were measured by real-time PCR and these measurements were
conducted as described in Materials and Methods. Data are expressed as mean ± SE (n
=6). Different letters above the bars indicate a significant difference at level of p<0.05.

250

Caspase-1/18s

5

c

4
3

c

b

2
1

a

a

a

b

0
I-Basal

III-basal

a

III-high-Ca

III-Milk

III-Yogurt

III-Cereal

a

a

Figure 5-4. Effect of dietary calcium on caspase-1 expression white adipose tissue of
aP2-agouti transgenic mice. Diet and animal administration was conducted as described
in Materials and Methods. Data are expressed as mean ± SE (n =8). Difference letters
above the bars indicate a significant difference at level of p<0.05.
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aP2-agouti transgenic mice. Diet and animal administration was conducted as described
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0.4%) (p<0.01). These data suggest that suppression 1α, 25-(OH)2-D3 physiologically in
vivo may stimulate adipocytes apoptosis.
Figure 5-7 shows the effect of 1α, 25-(OH)2-D3 on mitochondrial potential in 3T3
L1 and UCP2 stably transfectd 3T3 L1 cells. We found that lower-doses of 1α, 25-(OH)2D3 significantly increased mitochondrial potential in all three groups of cells whereas the
high-dose of 1α, 25-(OH)2-D3 caused mitochondrial potential collapse. Consistent with
these data, ATP production was markedly increased in response to low-dose 1α, 25(OH)2-D3 treatment (p<0.01)(Figure 5-8), while the high-dose of 1α, 25-(OH)2-D3
inhibited ATP production (p<0.05). These effects are consistent with our previous
observation that low-dose of 1α, 25-(OH)2-D3 inhibited UCP2 expression(6). Thus, by
inhibiting UCP2 expression, the low-dose of 1α, 25-(OH)2-D3 restored mitochondrial
potential and increased ATP production.
1α, 25-(OH)2-D3 also stimulated Ca2+ influx in both control and UCP2 transfected
cells. Figure 5-9 demonstrates a dose-dependent increase in cytosolic calcium levels in
response to 1α, 25-(OH)2-D3. Notably, the high-dose of 1α, 25-(OH)2-D3 induced a 10fold higher in increase in calcium influx than the lower doses.
Figure 5-10 shows the effect of 1α, 25-(OH)2-D3 on [Ca2+]m levels in control and
UCP2 transfected cells. Low-doses of 1α, 25-(OH)2-D3 decreased mitochondrial calcium
in both type of cells while the high-dose of 1α, 25-(OH)2-D3 significantly stimulated
[Ca2+]m. Since mitochondrial calcium overload might trigger apoptosis by inducing
mitochondrial collapse and cytochrome c release, the pro-apoptotic effect of the highdose of 1α, 25-(OH)2-D3 is most likely a result of the stimulation of [Ca2+]m. In contrast,
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Figure 5-7. Mitochondrial potential in 3T3-L1 and UCP2 transfected 3T3-L1
adipocytes. Primary-cultured adipocytes were treated with or without 1α, 25-(OH)2-D3
(0.1nM, 1nM, 5Nm, 10nM, and 100nM) for 4h before assay. Mitochondrial potential
were measured using fluorospectrometry as described in Materials and Methods. Data are
expressed as mean ± SE (n =6). Different letters above the bars indicate a significant
difference at level of p<0.05.
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Figure 5-9. Intracellular calcium levels in 3T3-L1 and UCP2 transfected 3T3-L1
adipocytes. Primary-cultured adipocytes were treated with or without 1α, 25-(OH)2-D3
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indicate a significant difference at level of p<0.05.
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the decreases in [Ca2+]m observed in response treatment lower doses of 1α, 25-(OH)2-D3
indicate that, in addition to the inhibitory effect on UCP2, reducing the mitochondrial
calcium load may contribute to the anti-apoptotic effect of low doses of 1α, 25-(OH)2-D3.

5.5 Discussion
Obesity is characterized by an increase in both adipocyte size and number.
Adipose tissue is thus linked to the dynamic role played by adipocytes. However, the
concept of adipocyte deletion by apoptosis as a significant contributor to adipose tissue
loss during weight reduction is a relatively recent one. Qian et al showed that rat
adipocytes underwent apoptosis following brain administration of leptin and thereby
demonstrated that leptin induced weight loss was a result not only of an decrease in food
intake and increase in energy expenditure, but also of adipocyte depletion (36). Niesler et
al. found a depot specific susceptibility to apoptosis in human preadipocytes. Omental
preadipocytes were more susceptible to apoptotic stimuli than were subcutaneous
preadipocytes, indicating a possible mechanism for regulation of adipocyte tissue
distribution (37). Several studies also demonstrated that conjugated linoleic acid (CLA)
reduces body fat content in part by inducing adipocyte apoptosis, and that some factors,
including PPARs (38), UCPs (39), leptin (39) and TNF-α (40), are involved in CLA
modestly induced adipocyte apoptosis. However, data on the mechanisms and regulation
of adiopcyte apoptosis are still limited.
Previous data from our laboratory have demonstrated that 1α, 25-(OH)2-D3
appears to modulates adipocyte lipid and energy metabolism via both genomic and non259

genomic mechanisms(3,4,7,8). We have reported that 1α, 25-(OH)2-D3 plays a direct role
in the modulation adipocyte Ca2+ signaling(8), resulting in an increased lipogenesis and
decreased lipolysis(1,5,8). In addition, 1α, 25-(OH)2-D3 also plays a role in regulating
human adipocyte UCP2 mRNA and protein levels, indicating that the suppression of 1α,
25-(OH)2-D3 and the resulting up-regulation of UCP2 may contribute to increased rates
of lipid oxidation(7). Accordingly, the suppression of 1α, 25-(OH)2-D3 by increasing
dietary calcium attenuates adipocyte triglyceride accumulation and caused a net reduction
in fat mass in both mice and humans in the absence of caloric restriction (4-5), a marked
augmentation of body weight and fat loss during energy restriction in both mice and
humans(4-5), and a reduction in the rate of weight and fat regain after food restriction in
mice(4, 41). Although these anti-obesity effects of dietary calcium are appear to be due,
in part, to effects on lipolysis and lipogenesis(1,4), it is also possible that a loss of
adipocytes would results in a cellular deficit lipid esterification as the body recovers from
energy restriction. Thus, a reduced number of available adipocytes may not be able to
store excess energy coming from rebound in food intake. Moreover, generating new cells
would require extra energy that would contribute to a further metabolic enhancement.
Accordingly, present study demonstrates that lower (physiological) doses of 1α, 25(OH)2-D3 inhibit apoptosis in differentiated 3T3-L1 adipocytes, and the suppression of 1α,
25-(OH)2-D3 in vivo by increasing dietary calcium stimulates adipocyte apoptosis during
refeeding following energy restriction in aP2 transgenic mice, suggesting that the
stimulation of adipocyte apoptosis contributes to reduced adipose tissue mass after
administration of high calcium diets.
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Key feature of apoptosis involves the proteolytic caspases (42) as well as
apoptotic proteins Bcl-2 and Bax (43). Activation of Bax induces apoptosis by disturbing
mitochondrial electron transport chain, counters the death repressor activity of Bcl-2, and
promotes the release of cytochrome c into the cytoplasm (44-45). This, in turn, activates
caspases that initiate execution of apoptotic death. Bcl-2, which is localized to
mitochondria, inhibits Bax induced apoptosis, and consequently, the Bcl-2/Bax ratio can
be used to determine the susceptibility to apoptosis. In the present study, we found that
lower doses of 1α, 25-(OH)2-D3(0.1nm, 1nm, 5nm and 10nm) dose-dependently inhibit
caspase-1 and caspase-3 gene expression, and increase the Bcl-2/Bax expression ratio in
control and UCP2 transfected 3T3-L1 adipocytes, indicating an inhibition of apoptosis.
We also found that UCP2 transfected 3T3-L1 adipocytes have higher basal level of
caspase-1 and caspase-3 expression but a lower Bcl-2/Bax ratio than non-transfected
3T3-L1 cells. These results are consistent with our observation that UCP2 stimulates
apoptosis by inducing mitochondrial potential collapse and inhibiting ATP production.
We previously demonstrated that 1α, 25-(OH)2-D3 inhibits UCP2 expression in human
adipocytes (7). Consistent with our this observation, we have found 1α, 25-(OH)2-D3
functionally inhibits UCP2 action by increasing mitochondrial potential and ATP
production in both non-tranfected and UCP2 transfected 3T3-L1 cells. Thus, the
suppression of apoptosis induced by 1α, 25-(OH)2-D3 is, in part, mediated by inhibiting
UCP2 expression and activity. Accordingly, we proposed that the suppression of 1α, 25(OH)2-D3 secondary to consumption of high calcium diets may stimulate adipocytes
apoptosis in vivo. We evaluated this concept in aP2 transgenic mice undergoing refeeding following energy restriction, and found a significant increases in white adipose
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tissue apoptosis in mice re-fed high calcium diets(1.3%) compared to low calcium diets
(0.4% Ca). These results further confirm that suppression of 1α, 25-(OH)2-D3 stimulates
apoptosis in white adipose tissue and suggest that this effect also contribute to the antiobesity effect of dietary calcium.
In contrast, very high doses of 1α, 25-(OH)2-D3, which are three to four fold
higher than physiological levels, exert the opposite effect. We found that a high-dose of
1α, 25-(OH)2-D3( 100nM) actually stimulated caspase-1 and caspase-3 expression and
inhibited Bcl-2/Bax ratio, a complete reversal of the effect of lower doses of 1α, 25(OH)2-D3 on apoptosis. Although lower doses of 1α, 25-(OH)2-D3 caused moderate
increases in cytosolic [Ca2+] levels in adipocytes, the high-dose of 1α, 25-(OH)2-D3
induced an extreme elevation, and excessive intracellular calcium has been reported to be
a pro-apoptotic factor(45-46). Ca2+ is a ubiquitous intracellular messenger involved in
many cellular processes. To generate such complex Ca2+ signals, cells rely on the rapid
release of the Ca2+ storage (such as ER/SR and mitochondria) as well as on the controlled
Ca2+ influx from the extracellular medium upon stimuli, and strive to maintain the Ca2+
concentration at extremely low levels by expelling Ca2+ ions to the exterior and by
compartmentalization of Ca2+ intracellular stores under physiological conditions of rest.
Mitochondria take up Ca2+ through the uniporter on the inner membrane at the expense of
∆ψ(48). Mitochondria are often located close to the ER, and therefore exposed to the
Ca2+ release by the Inositol-1,4,5-trisphosphate receptor(IP3R) and ryanodine receptor
(RyR). The high Ca2+ levels achieved at these contact sites favors Ca2+ uptake into
mitochondria. Because of their tight coupling to ER Ca2+ store, mitochondria are highly
susceptible to abnormalities in Ca2+ signaling (49). Recent evidence suggests that the
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amount of Ca2+ going through mitochondria is crucial in triggering a Ca2+-dependent
apoptosis response, probably by the opening of a sensitized state of permeability
transition pore (PTP) (50). Scorrano et al reported that mouse embryonic fiberblasts
deficient in Bax were protected from apoptosis because of reducing resting concentration
of calcium in ER and decreased uptake of Ca2+ by mitochondria from the ER(23).
Expression of SERCA, on the other hand, corrected [Ca2+]er and [Ca2+]m, thereby
restoring apoptotic death (51). In the present study, we also monitored the mitochondrial
Ca2+ concentration and found that low-does of 1α, 25-(OH)2-D3 decreased mitochondrial
Ca2+ levels in a dose-dependent manner while high-dose of 1α, 25-(OH)2-D3 markedly
stimulates the elevation of [Ca2+]m, indicating that the increase [Ca2+]m is associated with
the induction of apoptosis by high-dose of 1α, 25-(OH)2-D3. We have previously reported
that mitochondrial uncoupling stimulated [Ca2+]c level, which may in turn induce an
increase in[Ca2+]m to maintain cytoplasmic calcium homeostasis. Low-doses of 1α, 25(OH)2-D3 induce dose-dependent depletion [Ca2+]m by inhibiting UCP2, thereby
protecting adipocytes from apoptotic death. High-doses of 1α, 25-(OH)2-D3, on the other
hand, increases [Ca2+]c to extreme level, which may increase both [Ca2+]m and [Ca2+]er.
Since ER can open their Ca2+ release channel in response to elevations in [Ca2+]c and
contribute to Ca2+ induced Ca2+ release (CICR), this may further increases [Ca2+]m and
calcium overload in mitochondria in turn triggers apoptosis.
In summary, the present study demonstrates dual effects of 1α, 25-(OH)2-D3 on
apoptotic death. These are summarized in Figure 5-11 as follows: by inhibiting UCP2
and decreasing mitochondrial calcium, lower (physiological) doses of 1α, 25-(OH)2-D3
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Figure 5-11. Schematic illustration of effects and mechanisms of 1α, 25-(OH)2-D3 on
adipocyte apoptosis. Physiological low doses of 1α, 25-(OH)2-D3 restore mitochondrial
potential and ATP production by suppressing UCP2, thereby inhibiting apoptosis. By
contrast, high dose of 1α, 25-(OH)2-D3 induces mitochondrial calcium overload and
stimulates apoptosis.
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inhibit apoptosis in adipocytes, while suppression of 1α, 25-(OH)2-D3 using high calcium
diets stimulates adipose apoptosis in mice. In contrast, a high dose of 1α, 25-(OH)2-D3
stimulates mitochondrial calcium overload and apoptosis in adiocytes. These results
indicate that dietary calcium not only regulates adipocytes size by decreasing lipid
accumulation, but also modulates adipocyte number by stimulating apoptotic death. Thus,
these results provide a new mechanism in support of the “anti-obesity” of dietary calcium.
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Part Six
Mechanisms of Dual Effects of 1α, 25-Dihydroxyvitamin D3 on
Adipocyte Apoptosis
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6.1 Abstract

We have previously shown that 1α, 25-Dihydroxyvitamin D3 (1α, 25-(OH)2-D3)
has dual effects on apoptotic death in adipocytes: physiological doses of 1α, 25-(OH)2-D3
inhibit adipocyte apoptotic death while suppression of 1α, 25-(OH)2-D3 using high
calcium diets stimulates adipose apoptosis in mice; In contrast, pharmacological doses of
1α, 25-(OH)2-D3 stimulate apoptosis. We have also demonstrated that 1α, 25-(OH)2-D3
inhibits expression of mitochondrial uncoupling protein 2 (UCP2), which plays a key role
in regulation of mitochondrial potential and apoptosis. We therefore hypothesized that
low doses of 1α, 25-(OH)2-D3 inhibit adipocyte apoptotic death by inhibiting UCP2
expression while high doses stimulate adipocyte apoptotic death via a calcium dependent
mechanism. In the current study, Ca2+ ionophore Bay K 8644(BK8644) induced 3-4 fold
of increases in [Ca2+]i (within the response range to physiological low doses of 1α, 25(OH)2-D3) and dose-dependently stimulated caspase-3 expression by 94%-260% (p<0.01).
In contrast, GDP, a potent inhibitor of mitochondrial uncoupling, decreased [Ca2+]I, and
increased mitochondrial potential, and suppressed caspase-3 expression in a dose
dependent manner(47%-80%, p<0.05). To address the independent effect of
mitochondrial uncoupling, pretreatment of 3T3-L1 cells with BK 8644 prevented GDPinduced decreases in [Ca2+]i but preserved the effect on GDP stimulated mitochondrial
potential. GDP suppressed caspase-3 expression by 45% (p<0.05) in BK8644 pretreated
cells. Transfection of dsRNA specific for UCP2 mRNA into 3T3-L1 cells suppressed
UCP2 expression by 70%, and caused a 52% increase in mitochondrial potential but a
58% decrease in caspase-3 expression (p<0.05), indicating a direct role of mitochondrial
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uncoupling in adipocyte apoptosis. These data further demonstrate that physiological
doses of 1α, 25-(OH)2-D3 inhibit apoptosis and this effect is attributable to the inhibitory
effect on mitochondrial uncoupling. In contrast, high doses of 1α, 25-(OH)2-D3 stimulate
apoptosis via a calcium-dependent mechanism.

6.2 Introduction
A substantial body of recent evidence demonstrate that dietary calcium regulates
adiposity (1-5). High dietary calcium, by suppressing 1α, 25-(OH)2-D3, decreases
intracellular calcium and thereby inhibits lipogenesis and stimulates lipolysis (4-8), while
low dietary calcium intakes increase 1α, 25-(OH)2-D3 and thereby causes an increase in
adiposity (9). Although the anti-obesity effect of dietary calcium appears to be primarily
attributable to the regulatory effect of 1α, 25-(OH)2-D3 on intracellular calcium on
adipocyte lipid accumulation, regulation on adipocyte apoptosis may also involved.
We have recently shown that 1α, 25-(OH)2-D3 has dual effects on adipocyte
apoptosis, with low (within the physiological range) doses of 1α, 25-(OH)2-D3, which
can be induced by low calcium diets in vivo, inhibiting apoptosis and pharmacologically
high doses of 1α, 25-(OH)2-D3 stimulating apoptosis(10). The mechanism of these dual
effects on adipocyte apoptosis induced by 1α, 25-(OH)2-D3 is yet to be determined.
However, we have previously demonstrated that 1α, 25-(OH)2-D3 inhibits mitochondrial
uncoupling protein 2 (UCP2) expression in cultured human adipocyte via a calcium
independent mechanism(11). Because UCP2, which is highly expressed in white adipose
tissue, has been founded to function as mitochondrial uncoupler of oxidative
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phosphorylation and thus reduce efficiency of ATP synthesis (12), it is reasonable to
propose that UCP2 may stimulate adipocyte apoptosis. Accordingly, the inhibition of
UCP2 by low doses of 1α, 25-(OH)2-D3 may suppress apoptosis. This observation,
coupled with the observation that intracellular calcium plays a key role in apoptosis (13),
led us to test the hypothesis that low dose of 1α, 25-(OH)2-D3 inhibits apoptosis by
suppressing UCP2 expression while high dose of 1α, 25-(OH)2-D3 stimulates apoptosis
via a calcium dependent pathway.

6.3 Materials and Methods
6.3.1 Culture and Differentiation of 3T3-L1 Adipocytes
3T3-L1 preadipocytes were incubated at a density of 8000 cells/cm2 (10 cm2 dish)
and grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS and
antibiotics at 37°C in 5% CO2. Confluent preadipocytes were induced to differentiate
with a standard differentiation medium consisting of DMEM-F10 (1:1, vol/vol) medium
supplemented with 1% FBS, 1µM dexamethasone, IBMX (0.5 mM) and antibiotics (1%
penicillin/streptomycin). Preadipocytes were maintained in this differentiation medium
for 3 days and subsequently cultured in adipocyte medium. Cultures were refed every 2–3
days. Cell viability was measured via trypan blue exclusion.
6.3.2 UCP2 Transfection
UCP2 full-length cDNAs were amplified by RT-PCR using mRNAs isolated
from mouse brown and white adipose tissues, respectively. The PCR primers for this
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amplification

are

shown

as

follows:

UCP2

forward,

5’-

GCTAGCATGGTTGGTTTCAAG-3’,reverse, 5’-GCTAGCTCAGAAAGGTGAATC-3’.
The PCR products were then subcloned into pcDNA4/His expression vectors. The
linearized constructs were transfected into 3T3-L1 preadipocytes using lipofectamine
plus standard protocol (Invitrogen, Carlsbad, CA). After 48 hrs of transfection, cells were
split and cultured in selective medium containing 400 ug/ml zeocin for the selection of
resistant colonies. Cells were fed with selective medium every 3 days until resistant
colonies were identified. These resistant foci were picked, expanded, tested for
expression,and frozen for future experiments.
6.3.3 siRNA Preparation and Transfections
Duplex siRNA corresponding to UCP2 gene was designed and chemically
synthesized by Invitrogen. The following gene-specific sequences were used successfully:
Si-UCP2

sense

5'-GCCUCUACGACUCUGUCAA-3'

UUGACAGAGUCGAGGC-3'.

Transfection

of

siRNA

and

antisense

5'-

was

performed

with

OligofectamineTM reagent (Invitrogen Life Technologies, CA) in 6-well plates. Briefly,
Oligofectamine diluted in DMEM was applied to the duplex siRNA mixture, and the
formulation was continued for 20min to allow the Oligofectamine-oligonucleotide
complex to form. Per well, 800µl of plating medium and 10ul of 20µM duplex siRNA
duplex siRNA formulated with 4µl of Oligofectamine were applied in a final volume of
1ml. Cells were then incubated at 370C in a CO2 incubator for 4hrs. 500 ul of DMEM
medium containing 3x serum was added to transfection mixture after transfection, and
cells were incubated for 48 h~72h.
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6.6.4 Western Blot Analysis
Adipocytes were harvested and sonicated in a homogenization buffer containing
50 mM Tris-HCl (PH 7.4), 250mM sucrose, 1mM EDTA, 1mM dithiothreitol, 1% (v/v)
Triton X, 10% protease cocktail (Sigma). Cell homogenates were incubated on ice for 1h
to solublize all proteins, and the insoluble protein was removed by centrifugation at
12,500g at 40C for 15 min. Homogenate intrafranatant protein from equal numbers of
cells (determined via protein quantitation using Bradford method as described previously)
was boiled in Laemmli sample buffer and subject to 10% SDS-polyacrylamide gel
electrophoresis (PAGE). Proteins on the gels were transferred to Hybond ECL
nitrocellulose membrane (Amersham

Pharmacia Biotech, Piscataway,

NJ). The

transferred membranes with proteins were blocked, washed, incubated with 1:1000
dilution of anti-UCP2 polyclonal antibody or 1:500 dilution of anti-actin polyclonal
antibody (Santa Cruz Biotechnology, CA) followed by peroxidase-conjugated secondary
antibody (Santa Cruz Biotechnology, CA). Visualization was detected with
chemiluminescence reagent, using the Western Blotting Luminal Reagent(Santa Cruz
Biotechnology, CA ).
6.3.5 Determination of Mitochondrial Membrane Potential
Mitochondrial membrane potential were analyzed spectrophotometrically with a
lipophilic

cationic

dye

JC-1

(5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazol

carbocyanine iodide) using a mitochondrial potential detection kit (Biocarta, San Diego,
CA).
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6.3.6 Measurement of Cytosolic Ca2+([Ca2+]c) and Mitochondrial Calcium([Ca2+]m)
[Ca2+]c in adipocytes was measured using a fura-2 dual-wavelength fluorescence
imaging system. Cells were plated in 35-mm dishes (P35G-0-14-C, MatTek). Prior to
[Ca2+]c measurement, cells were put in serum-free medium overnight and rinsed with
HEPES balanced salt solution (HBSS) containing the following components (in mM):
138 NaCl, 1.8 CaCl2, 0.8 MgSO4, 0.9 NaH2PO4, 4 NaHCO3, 5 glucose, 6 glutamine, 20
HEPES, and 1% bovine serum albumin. Cells were loaded with fura-2 acetoxymethyl
ester (fura-2 AM) (10 µM) in the same buffer for 2 h at 37°C in a dark incubator with 5%
CO2. To remove extracellular dye, cells were rinsed with HBSS three times and then
post-incubated at room temperature for an additional 1h for complete hydrolysis of
cytoplasmic fura-2 AM. The dishes with dye-loaded cells were mounted on the stage of
Nikon TMS-F fluorescence inverted microscope with a Cohu model 4915 charge-coupled
device (CCD) camera. Fluorescent images were captured alternatively at excitation
wavelengths of 340 and 380 nm with an emission wavelength of 520 nm. After
establishment of a stable baseline, the responses to 1α, 25-(OH)2-D3 was determined.
[Ca2+]c was calculated using a ratio equation as described previously. Each analysis
evaluated responses of 5 representative whole cells. Images were analyzed with InCyt
Im2 version 4.62 imaging software (Intracellular Imaging, Cincinnati, OH). Images were
calibrated using a fura-2 calcium imaging calibration kit (Molecular Probes, Eugene, OR)
to create a calibration curve in solution, and cellular calibration was accomplished using
digitonin (25 µM) and pH 8.7 Tris-EGTA (100 mM) to measure maximal and minimal
[Ca2+]c levels respectively.
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Rhod-2/AM was used for qualitative measurement of [Ca2+]m(14). Cells were
incubated with the Ca2+ sensitive fluorescent indicator rhod-2 AM (1-1·5 µM), for at least
1 h at 370C in 5% CO2 in humidified air. Since rhod-2 AM consists of a cationic
rhodamine molecule, it accumulates preferentially inside the mitochondria due to their
negative membrane potential. After loading, the cells were kept in rhod-2 AM-free
standard solution for at least 1 h to allow conversion of the dye to its Ca2+-sensitive, free
acid form. Images of [Ca2+]m were acquired at the wavelength of 552nm excitation and
590nm emission using the intracellular imaging system described above. Since rhod-2 is
not a ratiometric dye, its fluorescence intensity was not calibrated to obtain absolute
values of [Ca2+]m. Instead, only relative values were recorded as fluorescence signal (F)
relative to the control value (F0).
6.3.7 Total RNA Extraction
A total cellular RNA isolation kit (Ambion, Austin, TX) was used to extract total
RNA from 3T3-L1 cells according to manufacturer’s instruction.
6.3.8 Quantitative Real-time PCR
Adipocyte caspase-3 was quantitatively measured using a Smart Cycler Real
Time PCR System (Cepheid, Sunnyvale, CA) with a TaqMan 1000 Core Reagent Kit
(Applied Biosystems, Branchburg, NJ). The primers and probe sets were designed and
synthesised by Applied Biosystems TaqMan® Assays-on-Demand™ Gene Expression
primes and probe set collection according to manufacture’s instruction. Pooled 3T3-L1
adipocyte total RNA was serial-diluted in the range of 1.5625-25 ng and used to establish
a standard curve; total RNAs for unknown samples were also diluted in this range.
280

Reactions of quantitative RT-PCR for standards and unknown samples were also
performed according to the instructions of Smart Cycler System (Cepheid, Sunnyvale,
CA) and TaqMan Real Time PCR Core Kit (Applied Biosystems, Branchburg, NJ). The
mRNA quantitation for each sample was further normalized using the corresponding 18s
quantitation, with a forward primer: 5’-AGTCCCTGCCCTTTGTACACA-3’ and a
reverse primer: 5’-GATCCGAGGGCCTCACTAAAC-3’.
6.3.9 Statistical analysis
All data are expressed as mean ± SE. Data were evaluated for statistical
significance by one-way analysis of variance (ANOVA), and significantly different group
means were then separated by the least significant difference test by using SPSS (SPSS
Inc, Chicago, IL.).

6.4 Results
We have previously shown that the increase of mitochondrial uncoupling by
either chemical uncouplers or UCP2 overexpression in 3T3-L1 cells stimulates apoptosis,
with significant increases in caspase-1 and caspase-3 expression as well as decrease in
Bcl-2/Bax expression ratio (10). Consistent with this observation, we found in this study
that suppression of UCP2 by siRNA transfection in 3T3-L1 cells caused a 70% decrease
in UCP2 expression and a 52% increase in mitochondrial potential (p<0.05) (Figures 6-1
and 6-2), indicating that suppression of UCP2 increases adipocyte mitochondrial
potential. Inhibition of UCP2 expression in transfected cells also induced a 58% decrease
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Figure 6-1. Western blot with anti-mouse UCP2 antibody of cell lysates harvested
48hrs after siRNA transfection for evaluation of UCP2 protein reduction (upper
panel).The internal control actin is shown in the low panel. Blot shown is representative
of three similar experiments.
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b
a

Figure 6-2. Mitochondrial potential in 3T3-L1 and siRNA transfected 3T3-L1
adipocytes (UCP2 ko). Data are expressed as mean ± SE (n =6). Different letters above
the bars indicate a significant difference at level of p<0.05.
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in caspase 3 expression (p<0.01) (Figure 6-3). These data suggest that UCP2 plays a
direct role in stimulation of adipocyte apoptosis. Accordingly, suppression of UCP2
expression decreases apoptotic stress.
Although we demonstrated that overexpression of UCP2 favors adipocyte
apoptosis while suppression of UCP2 decreases apoptotic stress (10), it is not clear
whether other UCP isoforms may also be regulated correspondingly during UCP2
manipulation and thereby affect apoptosis. Accordingly, we further used GDP as a
general mitochondrial uncoupling inhibitor to investigate the effect of mitochondrial
uncoupling inhibition on apoptosis. GDP at 100µM and 500 µM increased mitochondrial
potential by 27% and 48% (p<0.05) respectively (Figure 6-4), confirming an inhibitory
effect of GDP on mitochondrial uncoupling. Figure 6-5 shows that GDP treatments
inhibited apoptosis in 3T3-L1 cells, with 47%-81% decreases in caspase-3 expression
(p<0.01), indicating that general inhibition of mitochondrial uncoupling suppresses
adipocyte apoptosis.
Bay K 8644 (BK 8644) is a Ca2+ ionophore which stimulated adipocyte Ca2+
influx in a dose-dependent manner (Figure 6-6). This stimulation of BK8644 (1nM100nM) on [Ca2+]i is of comparable magnitude to the effect of 1α, 25-(OH)2-D3.
However, BK8644 exerted no effect on mitochondrial potential or UCP2 expression
(Figure 6-7). This result is consistent with our previous observation that 1α, 25-(OH)2-D3
regulates UCP2 expression via a calcium-independent mechanism(10). Notably, BK 8644
stimulated caspase-3 expression dose-dependently (Figure 6-8), indicating that increases
in intracellular calcium influx independently stimulate adipocyte apoptosis. Consistent
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Figure 6-3. Caspase-3 expression in 3T3-L1 and siRNA transfected 3T3-L1
adipocytes (UCP2 ko). Data are expressed as mean ± SE (n =6). Different letters above
the bars indicate a significant difference at level of p<0.05.
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Figure 6-4. Effect of mitochondrial uncoupling inhibitor GDP on mitochondrial
potential in 3T3-L1 adipocytes. Data are expressed as mean ± SE (n =6). Different
letters above the bars indicate a significant difference at level of p<0.05.
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Figure 6-5. Effect of mitochondrial uncoupling inhibitor GDP on caspase-3
expression in 3T3-L1 adipocytes. Data are expressed as mean ± SE (n =6). Different
letters above the bars indicate a significant difference at level of p<0.05.

287

Intracellular calcium (nM)

2500

e
2000

d

1500

c

1000
500

a

b

0
1nM
BK8644

5nM
BK8644

10nM
BK8644

50nM
BK8644

100nM
BK8644

Figure 6-6. Effect of calcium channel ionophore Bay K 8644 on intracellular calcium
levels in 3T3-L1 adipocytes. Data are expressed as mean ± SE (n =6). Different letters
above the bars indicate a significant difference at level of p<0.05.

288

mitochondrial potential

10

b

b

1mM GDP

1mM GDP
+
1nM BK8644

8
6

a

a

4
2
0

Control

1nM
BK8644

Figure 6-7. Effect of mitochondrial uncoupling inhibitor GDP and calcium channel
ionophore Bay K 8644 on mitochondrial potential in 3T3-L1 adipocytes. Data are
expressed as mean ± SE (n =6). Different letters above the bars indicate a significant
difference at level of p<0.05.
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Figure 6-8. Effect of calcium channel ionophore Bay K 8644 on caspase-3 expression
in 3T3-L1 adipocytes. Data are expressed as mean ± SE (n =6). Different letters above
the bars indicate a significant difference at level of p<0.05.
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with our previous finding that mitochondrial uncoupling increases cytosolic calcium level
(15), inhibition of mitochondrial uncoupling with GDP decreased [Ca2+]i level
significantly (data not shown). Combining 1mM GDP with 1nM BK 8644 exerted no
effect on [Ca2+]i but induced similar magnitude of increases in mitochondrial potential as
observed in GDP alone (Figure 6-7), indicating that the regulation of mitochondrial
potential is calcium independent. However, addition of Bay K 8644 caused a significant
increase in caspase-3 expression (Figure 6-9), suggesting that [Ca2+]i stimulates
apoptosis independent of mitochondrial potential.
Stimulation of calcium influx by BK 8644 increased mitochondrial calcium
(Figure 6-10) (p<0.05). Although 1α, 25-(OH)2-D3 induced similar effects on [Ca2+]i
increase as BK8644, the opposite effect on mitochondrial calcium was observed with low
dose of 1α, 25-(OH)2-D3 (0.1nM to 10nM) pretreated cells, with significant decreases in
mitochondrial calcium. The high dose of 1α, 25-(OH)2-D3, however, caused similar
increases in mitochondrial calcium as observed with BK 8644.

6.5 Discussion
We investigated the effects of the calcium channel ionophore BK 8644, a
mitochondrial uncoupling inhibitor (GDP) and UCP2 silencing using siRNA transfection
on apoptosis. BK 8644, which exerted no effect on mitochondrial uncoupling, caused a
dose dependent increase in intracellular calcium as well as mitochondrial calcium storage,
and stimulated caspase-3 expression, indicating that increases in intracellular calcium
influx, along with mitochondrial calcium load, stimulate apoptosis. Inhibition of
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Figure 6-9. Effect of mitochondrial uncoupling inhibitor GDP and calcium channel
ionophore Bay K 8644 on caspase-3 expression in 3T3-L1 adipocytes. Data are
expressed as mean ± SE (n =6). Different letters above the bars indicate a significant
difference at level of p<0.05.
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Figure 6-10. Effect of calcium channel ionophore Bay K 8644 on mitochondrial
calcium in 3T3-L1 adipocytes. Data are expressed as mean ± SE (n =6).
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mitochondrial uncoupling with GDP decreased intracellular calcium and mitochondrial
potential and thereby inhibited apoptosis. Consistent with our previous data that the
mitochondrial uncoupler 2, 4-dinitrophenol (DNP) stimulates apoptosis (10), these results
indicate a direct role of mitochondrial uncoupling in stimulating of apoptosis. Specific
suppression of UCP2 also decreased apoptosis while UCP2 overexpression caused the
opposite effect. Accordingly, the inhibitory effect of low dose of 1α, 25-(OH)2-D3 on
apoptosis may be mediated by its suppression of UCP2 expression (11). Although 1α, 25(OH)2-D3 increases [Ca2+]i, and such increases are often associated with apoptosis, only
the very high dose (>100nM) of 1, 25(OH)2D3 stimulated apoptosis. This result indicates
that the pro-apoptotic effect of intracellular calcium with the treatment of 1α, 25-(OH)2D3 may be overwhelmed by its anti-apoptotic effect induced by suppression of UCP2.
Early studies by Kaiser and Edelman demonstrated that glucocorticoid-stimulated
apoptosis is associated with enhanced [Ca2+]i influx (16), providing the first evidence that
increased [Ca2+]i might be involved in triggering apoptosis. This hypothesis was further
supported by the observation that increased level of inositol 1,4,5-triphosphate(InsP3)
receptor in lymphocytes stimulates apoptosis while IP3R-deficient cells are resistant to Tcell receptor (TCR)-induced apoptosis(17-18). Calcium was also linked to the release of
arachidonic acid from cells triggered to undergo apoptosis by various chemotherapeutic
agents (19), suggesting that calcium is important to many cPLA2-dependent apoptotic
responses. Consistent with this, the present study confirms that increases in intracellular
calcium influx stimulate apoptosis by increasing caspase-3 expression. This result may
explain the pro-apoptotic effect of high dose 1α, 25-(OH)2-D3. In addition, calcium
increases precede the cytolysis of the targets of cytotoxic T cells, indicating rapid,
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sustained intracellular calcium increase is required for the apoptotic process (20).
Although 1α, 25-(OH)2-D3 induced dose-dependent increases in [Ca2+]i, our data indicate
that the magnitude of this increases in [Ca2+]i may determine whether apoptosis results.
Previous studies demonstrate that intracellular calcium storage sites also appear to be
affected, as the cytosolic calcium undergo changes in response to apoptotic stimuli (2122). During apoptotic stress, the mitochondrial calcium pool may also be affected, since
mitochondrial potential, which plays a key role in maintaining mitochondrial calcium
homeostasis, drops very early during apoptotic death (23). Decreased mitochondrial
potential reduces ATP production and causes cytochrome c leakage and mitochondrial
swelling (24). Accordingly, mitochondrial uncoupling might stimulate apoptosis by
decreasing mitochondrial potential. This hypothesis is further supported by our
observations that the chemical uncoupler DNP decreases adipocyte mitochondrial
potential and stimulates apoptosis (10) while in present study, the mitochondrial
uncoupling inhibitor GDP causes the opposite effects. Consistent with this,
overexpression of UCP2 stimulated apoptotic proteases while suppression of UCP2
decreased expression of these genes, indicating that UCP2 plays a positive role in
regulation of apoptosis. 1α, 25-(OH)2-D3, which has been found to inhibit UCP2
expression via a calcium-independent pathway (11), suppressed apoptosis at
physiological low doses from 0.1nM to 10nM, suggesting that the anti-apoptotic effect of
low doses of 1α, 25-(OH)2-D3 might be mediated by suppression of UCP2 expression.
In the present study, 1α, 25-(OH)2-D3 induced similar effect on [Ca2+]i increase
as BK 8644 but the two compounds exerted different effects on mitochondrial calcium
storage, as low doses 1α, 25-(OH)2-D3 (0.1nM to 10nM) decreased mitochondrial calcium
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while BK 8644 increased mitochondrial calcium. However, the high dose of 1α, 25(OH)2-D3 (100nM) caused similar increases in mitochondrial calcium as observed in BK
8644. Since mitochondrial calcium overload might trigger apoptosis by inducing
mitochondrial potential collapse and cytochrome c release, the pro-apoptotic effect of the
high dose of 1α, 25-(OH)2-D3 is most likely a result of the stimulation of mitochondrial
calcium. In contrast, the decreases in mitochondrial calcium observed in response to
treatment with lower dose of 1α, 25-(OH)2-D3 indicates that reduction of mitochondrial
calcium load, along with the inhibitory effect on UCP2 contribute to the anti-apoptotic
effect of low dose of 1α, 25-(OH)2-D3.
Although low doses of 1α, 25-(OH)2-D3 may also induce apoptotic stress via a
calcium dependent mechanism, this signal is counter-balanced by the suppression of
UCP2, which may increase the capability to maintain intracellular homeostasis by
regulating mitochondrial potential and ATP production. Indeed, many calcium channel
and pumps located either on plasma membrane or intracellular organelles are ATP
dependent. High dose of 1α, 25-(OH)2-D3, however, induced much greater increases in
intracellular calcium, resulting in more rapid and stronger apoptotic signals, which could
not be offset by suppression of UCP2.
In summary, physiological low dose of 1, 25-(OH)2-D3 inhibits apoptosis by
suppression of UCP2 expression. Since the low doses of 1, 25-(OH)2-D3 used in this
study are within the range of physiological levels which response to dietary calcium, the
anti-obesity effect of high dietary calcium may, in addition to the previously cited
regulation of lipid metabolism(1-7), may also result from suppression of apoptosis by 1α,
25-(OH)2-D3.
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Part Seven
Summary and Conclusion
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Dietary calcium stimulates UCP2 expression in white adipose tissue and core
temperature in aP2 transgenic mice during ad lib feeding, energy restriction and refeeding
follwing energy restriction, resulting in an attenuation of fat accumulation, an
acceleration of fat loss and an inhibition of weight and fat regain. In addition, UCP2
appear toregulate lipid metabolism directly and mitochondrial uncoupling induced by
chemical uncouplers modulates both lipogenesis and lipolysis.Uncoupling protein 2 also
stimulates adipocyte apoptosis by decreasing mitochondrial potential and ATP
production, and disturbing cytosolic and mitochondrial calcium homeostasis. In addition,
inhibition of UCP2 expression with physiological low doses of 1α, 25(OH)2D3 inhibits
adipocyte apoptosis. Accordingly, suppression of 1α, 25(OH)2D3 by increasing dietary
calcium stimulates UCP2 expression and thus favors adipocyte apoptotic death.
In conclusion, adipocyte UCP2 plays an important role in modulation of adiposity
through regulating mitochondrial potential gradient, energy metabolism and cellular
calcium homeostasis, thus results in modulation of both adipocyte lipid metabolism and
adipocyte numbers, thereby regulating total adiposity. Thus, UCP2 appear to be a
potential molecular target for obesity management.
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